

CITATION REPORT

List of articles citing

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

DOI: 10.1056/nejmoa1707914

New England Journal of Medicine, 2017, 377, 1119-1131.

Source: <https://exaly.com/paper-pdf/66949651/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2211	Vitamin D and Risk of Cardiovascular Disease. 2017 , 37, 1981-1982		1
2210	CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting. 2017 , 121, 1119-1121		42
2209	NLRP3 inflammasome pathways in atherosclerosis. 2017 , 267, 127-138		119
2208	Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. 2017 , 6,		56
2207	Pretenders and Contenders: Inflammation, C-Reactive Protein, and Interleukin-6. 2017 , 6,		9
2206	Targeting inflammation to reduce cardiovascular disease risk. 2017 , 174, 3895-3897		9
2205	The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology. 2017 , 37, e174-e177		44
2204	Assessing the Risk of Aortic Aneurysm in Takayasu Arteritis. 2017 , 354, 531-532		1
2203	High-Risk Coronary Atherosclerosis: Is It the Plaque Burden, the Calcium, the Lipid, or Something Else?. 2017 , 10,		6
2202	Heterogeneity of atherosclerotic plaque macrophage origin, phenotype and functions: Implications for treatment. 2017 , 816, 14-24		21
2201	Monocyte-Macrophages and T Cells in Atherosclerosis. 2017 , 47, 621-634		300
2200	Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation. 2017 , 40, 1779-1786		80
2199	CANTOS Ushers in a New Calculus of Inflammasome Targeting for Vascular Protection-and Maybe More. 2017 , 26, 703-705		18
2198	Attenuation of Myeloid-Specific TGF β Signaling Induces Inflammatory Cerebrovascular Disease and Stroke. 2017 , 121, 1360-1369		9
2197	Targeting the immune response in atherosclerosis: It's time for clinical trials!. 2017 , 110, 643-645		5
2196	Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. 2017 , 70, 2278-2289		293
2195	From Eisenhower's heart attack to modern management: a true success story!. 2017 , 38, 3066-3069		26

2194	Functional diversity of macrophages in vascular biology and disease. 2017 , 99, 13-22	10
2193	A new lead to NLRP3 inhibition. 2017 , 214, 3147-3149	12
2192	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 2017 , 390, 1833-1842	634
2191	Targeting Inflammation in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1197-1198	76
2190	In Retrospect: The inflammasome turns 15. 2017 , 548, 534-535	27
2189	Frequency of Cholesterol Crystals in Culprit Coronary Artery Aspirate During Acute Myocardial Infarction and Their Relation to Inflammation and Myocardial Injury. 2017 , 120, 1699-1707	31
2188	Inflammation and Atherosclerosis: The End of a Controversy. 2017 , 136, 1875-1877	71
2187	Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer. 2017 , 14, 629	8
2186	Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment. 2017 , 136, 1155-1166	203
2185	C-Reactive Protein and Cardiovascular Risk: Will the Controversy End after CANTOS?. 2017 , 63, 1897-1898	3
2184	Primary Prevention of Atherosclerosis: Time to Take a Selfie?. 2017 , 70, 2992-2994	14
2183	Colors of Myocardial Infarction: Can They Predict the Future?. 2017 , 10,	
2182	Fibrates in the management of atherogenic dyslipidemia. 2017 , 15, 913-921	29
2181	Notable advances 2017. 2017 , 23, 1387-1389	
2180	Drugs that made headlines in 2017. 2017 , 23, 1392-1393	1
2179	Why the CANTOS Is a Game Changer in Cardiovascular Medicine. 2017 , 70, 353-355	8
2178	CANTOS: A Gigantic Proof-of-Concept Trial. 2017 , 121, 1320-1322	26
2177	The heart matters in diabetes: 10-Year outcomes of peripheral artery disease. 2017 , 5, 2050312117740988	4

2176	Swell, or Not Too Swell: Cytokines Regulate Arterial Aneurysm Formation. 2017 , 47, 814-816	2
2175	Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement. 2017 , 70, 2822-2830	4
2174	Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice. 2017 , 31, 489-500	9
2173	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). 2017 , 10,	114
2172	Hypercholesterolemia Enhances T Cell Receptor Signaling and Increases the Regulatory T Cell Population. 2017 , 7, 15655	37
2171	Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 1999	59.2 10
2170	Autonomic regulation of the immune system in cardiovascular diseases. 2017 , 41, 578-593	18
2169	Brain, Immunity, Gut: "BIG" Links between Pregnancy and Autism. 2017 , 47, 816-819	3
2168	Reducing medical comorbidities associated with long-term HIV infection: beyond optimizing antiretroviral therapy regimens. 2017 , 31, 2547-2549	1
2167	Targeting Interleukin-1 Protects from Aortic Aneurysms Induced by Disrupted Transforming Growth Factor β Signaling. 2017 , 47, 959-973.e9	29
2166	Association Between Diverticular Disease and Abdominal Aortic Aneurysms: Pooled Analysis of Two Population Based Screening Cohorts. 2017 , 54, 772-777	1
2165	Preface: Pathology and Pharmacology of Atherosclerosis. 2017 , 816, 1-2	15
2164	[Involvement of thrombophilia in coronary thrombosis]. 2017 , 66, 365-372	
2163	Blockage of inflammation: New arsenal against arteriosclerosis. 2017 , 64, 515-516	
2162	Blocking inflammation: a new arsenal against atherosclerosis. 2017 , 64, 515-516	1
2161	Frontiers of Prevention: Pollution, Infection, Cognitive Function and Frailty. 2017 , 38, 3179-3182	2
2160	Periodic fever syndromes. 2017 , 31, 596-609	54
2159	Platelets, Haemostasis and Inflammation. 2017 ,	2

2158 . **2017**, 159, 14

2157 Preface: Recent advances in autoimmune and auto-inflammatory diseases in childhood. **2017**, 31, 439-440

2156 Therapie schlafbezogener Atmungsstörungen. **2017**, 21, 255-256

2155 Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. **2017**, 113, e61-e63 3

2154 Research Roundup. **2017**, 12, 596-597

2153 Research roundup: October 2017. **2017**, 15, 476-478

2152 Implication of Free Fatty Acids in Thrombin Generation and Fibrinolysis in Vascular Inflammation in Zucker Rats and Evolution with Aging. **2017**, 8, 949 5

2151 Anti-inflammatory Nanomedicine for Cardiovascular Disease. **2017**, 4, 87 48

2150 The Aging Risk and Atherosclerosis: A Fresh Look at Arterial Homeostasis. **2017**, 8, 216 63

2149 Efferocytosis and Outside-In Signaling by Cardiac Phagocytes. Links to Repair, Cellular Programming, and Intercellular Crosstalk in Heart. **2017**, 8, 1428 15

2148 Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients. **2017**, 2017, 4719403 5

2147 Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence. **2017**, 2017, 9632846 25

2146 Genetics of coronary artery disease: fact or fiction?. **2017**, 58, 393-395 3

2145 Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. **2017**, 6, 1712 15

2144 Lipidomik identifiziert Ceramide als neue kardiovaskuläre Risikomarker. **2017**, 17, 56-61

2143 Updates on cardiovascular outcome trials in diabetes. **2017**, 16, 128 36

2142 Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance. **2017**, 14, 24 8

2141 GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. **2017**, 15, 219 89

2140	The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?. 2017 , 15, 255	1
2139	Langersehnter Erfolg ðEntzündungshemmer verhindert Herzinfarkte. 2017 , 17, 10-11	
2138	Antikörper: Erstmals Reduktion kardiovaskulärer Ereignisse nachgewiesen. 2017 , 17, 69-70	
2137	European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017. 2017 , 81, 1758-1763	2
2136	Inflammatory Biomarkers of Cardiometabolic Risk in Obese Egyptian Type 2 Diabetics. 2017 , 5,	2
2135	NACHT, LRR and PYD domains-containing protein 3 inflammasome is activated and inhibited by berberine via toll-like receptor 4/myeloid differentiation primary response gene 88/nuclear factor- κ B pathway, in phorbol 12-myristate 13-acetate-induced macrophages. 2018 , 17, 2673-2680	5
2134	The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired. 2017 , 9, 4922-4925	2
2133	Inflammatory Response During Myocardial Infarction. 2018 , 84, 39-79	15
2132	An unexpected link between fatty acid synthase and cholesterol synthesis in proinflammatory macrophage activation. 2018 , 293, 5509-5521	72
2131	Effect of Elevated C-Reactive Protein Level at Discharge on Long-Term Outcome in Patients Hospitalized for Acute Heart Failure. 2018 , 121, 961-968	7
2130	Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1/ β /NLRP3 Inflammasome. 2018 , 71, 875-886	252
2129	Clonal Hematopoiesis Wages War on the Myocardium. 2018 , 71, 887-889	0
2128	Platelets and Tuberculosis: Small Cells, Not So Innocent Bystanders. 2018 , 198, 153-154	2
2127	Redefining biomarkers in heart failure. 2018 , 23, 237-253	17
2126	GDF-15 levels and atherosclerosis. 2018 , 257, 36	5
2125	Does inflammation affect outcomes in dialysis patients?. 2018 , 31, 388-397	34
2124	[Cardiovascular Medication in Elderly Patients]. 2018 , 143, 236-243	0
2123	The search for new antithrombotic mechanisms and therapies that may spare hemostasis. 2018 , 131, 1899-1902	18

2122	Lipids in RA: Is Less Not Necessarily More?. 2018 , 20, 8	10
2121	Macrophages Remember Cheeseburgers and Promote Inflammation via NLRP3. 2018 , 24, 335-337	3
2120	Glucocorticoid sensitivity and inflammatory status of peripheral blood mononuclear cells in patients with coronary artery disease. 2018 , 50, 260-268	1
2119	Interferon Gamma Induces Reversible Metabolic Reprogramming of M1 Macrophages to Sustain Cell Viability and Pro-Inflammatory Activity. 2018 , 30, 303-316	93
2118	The Vasoreparative Function of Myeloid Angiogenic Cells Is Impaired in Diabetes Through the Induction of IL1 β . 2018 , 36, 834-843	13
2117	Response by Lerman et al to Letters Regarding Article, "Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study". 2018 , 137, 1092-1093	1
2116	Treatment of Inflammatory Diseases with IL-1 Blockade. 2018 , 6, 1-14	5
2115	The highs and lows of cardiovascular disease prevention. 2018 , 272, 222-224	
2114	Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. 2018 , 28, 369-379	39
2113	Translational Challenges in Atrial Fibrillation. 2018 , 122, 752-773	74
2112	Acute stress disorder and C-reactive protein in patients with acute myocardial infarction. 2018 , 25, 702-705	1
2111	Treating Gout in Patients With Cardiovascular Disease: Mutual Benefit or Unintended Consequences?. 2018 , 71, 1005-1008	3
2110	Vascular inflammation: A call for a specific and sensitive biomarker?. 2018 , 271, 235-236	2
2109	Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy. 2018 , 114, 40-44	4
2108	Vaspin and Omentin-1 in Obese Children with Metabolic Syndrome: Two New Kids on the Block?. 2018 , 16, 73-75	1
2107	Mechanisms of physiological and pathological cardiac hypertrophy. 2018 , 15, 387-407	468
2106	The Ins and Outs of Myeloid Cells in Atherosclerosis. 2018 , 10, 479-486	10
2105	Canakinumab and Lung Cancer: Intriguing, but Is It Real?. 2018 , 23, 637-638	13

2104 Schwungvoll durch die Neurologie. **2018**, 19, 8-9

2103 Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. **2018**, 15, 351-370 81

2102 Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. **2018**, 70, 1392-1398 8

2101 Trained immunity and cardiovascular disease: is it time for translation to humans?. **2018**, 114, e41-e42 4

2100 Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture. **2018**, 67, 785-790 15

2099 Cardiac eccentric remodeling in patients with rheumatoid arthritis. **2018**, 8, 5867 5

2098 The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. **2018**, 114, 944-953 25

2097 Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank. **2018**, 38, 1415-1423 32

2096 Towards the Clinical Management of Cardiac Involvement in Systemic Inflammatory Conditions: Central Role for CMR. **2018**, 11, 1 6

2095 Insulin resistance adipocyte-derived exosomes aggravate atherosclerosis by increasing vasa vasorum angiogenesis in diabetic ApoE mice. **2018**, 265, 181-187 36

2094 IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies. **2018**, 24, 458-471 48

2093 Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. **2018**, 2, 279-292 60

2092 Effects of gastric bypass surgery followed by supervised physical training on inflammation and endothelial function: A randomized controlled trial. **2018**, 273, 37-44 28

2091 Regulation of immune cell signaling by activated protein C. **2018**, 103, 1197 8

2090 Impact of Lipoproteins on Atherobiology: Emerging Insights. **2018**, 36, 193-201 9

2089 Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer. **2018**, 79, 69-70 12

2088 Poor oral health and coronary artery disease: Association or causality?. **2018**, 25, 596-597 1

2087 Association of Methylation Signals With Incident Coronary Heart Disease in an Epigenome-Wide Assessment of Circulating Tumor Necrosis Factor α . **2018**, 3, 463-472 17

2086	Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis. 2018 , 70, 1756-1763	25
2085	Cardiovascular disease after transplantation: an emerging role of the immune system. 2018 , 31, 689-699	10
2084	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. 2018 , 70, 1319-1330	22
2083	Arterial Thrombosis in Patients with Cancer. 2018 , 20, 40	32
2082	Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. 2018 , 17, 625-635	43
2081	Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. 2018 , 18, 454-466	177
2080	Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. 2018 , 8, 5667	16
2079	Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes. 2018 , 29, 528-530	3
2078	Targeting interleukin-22 for cancer therapy. 2018 , 14, 2012-2015	24
2077	Traumatic Brain Injury Leads to Accelerated Atherosclerosis in Apolipoprotein E Deficient Mice. 2018 , 8, 5639	7
2076	CANTOS: landmark study, modest benefits, more research needed. 2018 , 38, 518-519	
2075	Quantitative Extent of Atherosclerotic Plaque in the Major Epicardial Coronary Arteries in Patients with Fatal Coronary Heart Disease, in Coronary Endarterectomy Specimens, in Aorta-Coronary Saphenous Venous Conduits, and Means to Prevent the Plaques: A Review after Studying the Coronary Arteries for 50 Years. 2018 , 121, 1112-1125	11
2074	Old Drugs for New Indications in Cardiovascular Medicine. 2018 , 32, 223-232	7
2073	The role of microwave radiometry in carotid artery disease. Diagnostic and clinical prospective. 2018 , 39, 99-104	14
2072	The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. 2018 , 25, 923-931	20
2071	Novedades en el tratamiento médico de la cardiopatía isquémica estable. 2018 , 53, 101-105	1
2070	Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. 2018 , 261, 6-11	9
2069	CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. 2018 , 14, 361-377	203

2068	Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell-Independent Tumor Proliferation. 2018 , 6, 566-577	10
2067	Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). 2018 , 29, 429-437	22
2066	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. 2018 , 20, 12	46
2065	Association of salivary lactate dehydrogenase level with systemic inflammation in a Japanese population. 2018 , 53, 487-494	13
2064	DARC matter(s) for inflammatory cells. 2018 , 114, e11-e13	2
2063	Reply concerning "Colchicine in coronary artery disease: Role of anti-inflammatory medications redefined": Prime time for anti-inflammatory agents for the management of cardiovascular diseases. 2018 , 254, 52	
2062	Inflammasome biology, molecular pathology and therapeutic implications. 2018 , 187, 133-149	64
2061	Pathophysiological Links Between Diabetes and Blood Pressure. 2018 , 34, 585-594	24
2060	Subclinical Inflammation in Heart Failure: A Neutrophil Perspective. 2018 , 34, 717-725	10
2059	Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. 2018 , 71, 527-542	91
2058	STOP the TRAFFic and Reduce the Plaque. 2018 , 71, 543-546	3
2057	A positive feedback loop between IL-1 β /LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. 2018 , 103-105, 16-28	39
2056	Potential of anti-inflammatory agents for treatment of atherosclerosis. 2018 , 104, 114-124	61
2055	Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. 2018 , 175, 1377-1400	102
2054	CD301b/MGL2 Mononuclear Phagocytes Orchestrate Autoimmune Cardiac Valve Inflammation and Fibrosis. 2018 , 137, 2478-2493	10
2053	Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease. 2018 , 257, 24-29	12
2052	Frontiers in cardiovascular prevention. 2018 , 39, 329-332	1
2051	O-GlcNAc: a novel regulator of immunometabolism. 2018 , 50, 223-229	11

2050	Reply: LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient?. 2018 , 71, 706-707	
2049	Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. 2018 , 8, 2820	31
2048	Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromsø Study. 2018 , 271, 1-8	27
2047	Nutraceuticals as therapeutic agents for atherosclerosis. 2018 , 1864, 1562-1572	47
2046	Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs Cell Proliferation and Insulin Secretion. 2018 , 22, 1774-1786	37
2045	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). 2018 , 218, suppl 2, S21-S40	114
2044	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. 2018 , 114, 1178-1188	27
2043	High CRP Levels After Critical Illness are Associated With an Increased Risk of Rehospitalization. 2018 , 50, 525-529	0
2042	Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System. 2018 , 20, 5	16
2041	IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14). 2018 , 38, 599-609	49
2040	Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. 2018 , 118, 229-250	32
2039	Perspectives on diabetes mortality as the result of residual confounding and reverse causality by common disease. 2018 , 20, 1342-1349	3
2038	Cytosolic DNA Sensing Promotes Macrophage Transformation and Governs Myocardial Ischemic Injury. 2018 , 137, 2613-2634	77
2037	Systemic inflammation and functional capacity in elderly heart failure patients. 2018 , 107, 362-367	14
2036	All About the Albumin? Prognostic Capacity of Serum Albumin in Patients With Treated HIV Infection. 2018 , 217, 347-349	2
2035	Shedding New Light on the Magnitude of Thrombosis Risk in Patients With Myeloproliferative Neoplasms. 2018 , 168, 363-364	2
2034	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. 2018 , 20, 445-459	67
2033	What We Have Learned From the Recent Meta-analyses on Diagnostic Methods for Atherosclerotic Plaque Regression. 2018 , 20, 2	4

2032	The NLRP3 inflammasome: Role in metabolic disorders and regulation by metabolic pathways. 2018 , 419, 8-19	55
2031	Identifying and Treating Young Patients at Risk for Cardiovascular Events. 2018 , 71, 303-305	2
2030	[Prevention of cardiovascular diseases]. 2018 , 43, 87-100	1
2029	A COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept. 2018 , 39, 758-761	4
2028	Heart Failure with Preserved Ejection Fraction. 2018 , 69, 65-79	33
2027	Advances in lipid-lowering therapy through gene-silencing technologies. 2018 , 15, 261-272	63
2026	New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease. 2018 , 33, 543-548	32
2025	A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?. 2018 , 7, 25-44	62
2024	Will Cardio-Virology Be the Next Cardio-Oncology?. 2018 , 131, 726-727	
2023	Self-initiated physical activity is associated with high sensitivity C-reactive protein: A longitudinal study in 5,030 adults. 2018 , 273, 131-135	18
2022	Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease. 2018 , 122, 523-532	72
2021	Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 2018 , 17, 366-375	46
2020	LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient. 2018 , 71, 705-706	2
2019	Native T1 and ECV of Noninfarcted Myocardium and Outcome in Patients With Coronary Artery Disease. 2018 , 71, 766-778	62
2018	Relative Prognostic Value of Cardiac Troponin I and C-Reactive Protein in the General Population (from the Nord-Trøndelag Health [HUNT] Study). 2018 , 121, 949-955	46
2017	Selection of the Best of 2017 in Vascular Risk and Cardiac Rehabilitation. 2018 , 71, 227-228	
2016	Cholesterol efflux in the transplant patient. 2018 , 25, 143-146	2
2015	Regulation of low-density lipoprotein cholesterol by intestinal inflammation and the acute phase response. 2018 , 114, 226-232	17

2014	Effect size in CANTOS trial. 2018 , 23, 44	4
2013	Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications. 2018 , 137, 1763-1766	20
2012	The Gasdermin-D pore acts as a conduit for IL-1 β secretion in mice. 2018 , 48, 584-592	158
2011	Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. 2018 , 38, 164-171	6
2010	Calcium phosphate particles stimulate interleukin-1 β release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release. 2018 , 115, 82-93	26
2009	Canakinumab for secondary prevention of atherosclerotic disease. 2018 , 18, 215-220	7
2008	Inflammation and Cardiovascular Disease Risk: A Case Study of HIV and Inflammatory Joint Disease. 2018 , 131, 442.e1-442.e8	4
2007	Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming. 2018 , 172, 162-175.e14	435
2006	An Integrated View of Immunometabolism. 2018 , 172, 22-40	203
2005	Selecci3n de lo mejor del a3o 2017 en riesgo vascular y rehabilitaci3n cardiaca. 2018 , 71, 227-228	
2004	Redundancy and robustness versus division of labour and specialization in innate immunity. 2018 , 36, 28-30	10
2003	Immunometabolism in 2017: Metabolism and the inflammasome in health and ageing. 2018 , 14, 72-74	6
2002	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. 2018 , 34, 595-604	37
2001	The role of the interleukin-1 family in trained immunity. 2018 , 281, 28-39	67
2000	Interleukin 1 gene polymorphism and susceptibility to disease. 2018 , 281, 40-56	34
1999	Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. 2018 , 281, 5-7	40
1998	IL-1 and IL-1 regulatory pathways in cancer progression and therapy. 2018 , 281, 57-61	184
1997	Overview of the IL-1 family in innate inflammation and acquired immunity. 2018 , 281, 8-27	603

1996 Surveying the Literature. **2018**, 126, 27-28

1995 Inflammation and CVD in 2017: From clonal haematopoiesis to the CANTOS trial. **2018**, 15, 79-80 19

1994 Inflammation in 2017: Connectivity to other fields brings new ideas. **2018**, 14, 65-66 1

1993 Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome. **2018**, 13, 312-320 19

1992 The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. **2018**, 269, 262-271 133

1991 Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. **2018**, 12, 338-347 11

1990 Selective EGF-Receptor Inhibition in CD4⁺T Cells Induces Anergy and Limits Atherosclerosis. **2018**, 71, 160-172 30

1989 From clinical observations to molecular mechanisms and back to patients: the successful circuit of the CANTOS study. **2018**, 114, e3-e5 8

1988 Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. **2018**, 114, 368-377 41

1987 Oxidized low-density lipoprotein in inflammation-driven thrombosis. **2018**, 16, 418-428 40

1986 Strategies for Achieving Healthy Vascular Aging. **2018**, 71, 389-402 57

1985 Cell biological mechanisms in regulation of the post-infarction inflammatory response. **2018**, 1, 7-13 35

1984 Taming Immune and Inflammatory Responses to Treat Atherosclerosis. **2018**, 71, 173-176 43

1983 Canakinumab for Atherosclerotic Disease. *New England Journal of Medicine*, **2018**, 378, 199-200 59.2 5

1982 Targeting inflammation and immunity in pulmonary arterial hypertension: any easier after the CANTOS proof-of-concept that anti-inflammation cuts cardiovascular events?. **2018**, 8, 2045893218754855 1

1981 From the editor: A run of success in treating atherosclerotic vascular disease. **2018**, 12, 1-2

1980 The year in cardiology 2017: coronary interventions. **2018**, 39, 914-924 1

1979 Clinical and translational science in cardiovascular research: highlights from the American Heart Association Scientific Sessions 2017: Changing view on the concept of cardiovascular risk and blood pressure targets. **2018**, 114, e6-e8

1978	Targeted therapies and outcomes data: the inflammatory hypothesis matures. 2018 , 29, 56-57	
1977	Atherosclerosis: cell biology and lipoproteins - focus on anti-inflammatory therapies. 2018 , 29, 53-55	4
1976	Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials. 2018 , 14, 67-68	1
1975	The Rho(ad)-kinase for individualized treatment of vasospastic angina. 2018 , 39, 960-962	2
1974	The year in cardiology 2017: prevention. 2018 , 39, 345-353	3
1973	[Antibodies as treatment option in older adults]. 2018 , 51, 152-156	
1972	Selection of the Best of 2017 in Ischemic Heart Disease. 2018 , 71, 124-125	
1971	Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?. 2018 , 217, 521-528	14
1970	Self-related Health and Blood Hypercoagulability: A Possible Mechanism for Cardiovascular Risk. 2018 , 118, 4-5	3
1969	Resident and Monocyte-Derived Macrophages in Cardiovascular Disease. 2018 , 122, 113-127	120
1968	Inferring Causal Relationships Between Risk Factors and Outcomes from Genome-Wide Association Study Data. 2018 , 19, 303-327	57
1967	Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. 2018 , 17, 703-708	49
1966	Concentration-dependent systemic response after inhalation of nano-sized zinc oxide particles in human volunteers. 2018 , 15, 8	58
1965	IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. 2018 , 20, 27	31
1964	Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. 2018 , 138, 141-149	93
1963	Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. 2018 , 7, e1016	74
1962	Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. 2018 , 133, 101-107	32
1961	Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. 2018 , 361, k1036	139

1960	Targeting systemic inflammation in atherosclerosis: Who will benefit?. 2018 , 25, 921-922	
1959	The coagulation system in atherothrombosis: Implications for new therapeutic strategies. 2018 , 2, 188-198	25
1958	Atherosclerosis and clonal hematopoiesis: A new risk factor. 2018 , 30, 133-136	3
1957	Molecular and cellular insights into the pathogenesis of coronary artery ectasia. 2018 , 35, 37-47	19
1956	Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. 2018 , 28, 582-591	5
1955	Innate and adaptive immunity in atherosclerosis. 2018 , 107, 67-67	32
1954	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. 2018 , 15, 425-439	114
1953	Inflammatory Mechanisms of Cardiovascular Remodeling. 2018 , 82, 629-635	53
1952	Molecular Imaging of Inflammation in Ischemic Heart Disease. 2018 , 11, 1	4
1951	Improvement in dietary inflammatory index score after 6-month dietary intervention is associated with reduction in interleukin-6 in patients with coronary heart disease: The AUSMED heart trial. 2018 , 55, 108-121	28
1950	Extracellular and Intracellular Cyclophilin A, Native and Post-Translationally Modified, Show Diverse and Specific Pathological Roles in Diseases. 2018 , 38, 986-993	27
1949	Effect of simvastatin and ezetimibe on suPAR levels and outcomes. 2018 , 272, 129-136	4
1948	New methods to image unstable atherosclerotic plaques. 2018 , 272, 118-128	42
1947	Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. 2018 , 13, 477-488	12
1946	Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease. 2018 , 38, 193-205	28
1945	Heat shock proteins and cardiovascular disease. 2018 , 105, 19-37	23
1944	Lack of Association Between Heart Failure and Incident Cancer. 2018 , 71, 1501-1510	27
1943	Chlamydia and Lipids Engage a Common Signaling Pathway That Promotes Atherogenesis. 2018 , 71, 1553-1570	18

1942	Addressing Acute Coronary Syndromes: New Challenges and Opportunities After the CANTOS Trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study). 2018 , 137, 1100-1102	13
1941	Inflammatory and Cholesterol Risk in the FOURIER Trial. 2018 , 138, 131-140	127
1940	Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. 2018 , 135, 757-777	64
1939	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
1938	Single-Cell RNA-Seq Reveals the Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine Atherosclerosis. 2018 , 122, 1661-1674	316
1937	Higher dietary inflammation is associated with increased odds of depression independent of Framingham Risk Score in the National Health and Nutrition Examination Survey. 2018 , 54, 23-32	19
1936	Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. 2018 , 259, 198-204	28
1935	An update on trials of novel lipid-lowering drugs. 2018 , 33, 416-422	3
1934	Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. 2018 , 138, 898-912	131
1933	Recent major advances in cardiovascular pharmacotherapy. 2018 , 74, 853-862	3
1932	Atherosclerosis as an inflammatory disease: Doubts? No more. 2018 , 19, 1-2	12
1931	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. 2018 , 71, 2392-2401	170
1930	Cytokines and fatty liver diseases. 2018 , 2, 14-20	40
1929	Editorial commentary: Are cytokines ready for prime time? Insights from markers and trials. 2018 , 28, 380-381	
1928	Lipids, inflammation, and chronic kidney disease: a SHARP perspective. 2018 , 93, 784-786	2
1927	The Emerging Role of Inflammation in Cardiovascular Disease. 2018 , 52, 801-809	29
1926	Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice. 2018 , 20, 23	4
1925	Atherosclerotic Heart Disease in Women With Autoimmune Rheumatologic Inflammatory Conditions. 2018 , 34, 381-389	12

1924	Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies. 2018 , 29, 246-258	5
1923	All roads lead to IL-6: A central hub of cardiometabolic signaling. 2018 , 259, 213-215	25
1922	Interleukin-1 blockade in cardiovascular diseases: a clinical update. 2018 , 39, 2063-2069	85
1921	Identification and Complete Stereochemical Assignments of the New Resolvin Conjugates in Tissue Regeneration in Human Tissues that Stimulate Proresolving Phagocyte Functions and Tissue Regeneration. 2018 , 188, 950-966	33
1920	Biomarkers enter the world of peripheral artery disease. 2018 , 39, 2420-2422	3
1919	Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside. 2018 , 32, 111-118	19
1918	Highlights from the 2017 American Heart Association Scientific Sessions in Anaheim, California. 2018 , 45, 466-468	
1917	Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. 2018 , 319, 1331-1340	64
1916	Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy. 2018 , 33, 325-333	29
1915	Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor. 2018 , 11, 330-338	15
1914	Psoriasis-Related Visceral Adiposity and Arterial Inflammation: A New Adiposity Disease Entity?. 2018 , 11, 358-360	1
1913	Will Reducing Inflammation Reduce Vascular Event Rates?. 2018 , 11, 317-319	7
1912	Targeted antiplatelet therapy: novel treatment options for ischaemic heart disease. 2018 , 39, 117-118	4
1911	Biomarkers in stable coronary artery disease. 2018 , 196, 82-96	23
1910	PCSK9 antagonists and inflammation. 2018 , 268, 235-236	12
1909	Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk. 2018 , 77, e59	8
1908	Association of interleukin-6 with aortic stiffness in end-stage renal disease. 2018 , 12, 5-13	20
1907	Why women are not small men. 2018 , 107, A3-A4	3

1906	ANGPTL3 targeting: The power of versatile lipid-lowering. 2018 , 268, 185-187	4
1905	Anti-inflammatory agents in peripheral arterial disease. 2018 , 39, 1-8	16
1904	Low-dose of relaxin protects against arrhythmias and adverse left ventricle remodeling. 2018 , 250, 60-61	
1903	IL-1[Interleukin-1]and TNF-[Tumor Necrosis Factor-]Impact Abdominal Aortic Aneurysm Formation by Differential Effects on Macrophage Polarization. 2018 , 38, 457-463	46
1902	The polyunsaturated fatty acid balance in kidney health and disease: A review. 2018 , 37, 1829-1839	8
1901	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. 2018 , 34, 575-584	435
1900	The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease. 2018 , 48, 564-575	72
1899	Serendipity: How the search for meaning of serum uric acid might lead to the repurposing of an old drug in patients with cardiovascular disease. 2018 , 25, 231-232	1
1898	[Atherothrombosis : Novel therapeutic strategies]. 2018 , 43, 103-108	2
1897	A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective. 2018 , 11, 25-35	
1896	Inflammation and atherosclerosis: fulfilling Koch's postulates. 2018 , 12, 5-6	3
1895	Selección de lo mejor del año 2017 en cardiopatía isquémica. 2018 , 71, 124-125	
1894	Coronary versus carotid artery plaques. Similarities and differences regarding biomarkers morphology and prognosis. 2018 , 39, 9-18	16
1893	Anti-interleukin-1 therapy has mild hypoglycaemic effect in type 2 diabetes. 2018 , 20, 1024-1028	8
1892	Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod. 2018 , 26, 152-156	3
1891	Editorial: Tumor Necrosis Factor Antagonists: Killing Two Birds With One Biologic Stone. 2018 , 70, 326-329	3
1890	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. 2018 , 27, 606-619	11
1889	Renal effects of cytokines in hypertension. 2018 , 27, 70-76	16

1888	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. 2018 , 93, 1000-1007	21
1887	The NLRP3 inflammasome in acute myocardial infarction. 2018 , 15, 203-214	270
1886	Editorial commentary: Heart failure in systemic lupus erythematosus: A problem to address. 2018 , 28, 198-199	1
1885	The role of epigenetics in cardiovascular health and ageing: A focus on physical activity and nutrition. 2018 , 174, 76-85	18
1884	Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. 2018 , 27, 115-123	61
1883	The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. 2018 , 185, 34-49	112
1882	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. 2018 , 391, 319-328	430
1881	Treatment concentration of high-sensitivity C-reactive protein. 2018 , 391, 287-289	7
1880	Macrophages under pressure: the role of macrophage polarization in hypertension. 2018 , 191, 45-63	39
1879	Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. 2018 , 9, 33416-33439	59
1878	A case report of locally invasive infection in a patient on canakinumab. 2018 , 2, yty098	1
1877	Shear Stress Regulation of Endothelium: A Double-edged Sword. 2018 , 6, 58-61	8
1876	Management of complex gout in clinical practice: Update on therapeutic approaches. 2018 , 32, 813-834	7
1875	Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. 2018 , 38, 764-774	14
1874	Behalten Sie bei Rheuma Komorbiditäten im Auge. 2018 , 15, 32-32	
1873	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. 2018 , 7, 691-702	3
1872	Impact of a hospital-based educational intervention on dietary salt-related knowledge and behaviour in a cardiac care unit population in Lebanon. 2018 , 8, 146-155	2
1871	Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. 2018 , 10, 695-698	17

1870	CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis. 2018 , 2018, 2	4
1869	Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?. 2018 , 3, e96-e98	
1868	Importance of prognostic value of neutrophil to lymphocyte ratio in patients with ST-elevation myocardial infarction. 2018 , 97, e13471	19
1867	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. 2018 , 12, 29-40	15
1866	multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. 2018 , 8, 6195-6209	40
1865	Highlights From Vascular Discovery: From Genes to Medicine Scientific Sessions 2018. 2018 , 7, e009470	
1864	Cardiovascular Disease as a Result of the Interactions Between Obesity, Climate Change, and Inflammation: The COCCI Syndemic. 2018 , 118, 719-729	2
1863	Sex-specific risk factors for cardiovascular disease in women-making cardiovascular disease real. 2018 , 33, 500-505	16
1862	Adropin and Inflammation Biomarker Levels in Male Patients With Obstructive Sleep Apnea: A Link With Glucose Metabolism and Sleep Parameters. 2018 , 14, 1109-1118	21
1861	Untreated Obstructive Sleep Apnea Is Associated With Myocardial Injury Independent of Blood Pressure Control in Hypertension. 2018 , 14, 1841-1847	3
1860	Cardiac Manifestations in Systemic Lupus Erythematosus: A Case Report and Review of the Literature. 2018 , 6, 180-183	8
1859	Atherothrombosis as a Leading Cause of Acute Coronary Syndromes and Stroke: The Main Killers in Developed Countries. 2018 ,	
1858	The role of non-resolving inflammation in atherosclerosis. 2018 , 128, 2713-2723	117
1857	Full Issue PDF. 2018 , 3, I-CLVIII	
1856	Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease. 2018 , 29, 433-435	
1855	Targeting Non-coding RNA in Vascular Biology and Disease. 2018 , 9, 1655	38
1854	Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis. 2018 , 11, 253-258	32
1853	PRKAA1/AMPK β -driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis. 2018 , 9, 4667	37

1852	"Liquid Biopsy" of White Matter Hyperintensity in Functionally Normal Elders. 2018 , 10, 343	9
1851	Long Noncoding RNAs in Atherosclerosis: JACC Review Topic of the Week. 2018 , 72, 2380-2390	48
1850	Inflammation, Inflammasome Activation, and Atrial Fibrillation. 2018 , 138, 2243-2246	19
1849	Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. 2018 , 72, 2625-2641	187
1848	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. 2018 , 39, 4109-4111	16
1847	IL-23R Signaling Plays No Role in Myocardial Infarction. 2018 , 8, 17078	1
1846	Can we use interleukin-1 β blockade for lung cancer treatment?. 2018 , 7, S160-S164	15
1845	Qualitative evaluation of coronary atherosclerosis in a large cohort of young and middle-aged Dutch tissue donors implies that coronary thrombo-embolic manifestations are stochastic. 2018 , 13, e0207943	2
1844	Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism. 2018 , 5, 148	7
1843	Anakinra Therapy for Non-cancer Inflammatory Diseases. 2018 , 9, 1157	137
1842	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. 2018 , 19,	9
1841	IL-1 β Inhibition Reduces Atherosclerotic Inflammation in HIV Infection. 2018 , 72, 2809-2811	37
1840	Role of the NLRP3 inflammasome in cancer. 2018 , 17, 158	186
1839	Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis. 2018 , 41, 1439-1445	17
1838	A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia. 2018 , 25, 2044-2052.e5	84
1837	Mets and NETs: The Awakening Force. 2018 , 49, 798-800	3
1836	The Inter-Relationship of Platelets with Interleukin-1 β Mediated Inflammation in Humans. 2018 , 118, 2112-2125	19
1835	Is the amount of glow predicting the fire? Residual inflammatory risk after percutaneous coronary intervention. 2018 ,	4

1834	Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval. 2018 , 3, 690-703	9
1833	The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. 2018 , 3, 844-857	108
1832	Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities. 2018 , 2018, 8696543	23
1831	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. 2018 , 72, 2297-2305	24
1830	Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 Mice. 2018 , 123, e35-e47	93
1829	Platelet activity and hypercoagulation in type 2 diabetes. 2018 , 17, 141	56
1828	Who Done It? Macrophage Mayhem in Atherosclerosis. 2018 , 123, 1106-1108	3
1827	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. 2018 , 21, 80-86	2
1826	Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. 2018 , 72, 3320-3331	81
1825	Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. 2019 , 17, 1024-1029	12
1824	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. 2018 , 5, 177	9
1823	Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. 2018 , 7, e009217	34
1822	Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study. 2018 , 17, 273	5
1821	Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression?. 2018 , 15, 342	55
1820	The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice. 2018 , 6, 109-127	39
1819	Is clonal hematopoiesis a new risk factor for cardiovascular diseases?: Clinical and experimental evidences. 2018 , 151, 207-209	
1818	Jak-ing Up the Plaque's Lipid Core—and Even More. 2018 , 123, 1180-1182	6
1817	Psoriasis and Atherosclerosis. 2018 , 123, 1183-1184	6

1816	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. 2018 , 5, 178	10
1815	Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. 2018 , 9, 1488	17
1814	Prognostic Value of hs-CRP After Transcatheter Aortic Valve Implantation. 2018 , 11, e007213	3
1813	Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?. 2018 , 3, 858-860	5
1812	Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca/Calmodulin-Dependent Protein Kinase II Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. 2018 , 138, 2530-2544	109
1811	"First in Man": Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction. 2018 , 2018, 4767105	10
1810	Spark That Lights the Fire: Infection Triggers Cardiovascular Events. 2018 , 7, e011175	2
1809	Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. 2018 , 10, 93	21
1808	The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. 2018 , 19,	18
1807	Assessing myocardial ischaemia in epicardial coronaries and the microcirculation. 2018 , 39, 4047-4050	1
1806	Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study. 2018 , 5, e000849	9
1805	ORBITA - much ado about nothing?. 2018 , 48, 40-43	
1804	Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis. 2018 , 6, 177	16
1803	Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. 2018 , 7,	49
1802	Colchicine: an affordable anti-inflammatory agent for atherosclerosis. 2018 , 29, 467-473	16
1801	Common Mechanisms Linking Chronic Obstructive Pulmonary Disease and Lung Cancer. 2018 , 15, S273-S277	6
1800	Anti-Inflammatory Effects of a Vegan Diet Versus the American Heart Association-Recommended Diet in Coronary Artery Disease Trial. 2018 , 7, e011367	54
1799	MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke-A Comprehensive Review and Bioinformatic Analysis. 2018 , 7,	88

1798 Gustav Born: pioneer in imaging platelet and leukocyte biology. **2018**, 29, 766-770

1797 Current concepts in atherosclerosis. **2018**, 34, 198-205

1

1796 Full Issue PDF. **2018**, 3, I-CXLVII

1795 Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases. **2018**, 18, 166-175

15

1794 Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. **2018**, 72, 2886-2903

33

1793 The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation. **2018**, 29, 436-444

15

1792 Low density lipoprotein oxidation by ferritin at lysosomal pH. **2018**, 217, 51-57

6

1791 Inflammation: the new cardiovascular risk factor. **2018**, 39, 3483-3487

12

1790 Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. **2018**, 8, e022348

28

1789 Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. **2018**, 39, 4243-4254

113

1788 Inflammation and coronary artery disease: The exercise paradox. **2018**, 111, 371-372

1

1787 Pathophysiology of cardiovascular disease in diabetes mellitus. **2018**, 7, 4-9

21

1786 Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping. **2018**, 5, 141

7

1785 Lipid-driven immunometabolic responses in atherosclerosis. **2018**, 29, 375-380

26

1784 Medication-based versus target-based lipid management. **2018**, 10, 789-792

0

1783 Systemic immunosuppression and risk of age-related macular degeneration. **2018**, 13, e0203492

4

1782 Kr ppl-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-  signaling pathway. **2018**, 278, 39-48

16

1781 Inhibition of LDL oxidation and inflammasome assembly by nitroaliphatic derivatives. Potential use as anti-inflammatory and anti-atherogenic agents. **2018**, 159, 178-186

2

1780	It must be true □ read it in the tabloids. 2018 , 48, 251-256	1
1779	The integration of inflammaging in age-related diseases. 2018 , 40, 17-35	148
1778	Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. 2018 , 44, 457-464	133
1777	Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. 2018 , 11, 517-523	19
1776	Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease. 2018 , 38, 2519-2527	16
1775	Pro-resolving lipid mediators: Agents of anti-ageing?. 2018 , 40, 36-48	21
1774	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. 2018 , 206, 80-93	183
1773	Landmark Trials in Cardiology in 2017-Celebrating 40 Years of Angioplasty. 2018 , 27, 167-173	3
1772	Adipose Tissue as an Endocrine Organ. 2018 ,	1
1771	A multi-site coronary sampling study on CRP in non-STEMI: Novel insights into the inflammatory process in acute coronary syndromes. 2018 , 278, 117-123	5
1770	Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. 2018 , 18, 773-789	355
1769	Body Mass Index of 92,027 patients acutely admitted to general hospitals in Denmark: Associated clinical characteristics and 30-day mortality. 2018 , 13, e0195853	4
1768	Oxidative Stress and Inflammation, Key Targets of Atherosclerotic Plaque Progression and Vulnerability: Potential Impact of Physical Activity. 2018 , 48, 2725-2741	35
1767	The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). 2018 , 278, 217-225	21
1766	[Is cancer a factor or a marker of cardiovascular risk in women?]. 2018 , 47, 780-783	
1765	Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation. 2018 , 38, 2562-2575	39
1764	Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders. 2018 , 38, 2765-2779	33
1763	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. 2018 , 11, e005036	76

1762	Transcriptome Analysis Reveals Nonfoamy Rather Than Foamy Plaque Macrophages Are Proinflammatory in Atherosclerotic Murine Models. 2018 , 123, 1127-1142	153
1761	Atherosclerosis. 2018 , 123, 1118-1120	136
1760	In Pursuit of an Atherosclerosis Vaccine. 2018 , 123, 1121-1123	12
1759	Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger. 2018 , 138, 727-734	34
1758	Cardio-Oncology. 2018 , 138, 663-665	
1757	Kardiovaskuläre Erkrankungen bei Diabetes. 2018 , 14, 393-403	1
1756	HIV control: Is getting there the same as staying there?. 2018 , 14, e1007222	35
1755	Age-related differences in IL-1 signaling and capsule serotype affect persistence of <i>Streptococcus pneumoniae</i> colonization. 2018 , 14, e1007396	9
1754	Biomarker Glycoprotein Acetyls Is Associated With the Risk of a Wide Spectrum of Incident Diseases and Stratifies Mortality Risk in Angiography Patients. 2018 , 11, e002234	19
1753	Immunopharmacology of Post-Myocardial Infarction and Heart Failure Medications. 2018 , 7,	7
1752	Diabetes und Herz. 2018 , 14, 374-375	
1751	Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2). 2018 , 72, 2181-2197	76
1750	The Macrophage in Cardiac Homeostasis and Disease: JACC Macrophage in CVD Series (Part 4). 2018 , 72, 2213-2230	75
1749	Monocyte and Macrophage Dynamics in the Cardiovascular System: JACC Macrophage in CVD Series (Part 3). 2018 , 72, 2198-2212	31
1748	Pharmacotherapeutic management of gout in patients with cardiac disease. 2018 , 19, 2011-2018	1
1747	Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. 2018 , 6, 954-965	137
1746	Neurovascular dysfunction in vascular dementia, Alzheimer's and atherosclerosis. 2018 , 19, 62	65
1745	Cardiomyocytes and Macrophages Discourse on the Method to Govern Cardiac Repair. 2018 , 5, 134	21

1744	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. 2018 , 39, 4101-4108	43
1743	Report of the Annual Scientific Session of the American College of Cardiology (ACC) 2018, Orlando. 2018 , 82, 1491-1496	
1742	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. 2018 , 7, e009778	43
1741	Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. 2018 , 72, 2071-2081	256
1740	Vulnerable Plaques, Vulnerable Patients, and Intravascular Imaging. 2018 , 72, 2022-2026	5
1739	Growth differentiation factor-15 reveals the dark side of heart failure. 2018 , 20, 1710-1712	2
1738	New joint consensus initiative on quantifying atherogenic lipoproteins. 2018 , 279, 97-99	1
1737	Role of Allergic Inflammatory Cells in Coronary Artery Disease. 2018 , 138, 1736-1748	30
1736	IL-33 (Interleukin 33)/sST2 Axis in Hypertension and Heart Failure. 2018 , 72, 818-828	24
1735	CRP-Based Cardiovascular Risk Assessment: New Conventional CRP Assay Fit for Purpose?. 2018 , 2, 952-959	4
1734	The best in coronary artery disease management is yet to come. 2018 , 111, 621-624	0
1733	An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. 2018 , 49, 943-957.e9	82
1732	Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans. 2018 , 7, e009881	14
1731	Biomarkers as Surrogates for Coronary Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease. 2018 , 7, e010166	
1730	Cardiac Steatosis in HIV-A Marker or Mediator of Disease?. 2018 , 9, 529	2
1729	Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease. 2018 , 7, e009328	21
1728	Gouty Offense in Patients With Obstructive Coronary Artery Disease Despite State-of-the-Art Therapy. 2018 , 7, e010322	
1727	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. 2018 , 103, 691-706	151

1726	Interleukin-1 β is an intracellular alarmin in cancer biology. 2018 , 38, 3-14	20
1725	Targeting inflammation in diabetic nephropathy: a tale of hope. 2018 , 27, 917-930	84
1724	Genome Editing of Human Primary Keratinocytes by CRISPR/Cas9 Reveals an Essential Role of the NLRP1 Inflammasome in UVB Sensing. 2018 , 138, 2644-2652	42
1723	Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial. 2018 , 19, 168	19
1722	Associations of device-measured physical activity across adolescence with metabolic traits: Prospective cohort study. 2018 , 15, e1002649	24
1721	CANTOS - is selective targeting of inflammation in atherosclerosis enough?. 2018 , 48, 246-247	3
1720	Prognostic Value and Therapeutic Perspectives of Coronary CT Angiography: A Literature Review. 2018 , 2018, 6528238	5
1719	Anti-JNK2 peptide-siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice. 2018 , 13, 5187-5205	15
1718	Examining the Role of and Treatment Directed at IL-1 β in Atherosclerosis. 2018 , 20, 53	17
1717	Inflammation, protection, and the problems of translation. 2018 , 15, 729-730	2
1716	Ω 6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. 2018 , 9, 688-700	41
1715	Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. 2018 , 83, 2-11	25
1714	[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)]. 2018 , 59, 1224-1228	
1713	Targeting myeloperoxidase in inflammatory atherosclerosis. 2018 , 39, 3311-3313	10
1712	IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial. 2018 , 103, 3466-3476	21
1711	Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis. 2018 , 132, 1889-1899	9
1710	Psoriatic disease, aging, chronic inflammation and acute coronary syndromes. Two and two may not always make four. 2018 , 273, 47-48	
1709	Cardioimmunology: the immune system in cardiac homeostasis and disease. 2018 , 18, 733-744	240

1708	Relationship of Interleukin-1 β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. 2018 , 169, 535-542	51
1707	Pathology of Arterial Thrombosis. 2018 , 15-30	2
1706	Biologic bases of residual risk of cardiovascular events: A flawed concept. 2018 , 25, 1831-1835	2
1705	Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis. 2018 , 3, 949-956	38
1704	One Screening for Ischemic Heart Disease, Lung Cancer, and Chronic Obstructive Pulmonary Disease: A Systems Biology Bridge for Tobacco and Radiation Exposure. 2018 , 108, 1294-1295	4
1703	Inflammation, Superadded Inflammation, and Out-of-Proportion Inflammation in Atherosclerosis. 2018 , 3, 912-914	3
1702	The Inflammasomes in Cardiovascular Disease. 2018 , 108, 9-40	10
1701	Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER. 2018 , 122, 1817-1823	2
1700	Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease. 2018 , 13, e0202682	4
1699	Reply: Inflammatory Pathways in CVD and Diabetes: Broad-Spectrum Versus Selective Targeting. 2018 , 72, 1432-1433	0
1698	A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. 2018 , 132, 1811-1836	75
1697	Anti-tumor necrosis factor- α therapy increases plaque burden in a mouse model of experimental atherosclerosis. 2018 , 277, 80-89	13
1696	Inflammatory Mechanisms in Atherosclerosis. 2018 ,	3
1695	Is clonal hematopoiesis a new risk factor for cardiovascular diseases?: Clinical and experimental evidences. 2018 , 151, 207-209	
1694	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. 2018 , 39, 3641-3653	41
1693	Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications. 2018 , 9, 1115	28
1692	Subacute treatment of carprofen facilitate splenocardiac resolution deficit in cardiac injury. 2018 , 104, 1173-1186	16
1691	IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). 2018 , 36, 63-72	15

1690	E-selectin-targeted copolymer reduces atherosclerotic lesions, adverse cardiac remodeling, and dysfunction. 2018 , 288, 136-147	25
1689	Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. 2018 , 315, H1553-H1568	122
1688	Macrophages and Cardiovascular Health. 2018 , 98, 2523-2569	39
1687	Cardiovascular disease risk and mortality within inflammatory bowel disorders: Opposing or congruent effects?. 2018 , 25, 1621-1622	1
1686	Serum amyloid A - a review. 2018 , 24, 46	161
1685	The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. 2018 , 20, 194	15
1684	ASO Author Reflections: Parameters for Predicting Surgical Outcomes for Gastric Cancer Patients: Simple Is Better Than Complex. 2018 , 25, 699-700	4
1683	Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration. 2018 , 14, e1007268	2
1682	Clinical consequences of clonal hematopoiesis of indeterminate potential. 2018 , 2018, 264-269	23
1681	Clinical consequences of clonal hematopoiesis of indeterminate potential. 2018 , 2, 3404-3410	87
1680	Myeloid peroxisome proliferator-activated receptor gamma deficiency aggravates myocardial infarction in mice. 2018 , 274, 199-205	8
1679	Inflammatory patterns in Takotsubo cardiomyopathy and acute coronary syndrome: A propensity score matched analysis. 2018 , 274, 157-161	23
1678	Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL. 2018 , 71, 2507-2510	7
1677	A Deeper Dive Into the CANTOS "Responders" Substudy. 2018 , 93, 830-833	5
1676	Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly?. 2018 , 5, e000789	6
1675	5-Aminolevulinic Acid-Mediated Sonodynamic Therapy Alleviates Atherosclerosis via Enhancing Efferocytosis and Facilitating a Shift in the Th1/Th2 Balance Toward Th2 Polarization. 2018 , 47, 83-96	10
1674	Cholesterol and inflammation: The lesser the better in atherothrombosis. 2018 , 25, 944-947	7
1673	Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke. 2018 , 39, 3511-3517	33

1672	Further options for treating lipids in people with diabetes: targeting LDL-cholesterol and beyond. 2018 , 35, 1173	2
1671	Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. 2018 , 37, 1067-1074	9
1670	Regulation of macrophage immunometabolism in atherosclerosis. 2018 , 19, 526-537	168
1669	Is defective cholesterol efflux an integral inflammatory component in myelopoiesis-driven cardiovascular diseases?. 2018 , 39, 2168-2171	4
1668	Simvastatin Suppresses Interleukin IIRelease in Human Peripheral Blood Mononuclear Cells Stimulated With Cholesterol Crystals. 2018 , 23, 509-517	13
1667	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. 2018 , 267, 188-192	28
1666	Targeting Inflammation in the Prevention and Treatment of Type 2 Diabetes: Insights From CANTOS. 2018 , 71, 2402-2404	12
1665	Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. 2018 , 71, 2450-2467	27
1664	Inhibition of Interleukin-1by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. 2018 , 71, 2405-2414	114
1663	Cardiovascular Risk Reduction in Patients With Chronic Kidney Disease: Potential for Targeting Inflammation With Canakinumab. 2018 , 71, 2415-2418	5
1662	YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients. 2018 , 274, 152-156	5
1661	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. 2018 , 17, 53-68	1
1660	GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. 2018 , 215, 1519-1529	91
1659	The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. 2018 , 23, 483-493	25
1658	Plasma cytokines and risk of coronary heart disease in the PROCARDIS study. 2018 , 5, e000807	15
1657	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. 2018 , 11, e007394	81
1656	Evolutionaire geneeskunde. 2018 , 34, 391-425	
1655	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. 2018 , 25, 948-955	27

1654	Glycomics and Cardiovascular Disease: Advancing Down the Path Towards Precision. 2018 , 122, 1488-1490	6
1653	Mendelian randomization: Its impact on cardiovascular disease. 2018 , 72, 307-313	18
1652	Cardiomyopathy, oxidative stress and impaired contractility in a rheumatoid arthritis mouse model. 2018 , 104, 2026-2034	21
1651	Perivascular adipose tissue and coronary atherosclerosis. 2018 , 104, 1654-1662	41
1650	Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction. 2018 , 268, 187-192	10
1649	Testosterone Protects Against Atherosclerosis in Male Mice by Targeting Thymic Epithelial Cells-Brief Report. 2018 , 38, 1519-1527	12
1648	The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after >10 years of follow-up: The Multi-Ethnic Study of Atherosclerosis (MESA). 2018 , 264, 158-164	12
1647	Inflammation: A pathogenetic mechanism or a mediator, linking risk factors and cardiovascular disease?. 2018 , 264, 170-171	3
1646	Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. 2018 , 138, 2227-2242	174
1645	Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années. 2018 , 12, 174-181	1
1644	Inflammasomes in livestock and wildlife: Insights into the intersection of pathogens and natural host species. 2018 , 201, 49-56	15
1643	Magnesium and Blood Pressure: A Physiology-Based Approach. 2018 , 25, 244-250	15
1642	Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery?. 2018 , 23, 991-1017	13
1641	Quantitating Heart Damage: Part of the Story. 2018 , 355, 521-522	
1640	Protein biomarkers and coronary microvascular dilatation assessed by rubidium-82 PET in women with angina pectoris and no obstructive coronary artery disease. 2018 , 275, 319-327	8
1639	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. 2018 , 70, 331-334	
1638	Conflicting vascular and metabolic impact of the IL-33/sST2 axis. 2018 , 114, 1578-1594	53
1637	Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1 β and Cathepsin G. 2018 , 38, 1901-1912	135

1636	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. 2018 , 13, e0195174	14
1635	Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL-1-Mediated Mechanism. 2018 , 7,	12
1634	Association of IL-8 With Infarct Size and Clinical Outcomes in Patients With STEMI. 2018 , 72, 187-198	23
1633	Understanding and Targeting Inflammation in 'Acute Myocardial Infarction: An Elusive Goal. 2018 , 72, 199-201	7
1632	WITHDRAWN: Cytokines and fatty liver diseases. 2018 ,	
1631	C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up. 2018 , 41, 1201-1206	26
1630	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. 2018 , 35, 899-927	1
1629	Unmet Need for Adjunctive 'Dyslipidemia' Therapy in Hypertriglyceridemia Management. 2018 , 72, 330-343	107
1628	Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. 2018 , 833, 531-544	62
1627	Involvement of CD8+ T cell subsets in early response to vascular injury in patients with peripheral artery disease in vivo. 2018 , 194, 26-33	4
1626	Let thy food be thy medicine—when possible. 2018 , 836, 102-114	39
1625	The Role of Nutraceuticals in Statin Intolerant Patients. 2018 , 72, 96-118	157
1624	Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1 α in non-ST-elevation myocardial infarction. 2018 , 271, 1-7	13
1623	Ferulic acid may target MyD88-mediated pro-inflammatory signaling - Implications for the health protection afforded by whole grains, anthocyanins, and coffee. 2018 , 118, 114-120	21
1622	The Future of IL-1 Targeting in Kidney Disease. 2018 , 78, 1073-1083	10
1621	Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. 2018 , 122, 1272-1277	13
1620	Atherosclerosis and clonal hematopoiesis: A new risk factor. 2018 , 30, 133-136	2
1619	Predictors of poor clinical outcomes in patients with acute myocardial infarction and non-obstructed coronary arteries (MINOCA). 2018 , 267, 41-45	22

1618	ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. 2018 , 270, 336-342	13
1617	Interleukin-1 inhibition and ischaemic stroke: has the time for a major outcomes trial arrived?. 2018 , 39, 3518-3520	8
1616	Atherosclerosis and inflammation: overview and updates. 2018 , 132, 1243-1252	317
1615	Variability in atherogenic lipoproteins and coronary artery disease progression. 2018 , 39, 2559-2561	3
1614	2016 Jeffrey M. Hoeg Award Lecture. 2018 , 38, 1678-1688	8
1613	Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study. 2018 , 41, 2212-2219	18
1612	Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future. 2018 , 6, 199	29
1611	Amyloid- β (1-40) and Mortality in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study. 2018 , 168, 855-865	15
1610	Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. 2018 , 15, 505-522	802
1609	Low-Density Lipoprotein Cholesterol and Cardiovascular Risk Reduction: How Low Is Low Enough Without Causing Harm?. 2018 , 3, 802-803	1
1608	ASC specks: a biomarker for myelodysplastic syndromes?. 2018 , 5, e379-e380	2
1607	Future biomarkers in cardiology: my favourites. 2018 , 20, G37-G44	17
1606	Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?. 2018 , 20, 2515-2522	62
1605	Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity. 2018 , 98, 1911-1941	153
1604	Glycemic reduction alters white blood cell counts and inflammatory gene expression in diabetes. 2018 , 32, 1027-1034	4
1603	Potential Impact of Oral Inflammations on Cardiac Functions and Atrial Fibrillation. 2018 , 8,	11
1602	Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple. 2018 , 104, 220-224	2
1601	IFN β link between infections and cardiometabolic risk?. 2018 , 14, 567-568	1

1600	Can Anti-inflammatory Therapy Prevent Atrial Fibrillation in Myocardial Infarction Patients?. 2018 , 59, 3-5	2
1599	Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review. 2018 , 9, 55	50
1598	-Mediated Atherosclerosis Signaling and Inflammatory Response as a Common Protection Mechanism of Shuxuening Injection Against Both Myocardial and Cerebral Ischemia-Reperfusion Injuries. 2018 , 9, 312	19
1597	Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications. 2018 , 9, 114	102
1596	Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis. 2018 , 9, 654	41
1595	Physical Activity, Immune System, and the Microbiome in Cardiovascular Disease. 2018 , 9, 763	15
1594	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. 2018 , 20, 145-166	22
1593	Non-coronary predictors of elevated high-sensitive cardiac troponin T (hs-cTnT) levels in an unselected emergency patient cohort. 2018 , 41, 1055-1061	4
1592	Proinflammatory cytokines and ageing of the cardiovascular-renal system. 2018 , 175, 35-45	12
1591	Interleukin-1 β has atheroprotective effects in advanced atherosclerotic lesions of mice. 2018 , 24, 1418-1429	115
1590	Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. 2018 , 114, 1445-1461	45
1589	Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. 2018 , 32, 3717-3729	44
1588	Interleukin 1 receptor (IL-1R1) activation exacerbates toxin-induced acute kidney injury. 2018 , 315, F682-F691	14
1587	Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT. 2018 , 48, 591-601	6
1586	Clonal Hematopoiesis in Aging. 2018 , 4, 209-219	7
1585	Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. 2018 , 276, 98-108	172
1584	The pleiotropic role of interleukin-17 in atherosclerosis. 2018 , 106, 1412-1418	19
1583	Sex Differences in the Coronary System. 2018 , 1065, 257-278	28

1582	C/EBP β Acts Upstream of NF- κ B P65 Subunit in Ox-LDL-Induced IL-1 β Production by Macrophages. 2018 , 48, 1605-1615	12
1581	Chronic obstructive pulmonary disease (COPD) and lung cancer screening. 2018 , 7, 347-360	25
1580	Myeloid-Specific Deletion of Peptidylarginine Deiminase 4 Mitigates Atherosclerosis. 2018 , 9, 1680	48
1579	Goals of gout treatment: a patient perspective. 2018 , 37, 2557-2566	6
1578	High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. 2018 , 204, 151-155	5
1577	Interplay of inflammation, oxidative stress and cardiovascular disease in rheumatoid arthritis. 2018 , 104, 1991-1992	12
1576	High-Sensitivity C-Reactive Protein Is a Predictor of Coronary Microvascular Dysfunction in Patients with Ischemic Heart Disease. 2017 , 4, 81	9
1575	Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis. 2017 , 4, 86	116
1574	Inflammation in Vein Graft Disease. 2018 , 5, 3	53
1573	Long Non-Coding RNAs in Vascular Inflammation. 2018 , 5, 22	15
1572	Insights From Pre-Clinical and Clinical Studies on the Role of Innate Inflammation in Atherosclerosis Regression. 2018 , 5, 32	18
1571	Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond. 2018 , 5, 62	45
1570	K α ppel-Like Factors in Metabolic Homeostasis and Cardiometabolic Disease. 2018 , 5, 69	20
1569	GWAS Reveal Targets in Vessel Wall Pathways to Treat Coronary Artery Disease. 2018 , 5, 72	10
1568	Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease. 2018 , 9, 225	20
1567	A20/Tumor Necrosis Factor β -Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models. 2018 , 9, 104	72
1566	Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. 2018 , 9, 579	102
1565	Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. 2018 , 9, 586	406

1564	IL-19 and Other IL-20 Family Member Cytokines in Vascular Inflammatory Diseases. 2018 , 9, 700	25
1563	Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease. 2018 , 9, 706	87
1562	The Contribution of Autoantibodies to Inflammatory Cardiovascular Pathology. 2018 , 9, 911	27
1561	Potential Immunological Links Between Psoriasis and Cardiovascular Disease. 2018 , 9, 1234	31
1560	Myocarditis: An Interleukin-1-Mediated Disease?. 2018 , 9, 1335	30
1559	Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. 2017 , 4, 262	42
1558	Molecular Regulatory Pathways Link Sepsis With Metabolic Syndrome: Non-coding RNA Elements Underlying the Sepsis/Metabolic Cross-Talk. 2018 , 11, 189	13
1557	Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis. 2018 , 11, e001926	20
1556	Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the 'common soil' hypothesis. 2018 , 17, 87	30
1555	Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. 2018 , 276, 1-9	24
1554	Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study. 2018 , 17, 75	18
1553	Ageing with HIV. 2018 , 6,	13
1552	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. 2018 , 50, 461-484	18
1551	Radionuclide Imaging in Decision-Making for Coronary Revascularization in Stable Ischemic Heart Disease. 2018 , 11, 1	2
1550	Clinical Implications of Clonal Hematopoiesis. 2018 , 93, 1122-1130	55
1549	High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation. 2018 , 293, 13257-13269	38
1548	Looking to the Future: Spotlight on Emerging Biomarkers for Predicting Cardiovascular Risk. 2018 , 5, 230-242	1
1547	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. 2018 , 72, 300-310	39

1546	Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels: Are We Aiming for a Dual Target Concept?. 2018 , 138, 150-153	15
1545	Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. 2017 , 19,	62
1544	Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases. 2018 , 19,	72
1543	Roles of Oral Infections in the Pathomechanism of Atherosclerosis. 2018 , 19,	27
1542	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). 2018 , 10,	19
1541	Double-Strand DNA Sensing Aim2 Inflammasome Regulates Atherosclerotic Plaque Vulnerability. 2018 , 138, 321-323	33
1540	Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. 2018 , 39, 3253-3261	26
1539	Growth Hormone (GH) and Cardiovascular System. 2018 , 19,	35
1538	The Crosstalk between Nrf2 and Inflammasomes. 2018 , 19,	105
1537	Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut?. 2018 , 10,	19
1536	Arrhythmogenic mechanisms of obstructive sleep apnea in heart failure patients. 2018 , 41,	9
1535	Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy. 2018 , 9, 438	50
1534	Coronary Artery Calcium Score: the "Mammogram" of the Heart?. 2018 , 20, 70	6
1533	Inflammasome, T Lymphocytes and Innate-Adaptive Immunity Crosstalk: Role in Cardiovascular Disease and Therapeutic Perspectives. 2018 , 118, 1352-1369	8
1532	Low-Density Lipoprotein-Reactive T Cells Regulate Plasma Cholesterol Levels and Development of Atherosclerosis in Humanized Hypercholesterolemic Mice. 2018 , 138, 2513-2526	32
1531	Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk. 2018 , 20, 77	17
1530	LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. 2018 , 104, 235-238	5
1529	LDL-Cholesterol Is Not the Only Clinically Relevant Biomarker for Coronary Artery Disease or Acute Coronary Syndrome. 2018 , 104, 232-234	5

1528	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. 2018 , 17, 919-925	21
1527	Targeting the NLRP3 inflammasome in inflammatory diseases. 2018 , 17, 588-606	535
1526	The Gut Microbiota in Cardiovascular Diseases: From Biomarkers and Potential Targets to Personalized Interventions. 2018 , 16, 75-85	3
1525	Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data. 2018 , 4, e000712	15
1524	Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein. 2018 , 122, 1366-1370	35
1523	Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. 2018 , 13, 839-844	32
1522	Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. 2018 , 276, 39-43	37
1521	A CRISPR Take on Clonal Hematopoiesis. 2018 , 123, 313-314	1
1520	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. 2018 , 6, 56	36
1519	Regarding minimal clinically relevant differences for superiority margins. 2018 , 23, 80	
1518	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. 2018 , 104, 257-268	8
1517	Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. 2018 , 6, 538-546	84
1516	The art of cardiovascular risk assessment. 2018 , 41, 677-684	16
1515	Endothelial PPAR[α] Is Essential for Preventing Endothelial Dysfunction With Aging. 2018 , 72, 227-234	22
1514	It's reticulated: the liver at the heart of atherosclerosis. 2018 , 238, R1-R11	3
1513	[Do you know your risk of getting a heart attack?]. 2018 , 160, 38-44	
1512	Was ein junges Herz ausmacht und wie wir es lange erhalten können. 2018 , 13, 16-17	
1511	Gut microbial diversity is associated with lower arterial stiffness in women. 2018 , 39, 2390-2397	118

1510	Biologics and Cardiovascular Disease. 2018 , 72, 77-85	9
1509	Inflammation-targeted vascular nanomedicine. 2018 , 2, 269-270	4
1508	Clinical trials. 2018 , 29, 277-278	
1507	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥ 90 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. 2018 , 11, e004652	25
1506	Canakinumab and cardiovascular outcomes: results of the CANTOS trial. 2018 , 8, 21-22	14
1505	Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. 2018 , 114, 1360-1371	74
1504	ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages. 2018 , 138, 1693-1705	81
1503	Dose-dependent INhibitory effect of rosuVastatin In Japanese patientS with Acute myocardial infarCTION on serum concentration of matrix metalloproteinases - INVITATION trial. 2018 , 72, 350-355	2
1502	Linking Heart Failure to Cancer: Background Evidence and Research Perspectives. 2018 , 138, 735-742	51
1501	High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. 2018 , 13, e0201836	39
1500	Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE ^{-/-} mice. 2018 , 13, e0197751	10
1499	Emerging role of the P2X7-NLRP3-IL1 β pathway in mood disorders. 2018 , 98, 95-100	44
1498	Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. 2018 , 123, 1091-1102	66
1497	Inflammatory stress in islet β cells: therapeutic implications for type 2 diabetes?. 2018 , 43, 40-45	16
1496	Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases. 2018 , 114, e81-e83	2
1495	Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. 2018 , 3,	184
1494	Nuclear Receptor Nur77 Limits the Macrophage Inflammatory Response through Transcriptional Reprogramming of Mitochondrial Metabolism. 2018 , 24, 2127-2140.e7	51
1493	Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2018 , 379, 924-933	59.2 471

1492	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). 2018 , 39, 3499-3507	233
1491	CANTOS: a seductive song with several verses. 2018 , 39, 3508-3510	3
1490	Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. 2018 , 19, 1719-1734	98
1489	PPAR δ Deficiency Suppresses the Release of IL-1 β and IL-1 β in Macrophages via a Type 1 IFN-Dependent Mechanism. 2018 , 201, 2054-2069	15
1488	Declining Lung Function and Cardiovascular Risk: The ARIC Study. 2018 , 72, 1109-1122	30
1487	Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. 2018 , 392, 929-939	255
1486	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
1485	Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro. 2018 , 8, 12087	12
1484	A Systemic Inflammatory Signature Reflecting Cross Talk Between Innate and Adaptive Immunity Is Associated With Incident Polyneuropathy: KORA F4/FF4 Study. 2018 , 67, 2434-2442	28
1483	Gazing into smoldering volcanoes: precision cardiac imaging. 2018 , 4, FSO294	
1482	Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study. 2018 , 41, 1004-1008	32
1481	Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries. 2018 , 72, 1015-1026	23
1480	Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease. 2018 , 5, 97	14
1479	Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis. 2018 , 175, 4439-4449	13
1478	Myeloid cell contributions to cardiovascular health and disease. 2018 , 24, 711-720	122
1477	Treatment of Angina: Where Are We?. 2018 , 140, 52-67	22
1476	Innate Immunity in Inflammation. 2018 , 179-190	1
1475	Immune Mechanisms in Atherosclerosis and Potential for Immunomodulatory Therapies. 2018 , 211-224	

1474	Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic Mice. 2018 , 67, 1880-1891	15
1473	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. 2018 , 20, 61	21
1472	Regulation of Immunity and Disease by the IL-1 Receptor Family Members IL-1R2 and IL-1R8. 2018 , 225-246	1
1471	Inflammatory residual risk: An emerging target to reduce cardiovascular disease?. 2018 , 41, 437-439	4
1470	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. 2018 , 277, 195-203	147
1469	Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases. 2018 , 44, 475-487	22
1468	Erratum to: Dr Mary Norine Walsh, President of ACC: As the new President of the American College of Cardiology (ACC), Dr Mary N. Walsh explains how she hopes her election will help advance new opportunities for women in the field. 2018 , 39, 2171	
1467	Validity of inducible ischaemia as a surrogate for adverse outcomes in stable coronary artery disease. 2018 , 104, 1733-1738	6
1466	NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. 2018 , 122, 1722-1740	293
1465	First Giant Steps Toward a Cell Atlas of Atherosclerosis. 2018 , 122, 1632-1634	2
1464	Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. 2018 , 17, 697-708	8
1463	Acute Loss of Apolipoprotein E Triggers an Autoimmune Response That Accelerates Atherosclerosis. 2018 , 38, e145-e158	27
1462	Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. 2018 , 49, 1639-1646	10
1461	Inhibition of interleukin-1 suppresses angiotensin II-induced aortic inflammation and aneurysm formation. 2018 , 270, 221-227	22
1460	Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1 Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis. 2018 , 28, 432-448.e4	41
1459	Prädiktiver und diagnostischer Wert von Biomarkern in der Kardiologie. 2018 , 14, 159-176	1
1458	Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction. 2018 , 123, 579-589	41
1457	Atherosclerotic Coronary Plaque Development Visualized by In Vivo Coronary Imaging. 2018 , 82, 1727-1734	7

1456	Commonly available hematological biomarkers are associated with the extent of coronary calcifications. 2018 , 275, 166-173	3
1455	Chronic oral infection: An emerging risk factor of cerebral small vessel disease. 2019 , 25, 710-719	11
1454	Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. 2019 , 70, 47-55	9
1453	Monocytes as immune targets in arterial hypertension. 2019 , 176, 1966-1977	15
1452	Critical roles of inflammation in atherosclerosis. 2019 , 73, 22-27	129
1451	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. 2019 , 70, 197-209	10
1450	Contributions of innate type 2 inflammation to adipose function. 2019 , 60, 1698-1709	23
1449	Interleukin 6 trans-signalling and risk of future cardiovascular events. 2019 , 115, 213-221	25
1448	Elevated GlycA in severe obesity is normalized by bariatric surgery. 2019 , 21, 178-182	16
1447	Human monocyte transcriptional profiling identifies IL-18 receptor accessory protein and lactoferrin as novel immune targets in hypertension. 2019 , 176, 2015-2027	12
1446	Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment. 2019 , 71, 512-520	5
1445	Inflammasomes: a novel therapeutic target in pulmonary hypertension?. 2019 , 176, 1880-1896	19
1444	Aging- and vascular-related pathologies. 2019 , 26, e12463	14
1443	Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. 2019 , 112, 72-78	18
1442	Utilizing state-of-the-art "omics" technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease. 2019 , 26, e12488	27
1441	Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival. 2019 , 69, 414-422	35
1440	Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy. 2019 , 33, 1482-1495	22
1439	A New Perspective for Chinese Medicine Intervention for Coronary Artery Disease: Targeting Inflammation. 2019 , 25, 3-8	8

1438	Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. 2019 , 193, 50-62	25
1437	Premature coronary artery disease following allogeneic stem cell transplantation: an NHLBI Cohort Study. 2019 , 54, 320-322	
1436	Whole-body magnetic resonance angiography. 2019 , 74, 3-12	3
1435	Editorial Commentary: Oxidized LDL: The next "big thing"?. 2019 , 29, 27-28	
1434	Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention. 2019 , 73, 45-50	7
1433	Age-Related Adverse Inflammatory and Metabolic Changes Begin Early in Adulthood. 2019 , 74, 283-289	12
1432	Inflammatory Biomarkers for Predicting High SYNTAX and SYNTAX II Scores. 2019 , 70, 369-370	
1431	One hits (almost) all. 2019 , 20, 1095-1097	2
1430	IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. 2019 , 20, 1138-1149	30
1429	Un-JAMming atherosclerotic arteries: JAM-L as a target to attenuate plaque development. 2019 , 133, 1581-1585	2
1428	Update on novel pharmacological therapies for osteoarthritis. 2019 , 11, 1759720X19864492	41
1427	Association of aortic vascular uptake of FDG by PET/CT and aortic wall thickness by MRI in psoriasis: a prospective observational study. 2019 , 46, 2488-2495	7
1426	Biomarkers of Cardiovascular Disease. 2019 , 319-330	
1425	Impact of optimized PET imaging conditions on F-FDG uptake quantification in patients with apparently normal aortas. 2021 , 28, 1349-1359	6
1424	Strategies to Overcome Residual Risk During Statins Era. 2019 , 83, 1973-1979	14
1423	Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetes. 2019 , 33, 107413	9
1422	A Traditional Mediterranean Diet Effectively Reduces Inflammation and Improves Cardiovascular Health. 2019 , 11,	21
1421	Renal Effects of Cytokines in Hypertension. 2019 , 1165, 443-454	10

1420	Inflammation and Cardiovascular Diseases: The Most Recent Findings. 2019 , 20,	27
1419	Sarkopene Adipositas und Inflammation. 2019 , 15, 311-317	0
1418	Inflammation als therapeutisches Target. 2019 , 19, 28-33	
1417	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. 2019 , 8, e012428	5
1416	Atherosclerosis. 2019 , 5, 56	657
1415	Macrophage Plasticity and Function in the Eye and Heart. 2019 , 40, 825-841	18
1414	High-Sensitivity C-Reactive Protein in Transcatheter Aortic Valve Implantation: Prognostic Biomarker and New Potential Therapeutic Avenue. 2019 , 3, 321-323	
1413	Low Cellular NAD Compromises Lipopolysaccharide-Induced Inflammatory Responses via Inhibiting TLR4 Signal Transduction in Human Monocytes. 2019 , 203, 1598-1608	16
1412	Potential Interplay between Dietary Saturated Fats and Genetic Variants of the NLRP3 Inflammasome to Modulate Insulin Resistance and Diabetes Risk: Insights from a Meta-Analysis of 19'005 Individuals. 2019 , 63, e1900226	11
1411	Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. 2019 , 14, e0220178	29
1410	Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1 β release. 2019 , 9, 11128	16
1409	Prognostic efficacy of high-sensitivity C-reactive protein to albumin ratio in patients with acute coronary syndrome. 2019 , 13, 811-820	17
1408	Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. 2019 , 4, 885-891	72
1407	The synergistic action of phosphate and interleukin-6 enhances senescence-associated calcification in vascular smooth muscle cells depending on p53. 2019 , 182, 111124	14
1406	Myocardial Infarction-From Atherosclerosis to Thrombosis. 2019 , 39, e176-e185	39
1405	Role of AIM2 inflammasome in inflammatory diseases, cancer and infection. 2019 , 49, 1998-2011	75
1404	Omega-3 Fatty Acids (Prong-1). 2019 , 37-70	
1403	Oxidative Stress Reduction (Prong-3). 2019 , 139-254	

1402	Obesity, risk of diabetes and role of physical activity, exercise training and cardiorespiratory fitness. 2019 , 62, 327-333	60
1401	Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. 2019 , 11,	31
1400	Double bond configuration of palmitoleate is critical for atheroprotection. 2019 , 28, 58-72	10
1399	PCSK9 inhibition and inflammation: A narrative review. 2019 , 288, 146-155	52
1398	The tumor suppressor RASSF1A modulates inflammation and injury in the reperfused murine myocardium. 2019 , 294, 13131-13144	7
1397	Imaging residual inflammatory cardiovascular risk. 2020 , 41, 748-758	40
1396	New Promises and Challenges on Inflammation and Atherosclerosis: Insights From CANTOS and CIRT Trials. 2019 , 6, 90	6
1395	Another Call to Address Inflammation in Heart Failure. 2019 , 74, 477-478	1
1394	Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. 2019 , 39, 1762-1775	13
1393	Dietary Toll-Like Receptor Stimulants Promote Hepatic Inflammation and Impair Reverse Cholesterol Transport in Mice via Macrophage-Dependent Interleukin-1 Production. 2019 , 10, 1404	3
1392	Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms. 2019 , 26, 321-329	13
1391	Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. 2019 , 15, 461-474	45
1390	Endothelial Foxp1 Suppresses Atherosclerosis via Modulation of Nlrp3 Inflammasome Activation. 2019 , 125, 590-605	50
1389	Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. 2019 , 2019, 8563845	191
1388	Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. 2019 , 40, 1080-1091	38
1387	Association between temporal changes in C-reactive protein levels and prognosis in patients with previous myocardial infarction - A report from the CHART-2 Study. 2019 , 293, 17-24	3
1386	Inflammasome inhibition blocks cardiac glycoside cell toxicity. 2019 , 294, 12846-12854	10
1385	Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). 2019 , 124, 696-701	24

1384 Reply: Interleukin-1 α and sST2. **2019**, 74, 479-480

1383 Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. **2019**, 39, 1510-1519 36

1382 Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations. **2019**, 21, 41 6

1381 Inflammation, Immunity, and Oxidative Stress in Hypertension-Partners in Crime?. **2019**, 26, 122-130 33

1380 A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. **2019**, 24, 414-421 13

1379 Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. **2019**, 47, 2775-2782 8

1378 The Triglyceride-Glucose Index Predicts Coronary Artery Disease Severity and Cardiovascular Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. **2019**, 2019, 6891537 51

1377 Changes in store for early-stage non-small cell lung cancer. **2019**, 11, 2117-2125 6

1376 Inflammation as a mediator of arterial ageing. **2019**, 104, 1455-1471 6

1375 Impact of B-Cell-Targeted Therapies on Cardiovascular Disease. **2019**, 39, 1705-1714 16

1374 Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report. **2019**, 39, 1884-1892 7

1373 Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases. **2019**, 10, 1592 58

1372 Atherosclerosis Pathogenesis and Microvascular Dysfunction. **2019**, 2 2

1371 Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD: JACC Review Topic of the Week. **2019**, 74, 578-586 27

1370 The Notch pathway: a novel therapeutic target for cardiovascular diseases?. **2019**, 23, 695-710 13

1369 Eosinopenia as an Adverse Marker of Clinical Outcomes in Patients Presenting with Acute Myocardial Infarction. **2019**, 132, e827-e834 12

1368 Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. **2019**, 2019, 8541402 3

1367 Effect of sarpogrelate and high-dose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study. **2019**, 42, 899-907 4

1366	Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. 2019 , 2019, 7092151	190
1365	Hesperetin and naringenin: Protective effects against metabolic syndrome-associated inflammation. 2019 , 207-239	1
1364	A Pro-Inflammatory Biomarker-Profile Predicts Amputation-Free Survival in Patients with Severe Limb Ischemia. 2019 , 9, 10740	3
1363	Heterogeneity and plasticity in healthy and atherosclerotic vasculature explored by single-cell sequencing. 2019 , 115, 1705-1715	16
1362	Cholesterol-embolization syndrome: current perspectives. 2019 , 15, 209-220	13
1361	Vulnerable Plaque, Characteristics, Detection, and Potential Therapies. 2019 , 6,	31
1360	Inflammation as a Therapeutic Target in Atherosclerosis. 2019 , 8,	79
1359	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. 2019 , 21, 1259-1266	26
1358	PCSK9 and inflammation: a review of experimental and clinical evidence. 2019 , 5, 237-245	46
1357	Inflammasome inhibitors: promising therapeutic approaches against cancer. 2019 , 12, 64	40
1356	Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System. 2019 , 17,	46
1355	Vascular smooth muscle cells in atherosclerosis. 2019 , 16, 727-744	318
1354	Risk stratification of elderly patients with acute pulmonary embolism. 2019 , 49, e13154	2
1353	Current perspectives on the interleukin-1 family as targets for inflammatory disease. 2019 , 49, 1306-1320	18
1352	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. 2019 , 21, 38	
1351	The role of smooth muscle cells in plaque stability: Therapeutic targeting potential. 2019 , 176, 3741-3753	34
1350	Monocytes, Macrophages, and Metabolic Disease in Atherosclerosis. 2019 , 10, 666	44
1349	Periodontitis-induced systemic inflammation exacerbates atherosclerosis partly via endothelial-mesenchymal transition in mice. 2019 , 11, 21	22

1348	Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events. 2019 , 25, 1076029619845056	3
1347	Caspases in Cell Death, Inflammation, and Disease. 2019 , 50, 1352-1364	319
1346	Heterogeneity of Macrophages in Atherosclerosis. 2019 , 119, 1237-1246	4
1345	Platelet-Neutrophil Crosstalk in Atherothrombosis. 2019 , 119, 1274-1282	40
1344	Nuclear Focal Adhesion Kinase. 2019 , 125, 167-169	1
1343	NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. 2019 , 20, 1826-1836	12
1342	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. 2019 , 37, 100587	13
1341	Vascular Consequences of Hyperuricemia and Hypouricemia. 2019 , 45, 453-464	7
1340	The Effects of Anti-IL-23p19 Therapy on Atherosclerosis Development in ApoE Mice. 2019 , 39, 564-571	3
1339	The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. 2019 , 215, 62-69	57
1338	Serum FHR1 binding to necrotic-type cells activates monocyctic inflammasome and marks necrotic sites in vasculopathies. 2019 , 10, 2961	28
1337	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocyctic Tissue Factor. 2019 , 203, 853-863	17
1336	Cholesterol-crystalized coronary atheroma as a potential precursor lesion causing acute coronary syndrome: a case report. 2019 , 3, ytz128	2
1335	Impaired Autophagy in CD11b Dendritic Cells Expands CD4 Regulatory T Cells and Limits Atherosclerosis in Mice. 2019 , 125, 1019-1034	25
1334	Cyclodextrin-Derived Intrinsically Bioactive Nanoparticles for Treatment of Acute and Chronic Inflammatory Diseases. 2019 , 31, e1904607	43
1333	Klonale Hmatopoesis Teil 2. 2019 , 14, 360-372	
1332	Antisense Oligonucleotide Inhibition of MicroRNA-494 Halts Atherosclerotic Plaque Progression and Promotes Plaque Stabilization. 2019 , 18, 638-649	10
1331	A novel therapy for an unusual problem: IL-1 receptor antagonist for recurrent post-transplant pericarditis. 2019 , 33, e13699	2

1330	Ischemia Reperfusion Injury: Mechanisms of Damage/Protection and Novel Strategies for Cardiac Recovery/Regeneration. 2019 , 20,	33
1329	Targeting NLRP3 Inflammasome Activation in Severe Asthma. 2019 , 8,	27
1328	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. 2019 , 74, 1926-1942	19
1327	Iron Deficiency in Acute Decompensated Heart Failure. 2019 , 8,	6
1326	Altered long noncoding RNA profile after intracerebral hemorrhage. 2019 , 6, 2014-2025	10
1325	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. 2019 , 218, 46-56	30
1324	A point-of-care assay for alpha-1-acid glycoprotein as a diagnostic tool for rapid, mobile-based determination of inflammation. 2019 , 1, 41-48	11
1323	Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. 2019 , 17, 197	18
1322	Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. 2019 , 25, 1761-1771	90
1321	Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial. 2019 , 47, 102209	5
1320	Effect of Biologic Therapy on Cardiovascular Risk in Patients With Psoriasis. 2019 , 110, 685-686	
1319	Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation. 2019 , 140, 2089-2107	93
1318	Implications for REDUCE IT in clinical practice. 2019 , 62, 395-400	6
1317	Role of Serum High-Sensitivity C-Reactive Protein as a Predictor of Therapeutic Response to Tadalafil in Patients With Erectile Dysfunction: A Prospective Observational Study. 2019 , 16, 1912-1921	6
1316	The enigma of anti-inflammatory therapy for the management of heart failure. 2020 , 116, 6-8	2
1315	Omega-3 Polyunsaturated Fatty Acids and Stroke Burden. 2019 , 20,	8
1314	Nano-Antagonist Alleviates Inflammation and Allows for MRI of Atherosclerosis. 2019 , 3, 342-355	15
1313	Aortic wall stiffness as a side-effect of anti-cancer medication. 2019 , 17, 791-799	1

1312	Hospital mortality in acute coronary syndrome: adjustment of GRACE score by D-dimer enables a more accurate prediction in a prospective cohort study. 2019 , 19, 252	5
1311	Augmented Brain Infiltration and Activation of Leukocytes After Cerebral Ischemia in Type 2 Diabetic Mice. 2019 , 10, 2392	5
1310	The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. 2019 , 41, 757-766	35
1309	Triptolide inhibits angiogenesis in microvascular endothelial cells through regulation of miR-92a. 2019 , 75, 573-583	9
1308	Fifty years of research on antithrombotic therapy: Achievements and disappointments. 2019 , 70, 1-7	9
1307	The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney. 2019 , 8,	45
1306	Pathophysiology of abdominal aortic aneurysm: biomarkers and novel therapeutic targets. 2019 , 31, 166-177	2
1305	Elevated serum alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality. 2019 , 14, e0223692	10
1304	Prdx4 limits caspase-1 activation and restricts inflammasome-mediated signaling by extracellular vesicles. 2019 , 38, e101266	18
1303	The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. 2019 , 106, 1198-1208	9
1302	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. 2019 , 12, 861-870	8
1301	Immunobiology of Atherosclerosis: A Complex Net of Interactions. 2019 , 20,	44
1300	Role of Insulin Resistance in Vascular Inflammation. 2019 ,	
1299	Au-delà du risque cardiovasculaire : le rôle des lipoprotéines contenant l'apoB athérogènes dans l'étiologie du diabète de type 2. 2019 , 13, 129-139	2
1298	Sea Change for Marine Omega-3s: Randomized Trials Show Fish Oil Reduces Cardiovascular Events. 2019 , 94, 2524-2533	13
1297	[Does sleep preserve blood vessels?]. 2019 , 35, 743-746	
1296	Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure. 2019 , 23, 7505-7516	15
1295	Inflammatory Targets for Preventing Atherothrombotic Events: An Update. 2019 , 25, 3097	

1294	IL-1 β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. 2019 , 8,	13
1293	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. 2019 , 115, 510-518	41
1292	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. 2019 , 39, e1-e9	19
1291	A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease. 2019 , 85, 2878-2885	5
1290	GDF-15 in solid vs non-solid treatment-naïve malignancies. 2019 , 49, e13168	6
1289	Endothelial Response to Pathophysiological Stress. 2019 , 39, e233-e243	36
1288	An Effective Method for Acute Vagus Nerve Stimulation in Experimental Inflammation. 2019 , 13, 877	17
1287	Inflammation in atherosclerosis: A key role for cytokines. 2019 , 122, 154819	7
1286	A new dawn for managing dyslipidemias: The era of rna-based therapies. 2019 , 150, 104413	39
1285	Inflammation in atherosclerotic cardiovascular disease. 2019 , 8,	23
1284	Immune-Mediated Inflammation in Vulnerable Atherosclerotic Plaques. 2019 , 24,	21
1283	Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans. 2019 , 14, e0221477	4
1282	The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis. 2019 , 9,	13
1281	The unprecedented era of aging. 2019 , 39, 15	2
1280	Radionuclide imaging of inflammation in atherosclerotic vascular disease among people living with HIV infection: current practice and future perspective. 2019 , 3, 5	6
1279	An update on pharmacotherapies in diabetic dyslipidemia. 2019 , 62, 334-341	11
1278	Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling. 2019 , 317, H877-H890	22
1277	Transforming endothelial cells in atherosclerosis. 2019 , 1, 856-857	4

1276	Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease. 2019 , 8, e012826	24
1275	Sex Differences in the Association between Inflammation and Ischemic Heart Disease. 2019 , 119, 1471-1480	12
1274	Non-coding RNAs in cardiovascular cell biology and atherosclerosis. 2019 , 115, 1732-1756	60
1273	Epigenetic Regulation of Vascular Smooth Muscle Cells by Histone H3 Lysine 9 Dimethylation Attenuates Target Gene-Induction by Inflammatory Signaling. 2019 , 39, 2289-2302	17
1272	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. 2019 , 40, 3901-3909	25
1271	2018 George Lyman Duff Memorial Lecture: Genetics and Genomics of Coronary Artery Disease: A Decade of Progress. 2019 , 39, 1925-1937	2
1270	A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography. 2019 , 40, 3529-3543	127
1269	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. 2019 , 125, 773-782	47
1268	Gene Therapy for Cardiomyopathies. 2019 ,	1
1267	A Novel Orally Available Delta-5 Desaturase Inhibitor Prevents Atherosclerotic Lesions Accompanied by Changes in Fatty Acid Composition and Eicosanoid Production in Knockout Mice. 2019 , 371, 290-298	3
1266	The Role of Neutrophils and Neutrophil Extracellular Traps in Vascular Damage in Systemic Lupus Erythematosus. 2019 , 8,	20
1265	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 2019 , 290, 140-205	259
1264	FOXP1: A Gatekeeper of Endothelial Cell Inflammation. 2019 , 125, 606-608	4
1263	Immunology of the ageing kidney. 2019 , 15, 625-640	36
1262	Coronary Inflammation by Computed Tomography Pericoronary Fat Attenuation in MINOCA and Tako-Tsubo Syndrome. 2019 , 8, e013235	22
1261	Cell- and Sex-Specific Role of FcR (Fc[Receptor] IIb in Experimental Atherosclerosis. 2019 , 39, 1269-1271	1
1260	Long-term prognostic value of coronary flow reserve in psoriasis patients. 2019 , 289, 57-63	7
1259	Systemic Inflammation Precedes Microalbuminuria in Diabetes. 2019 , 4, 1373-1386	15

1258	Targeting innate immune mediators in type 1 and type 2 diabetes. 2019 , 19, 734-746	117
1257	Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications. 2019 , 40, 3910-3912	10
1256	Interleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases. 2019 , 10, 2014	45
1255	Future Needs in Mast Cell Biology. 2019 , 20,	44
1254	The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. 2019 , 8,	10
1253	The IL-1 family of cytokines and receptors in rheumatic diseases. 2019 , 15, 612-632	142
1252	Electronegative LDL from Rabbits Fed with Atherogenic Diet Is Highly Proinflammatory. 2019 , 2019, 6163130	11
1251	Cardiac imaging and circulating biomarkers for primary prevention in the era of precision medicine. 2019 , 4, 299-308	
1250	Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. 2019 , 140, 1491-1505	57
1249	Relationship of rheumatoid arthritis and coronary artery disease in the Korean population: a nationwide cross-sectional study. 2019 , 59, 40	7
1248	The Impending Epidemic of Cardiovascular Diseases in Patients With Cancer in Japan. 2019 , 83, 2191-2202	5
1247	From Detecting the Vulnerable Plaque to Managing the Vulnerable Patient: JACC State-of-the-Art Review. 2019 , 74, 1582-1593	49
1246	Activation of 5-HT Receptors Reduces Inflammation in Vascular Tissue and Cholesterol Levels in High-Fat Diet-Fed Apolipoprotein E Knockout Mice. 2019 , 9, 13444	16
1245	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. 2019 , 140, 1308-1317	85
1244	Association of T Cell-Derived Inflammatory Cytokines With Acute Kidney Injury and Mortality After Cardiac Surgery. 2019 , 4, 1689-1697	15
1243	Cardiac Computed Tomography: Assessment of Coronary Inflammation and Other Plaque Features. 2019 , 39, 2207-2219	18
1242	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. 2019 , 16, e1002901	57
1241	Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments. 2019 , 20,	136

1240	Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. 2019 , 120, 122-131	36
1239	Association of Anti-Mullerian Hormone with C-Reactive Protein in Men. 2019 , 9, 13081	0
1238	Full blood count as potential predictor of outcomes in patients undergoing cardiac resynchronization therapy. 2019 , 9, 13016	1
1237	Novel risk factors in coronary artery disease: are they clinically relevant?. 2019 , 60, 149-151	6
1236	From Focal Lipid Storage to Systemic Inflammation: JACC Review Topic of the Week. 2019 , 74, 1594-1607	65
1235	MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. 2019 , 17, e3000354	50
1234	Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products. 2019 , 71, 596-670	63
1233	Looking back and thinking forwards - 15 years of cardiology and cardiovascular research. 2019 , 16, 651-660	7
1232	Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications. 2019 , 40, 3421-3433	70
1231	Cholesterol versus Inflammation as Cause of Chronic Diseases. 2019 , 11,	7
1230	A Novel Anti-Inflammatory Role of Omega-3 PUFAs in Prevention and Treatment of Atherosclerosis and Vascular Cognitive Impairment and Dementia. 2019 , 11,	47
1229	A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. 2019 , 4, 23	45
1228	Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study. 2019 , 9, e028649	20
1227	Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques. 2019 , 39, e253-e272	52
1226	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. 2019 , 39, 2402-2410	18
1225	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. 2019 , 217, 72-83	27
1224	Forced expression of microRNA-146b reduces TRAF6-dependent inflammation and improves ischemia-induced neovascularization in hypercholesterolemic conditions. 2019 , 289, 73-84	14
1223	Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide. 2019 , 297, 111-117	11

1222	Using High-Dimensional Approaches to Probe Monocytes and Macrophages in Cardiovascular Disease. 2019 , 10, 2146	13
1221	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. 2019 , 285, 1-5	9
1220	Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes. 2019 , 286, 7-12	10
1219	Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders. 2019 , 52, 334-339	11
1218	NLRP1 inhibiting pathway to be explored in anti-atherosclerosis treatment approach. 2019 , 278, 265	1
1217	Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. 2019 , 281, 35-39	36
1216	Autophagy and cardiac aging. 2019 , 26, 653-664	29
1215	Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation. 2019 , 105, 377-399	45
1214	[Acute coronary syndrome : Prevention]. 2019 , 44, 45-52	
1213	Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. 2019 , 40, 2482-2491	62
1212	Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation. 2019 , 33, 1536-1539	37
1211	Editorial: Update in myeloid biology. 2019 , 26, 1-5	
1210	Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. 2019 , 124, 437-450	104
1209	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. 2019 , 124, 416-425	22
1208	Cholesterol-Lowering Agents. 2019 , 124, 364-385	25
1207	Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. 2019 , 8, 29-41	5
1206	The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. 2019 , 670, 82-93	29
1205	Inflammation, infection and atherosclerosis. 2019 , 29, 468-472	49

1204	Should inflammatory pathways be targeted for the prevention and treatment of hypertension?. 2019 , 105, 665-667	5
1203	Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart. 2019 , 124, 881-890	45
1202	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. 2019 , 133, 1039-1048	90
1201	PCSK9 inhibition 2018: riding a new wave of coronary prevention. 2019 , 133, 205-224	7
1200	Cell Type-Specific Roles of NF- κ B Linking Inflammation and Thrombosis. 2019 , 10, 85	197
1199	Blocking the IL-1 β signalling pathway prevents chronic viral myocarditis and cardiac remodeling. 2019 , 114, 11	50
1198	Serum protein signature of coronary artery disease in type 2 diabetes mellitus. 2019 , 17, 17	19
1197	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. 2019 , 132, e569-e580	11
1196	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. 2019 , 21, 272-285	99
1195	Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. 2019 , 137, 599-617	129
1194	The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. 2019 , 282, 91-99	15
1193	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. 2019 , 25, 328-340	23
1192	Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. 2019 , 115, 721-728	112
1191	C-Reactive Protein and Chronic Inflammation - Is It a Novel Therapeutic Target for Subsequent Cancer Death in Patients With Coronary Artery Disease?. 2019 , 83, 513-514	
1190	Mechanisms of Cardiovascular Disease in the Setting of HIV Infection. 2019 , 35, 238-248	23
1189	Sex Differences in Coronary Artery and Thoracic Aorta Calcification and Their Association With Cardiovascular Mortality in Heavy Smokers. 2019 , 12, 1808-1817	8
1188	Long noncoding RNA regulates endothelial cell activities associated with coronary artery disease by up-regulating , , and genes. 2019 , 294, 3881-3898	27
1187	1,2,3,4,6-Penta-O-galloyl- β -D-glucose modulates perivascular inflammation and prevents vascular dysfunction in angiotensin II-induced hypertension. 2019 , 176, 1951-1965	13

1186	Obesity paradox in cardiovascular disease: where do we stand?. 2019 , 15, 89-100	126
1185	Nobiletin Prevents Trimethylamine Oxide-Induced Vascular Inflammation via Inhibition of the NF- κ B/MAPK Pathways. 2019 , 67, 6169-6176	27
1184	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. 2019 , 124, 1618-1632	21
1183	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. 2019 , 21, 1169-1186	325
1182	IL-7R blockade reduces post-myocardial infarction-induced atherosclerotic plaque inflammation in ApoE mice. 2019 , 19, 100647	3
1181	Activation of Interleukin-1 Beta in Arterialized Vein Grafts and the Influence of the -511C/T IL-1 β Gene Polymorphism. 2019 , 6,	1
1180	Trimetazidine in cardiovascular medicine. 2019 , 293, 39-44	28
1179	A transcriptomic model to predict increase in fibrous cap thickness in response to high-dose statin treatment: Validation by serial intracoronary OCT imaging. 2019 , 44, 41-49	6
1178	Nuclear Imaging: Focus on Vascular Probes. 2019 , 39, 1369-1378	6
1177	Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases. 2019 , 9,	12
1176	G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis. 2019 , 10, 531	8
1175	Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. 2019 , 20, 802-811	93
1174	Metabolic adaptations of tissue-resident immune cells. 2019 , 20, 793-801	58
1173	Could cyanogenic glycoside rich diet cause increased risk for carbamylation-induced protein damage in individuals with chronic inflammatory diseases?. 2019 , 130, 109275	3
1172	Cohort Study of Repeated Measurements of Serum Urate and Risk of Incident Atrial Fibrillation. 2019 , 8, e012020	23
1171	Smad3 Cranks Up the Appetite of Infarct Macrophages. 2019 , 125, 71-73	1
1170	Systemic Immunologic Consequences of Chronic Periodontitis. 2019 , 98, 985-993	18
1169	Impacts of unfavourable lifestyle factors on biomarkers of liver function, inflammation and lipid status. 2019 , 14, e0218463	7

1168	Chondroprotective Factors in Osteoarthritis: a Joint Affair. 2019 , 21, 41	9
1167	TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients. 2019 , 95, 372-377	0
1166	Type 2 Diabetes: How Much of an Autoimmune Disease?. 2019 , 10, 451	42
1165	Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. 2019 , 115, 1385-1392	40
1164	The gut microbiome: a novel cardio-metabolic target?. 2019 , 115, e82-e84	1
1163	Imaging for screening cardiovascular involvement in patients with systemic rheumatologic diseases: more questions than answers. 2019 , 20, 967-978	3
1162	Inflammasome-Driven Interleukin-1 α and Interleukin-1 β Production in Atherosclerotic Plaques Relates to Hyperlipidemia and Plaque Complexity. 2019 , 4, 304-317	13
1161	The role of sodium in modulating immune cell function. 2019 , 15, 546-558	33
1160	O-GlcNAcylation in immunity and inflammation: An intricate system (Review). 2019 , 44, 363-374	24
1159	Long Non-coding RNAs in Vascular Health and Disease. 2019 , 151-179	
1158	Betalain- and betacyanin-rich supplements impacts on the PBMC SIRT1 and LOX1 genes expression and Sirtuin-1 protein levels in coronary artery disease patients: A pilot crossover clinical trial. 2019 , 60, 103401	19
1157	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. 2019 , 42, 1783-1793	5
1156	Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology. 2019 , 5, 106-111	17
1155	Inflammation and type 2 diabetes: from basic science to treatment. 2019 , 41, 411-412	4
1154	Stress-Associated Neurobiological Pathway Linking Socioeconomic Disparities to Cardiovascular Disease. 2019 , 73, 3243-3255	55
1153	Interferon- γ regulates cardiac myeloid cells in myocardial infarction. 2019 , 115, 1815-1816	5
1152	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. 2019 , 18, 71	64
1151	Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease. 2019 , 82, 101-105	2

1150	MARK4 (Microtubule Affinity-Regulating Kinase 4)-Dependent Inflammasome Activation Promotes Atherosclerosis-Brief Report. 2019 , 39, 1645-1651	9
1149	Carotid Plaque Inflammation Imaged by F-Fluorodeoxyglucose Positron Emission Tomography and Risk of Early Recurrent Stroke. 2019 , 50, 1766-1773	40
1148	ST-segment elevation myocardial infarction. 2019 , 5, 39	78
1147	The role of inflammation in diabetic eye disease. 2019 , 41, 427-445	49
1146	Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation. 2019 , 34, 1993-2001	2
1145	NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes. 2019 , 16, 121	60
1144	HIV infection and coronary heart disease: mechanisms and management. 2019 , 16, 745-759	44
1143	Leducq Epigenetics of Atherosclerosis Network. 2019 , 124, 1697-1700	2
1142	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. 2019 , 42, 1504-1511	8
1141	Molecular Imaging in Ischemic Heart Disease. 2019 , 12, 31	2
1140	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. 2019 , 292, 171-179	23
1139	Immune Responses in Context. 2019 , 139, 2567-2569	0
1138	Immunometabolism around the Clock. 2019 , 25, 612-625	22
1137	The role of inflammation in the association between overall and visceral adiposity and subclinical atherosclerosis. 2019 , 29, 728-735	12
1136	Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?. 2019 , 41, 447-459	19
1135	hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study. 2019 , 8, e012638	35
1134	Assessing the performance of monocyte to high-density lipoprotein ratio for predicting ischemic stroke: insights from a population-based Chinese cohort. 2019 , 18, 127	22
1133	Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?. 2019 , 11, S28-S39	

1132	Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects. 2019 , 120, 106565	28
1131	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. 2019 , 73, 2791-2802	152
1130	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. 2019 , 140, e98-e124	176
1129	B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells. 2020 , 116, 295-305	7
1128	Clinical determinants of plasma cardiac biomarkers in patients with stable chest pain. 2019 , 105, 1748-1754	2
1127	The role of inflammasomes in kidney disease. 2019 , 15, 501-520	99
1126	Molecular Biology of Long Non-coding RNAs. 2019 ,	1
1125	Nanoparticle Imaging of Vascular Inflammation and Remodeling in Atherosclerotic Disease. 2019 , 12, 1	4
1124	Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. 2019 , 24, 100370	19
1123	Cell death-mediated cytokine release and its therapeutic implications. 2019 , 216, 1474-1486	29
1122	Editorial: Novel and potential markers for prediction of outcome in patients with acute and chronic coronary heart disease. 2019 , 6, 66	
1121	Frontline Science: Acyl-CoA synthetase 1 exacerbates lipotoxic inflammasome activation in primary macrophages. 2019 , 106, 803-814	12
1120	Novel Insights Into the NLRP 3 Inflammasome in Atherosclerosis. 2019 , 8, e012219	50
1119	The role of interleukin-1 in general pathology. 2019 , 39, 12	127
1118	Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications. 2019 , 15, 1345-1357	103
1117	Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study. 2019 , 45, 957-967	6
1116	Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. 2019 , 30, 1-2	78
1115	Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. 2019 , 18, 79	16

1114	Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus. 2019 , 11, 419-428	9
1113	Interleukin-1 β inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes. 2019 , 10, 1223	28
1112	Smooth muscle cells-derived CXCL10 prevents endothelial healing through PI3K-dependent T cells response. 2020 , 116, 438-449	15
1111	Targeting interleukin-1: implications for long-term cardiovascular management following radiotherapy. 2019 , 40, 2504-2506	0
1110	Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?. 2019 , 10, 817	6
1109	Aldosterone induces trained immunity: the role of fatty acid synthesis. 2020 , 116, 317-328	28
1108	Immunotherapy for cardiovascular disease. 2019 , 40, 3937-3946	61
1107	Management of Myocarditis-Related Cardiomyopathy in Adults. 2019 , 124, 1568-1583	96
1106	IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD. 2019 , 14, 702-711	13
1105	Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials. 2019 , 36, 1549-1573	3
1104	Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. 2019 , 1, 30-43	100
1103	Therapeutic options for targeting inflammatory osteoarthritis pain. 2019 , 15, 355-363	97
1102	The Link between Hematopoiesis and Atherosclerosis. <i>New England Journal of Medicine</i> , 2019 , 380, 1869-1871	9
1101	Cardiovascular Research at the American College of Cardiology Scientific Sessions 2019: the meeting's highlights. 2019 , 115, e66-e68	0
1100	SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease. 2019 , 24, 422-427	5
1099	Effects of dietary intervention and n-3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population. 2019 , 286, 53-59	5
1098	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. 2019 , 62, 758-770	5
1097	The emerging roles of inflammasome-dependent cytokines in cancer development. 2019 , 20,	43

1096	Notch Signaling Regulates Immune Responses in Atherosclerosis. 2019 , 10, 1130	40
1095	Role of Macrophages in Cardioprotection. 2019 , 20,	27
1094	Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. 2019 , 34, 1961-1968	23
1093	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. 2019 , 1, 100002	2
1092	NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy. 2019 , 73, 146-155	33
1091	Vascular biomedicine in an era of chronic disease and multimorbidity. 2019 , 133, 1137-1143	4
1090	Atherosclerosis. 2019 , 195-233	1
1089	Heart Inflammation: Immune Cell Roles and Roads to the Heart. 2019 , 189, 1482-1494	30
1088	Pentraxin 3 in Cardiovascular Disease. 2019 , 10, 823	50
1087	Perspectives on Small Animal Radionuclide Imaging; Considerations and Advances in Atherosclerosis. 2019 , 6, 39	10
1086	Cardiovascular disease in kidney transplant recipients: leave no stone unturned. 2019 , 34, 727-730	1
1085	Adaptive immune cells in calcific aortic valve disease. 2019 , 317, H141-H155	26
1084	Human Inflammaging. 2019 , 65, 495-504	70
1083	Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. 2019 , 40, 2495-2503	26
1082	Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. 2019 , 20,	30
1081	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. 2019 , 21, 965-973	81
1080	C-Reactive Protein Levels and the Risk of Incident Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep Apnea. 2019 , 197, 459-464	7
1079	Postnatal inflammation following intrauterine inflammation exacerbates the development of atherosclerosis in ApoE mice. 2019 , 133, 1185-1196	3

1078	Regulation of lipoprotein-associated phospholipase A2 silencing on myocardial fibrosis in mice with coronary atherosclerosis. 2019 , 514, 450-455	4
1077	The Role of Inflammation in HIV-Associated Atherosclerosis-One Size May Not Fit All. 2020 , 221, 495-497	5
1076	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. 2019 , 73, 2401-2409	25
1075	Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular Events. 2019 , 73, 2410-2412	5
1074	Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease. 2019 , 72, 760-766	2
1073	Immunometabolism orchestrates training of innate immunity in atherosclerosis. 2019 , 115, 1416-1424	28
1072	Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals. 2020 , 221, 506-509	6
1071	Immunometabolic function of cholesterol in cardiovascular disease and beyond. 2019 , 115, 1393-1407	30
1070	Baseline hs-CRP predicts hypertension remission in metabolic syndrome. 2019 , 49, e13128	9
1069	Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. 2019 , 78, 1048-1054	69
1068	Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease. 2019 , 39, 1275-1287	17
1067	Evaluation and Management of the Vulnerable Plaque. 2019 , 13, 1	1
1066	Dietary Inflammatory Index Is Associated with Risk of All-Cause and Cardiovascular Disease Mortality but Not with Cancer Mortality in Middle-Aged and Older Japanese Adults. 2019 , 149, 1451-1459	14
1065	An updated review of lipid-modifying therapy. 2019 , 211, 87-92	6
1064	Interleukin-1 β Induces Intracellular Serum Amyloid A1 Expression in Human Coronary Artery Endothelial Cells and Promotes its Intercellular Exchange. 2019 , 42, 1413-1425	3
1063	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. 2019 , 73, 2049-2058	12
1062	CuCoS nanocrystals as a nanoplatform for photothermal therapy of arterial inflammation. 2019 , 11, 9733-9742	22
1061	Elevated -GlcNAcylation enhances pro-inflammatory Th17 function by altering the intracellular lipid microenvironment. 2019 , 294, 8973-8990	20

1060	Bariatric surgery as a model to explore the basis and consequences of the Reaven hypothesis: Small, dense low-density lipoprotein and interleukin-6. 2019 , 16, 144-152	8
1059	Inflammasomes in neuroinflammatory and neurodegenerative diseases. 2019 , 11,	230
1058	The Cytokines of Asthma. 2019 , 50, 975-991	340
1057	Sirt6-induced autophagy restricted TREM-1-mediated pyroptosis in ox-LDL-treated endothelial cells: relevance to prognostication of patients with acute myocardial infarction. 2019 , 5, 88	24
1056	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. 2019 , 12, e002470	13
1055	Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. 2019 , 21 Suppl 1, 52-62	10
1054	Residual cardiovascular risk among people with diabetes. 2019 , 21 Suppl 1, 28-38	25
1053	Liquid Biopsy of Extracellular Microvesicles Predicts Future Major Ischemic Events in Genetically Characterized Familial Hypercholesterolemia Patients. 2019 , 39, 1172-1181	19
1052	Cardiovascular Risk in Type 1 Diabetes Mellitus. 2019 , 10, 773-789	48
1051	A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. 2019 , 25, 805-813	136
1050	The Two-way Relationship Between Cancer and Atherosclerosis. 2019 , 72, 487-494	5
1049	Group IIA Secretory Phospholipase A, Vascular Inflammation, and Incident Cardiovascular Disease. 2019 , 39, 1182-1190	12
1048	Galectin 3 and Galectin 3 Binding Protein Improve the Risk Stratification after Myocardial Infarction. 2019 , 8,	5
1047	Rheumatoid arthritis (RA) and cardiovascular disease. 2019 , 18, 679-690	42
1046	Photoacoustic imaging for guidance of interventions in cardiovascular medicine. 2019 , 64, 16TR01	12
1045	Methotrexate in Our Hearts. 2019 , 46, 447-449	0
1044	Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. 2019 , 290, 106-112	9
1043	Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. 2019 , 11, 601-604	1

1042	Mechanistic Links between Non-Coding RNAs and Myeloid Cell Inflammation in Atherosclerosis. 2019 , 119, 1205-1211	1
1041	GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. 2019 , 70, 737-746	13
1040	Statin-associated muscle symptoms in coronary patients: design of a randomized study. 2019 , 53, 162-168	4
1039	Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous coronary intervention with drug-eluting stents. 2019 , 14, e0216297	1
1038	Immunometabolism of Phagocytes and Relationships to Cardiac Repair. 2019 , 6, 42	14
1037	Inflammatory diet and preclinical cardiovascular phenotypes in 11-12 year-olds and mid-life adults: A cross-sectional population-based study. 2019 , 285, 93-101	8
1036	Immune mechanisms of hypertension. 2019 , 19, 517-532	146
1035	Inflammation and Its Role in Regeneration and Repair. 2019 , 124, 1166-1168	40
1034	Islet inflammation in type 2 diabetes. 2019 , 41, 501-513	64
1033	Cytokine Circuits in Cardiovascular Disease. 2019 , 50, 941-954	73
1032	Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. 2019 , 50, 778-795	307
1031	Macrophage Death as a Pharmacological Target in Atherosclerosis. 2019 , 10, 306	69
1030	The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. 2019 , 286, 1-6	18
1029	Treatment of atherosclerotic plaque: perspectives on theranostics. 2019 , 71, 1029-1043	38
1028	Psychosocial Stress and Cardiovascular Disease. 2019 , 21, 23	41
1027	Neuroimmune crosstalk in the pathophysiology of hypertension. 2019 , 16, 476-490	34
1026	Immunotherapy for Atherosclerosis- Novel Concepts. 2019 , 119, 515-516	2
1025	The Association between Chronic Obstructive Pulmonary Disease and Coronary Artery Disease in Patients Undergoing Coronary Angiography. 2019 , 16, 66-71	3

1024	Germinal Center-Derived Antibodies Promote Atherosclerosis Plaque Size and Stability. 2019 , 139, 2466-2482	28
1023	Identification of Residues Critical for FPR2 Activation by the Cryptic Peptide Mitocryptide-2 Originating from the Mitochondrial DNA-Encoded Cytochrome. 2019 , 202, 2710-2719	6
1022	Fibrosis Inflammation of the Cardiovascular System. 2019 , 321-338	
1021	Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI. 2019 , 73, 1371-1382	70
1020	Arterial Inflammation: The Heat Before the Storm. 2019 , 73, 1383-1385	7
1019	IL-10-specific autoantibodies predict major adverse cardiovascular events in kidney transplanted patients - a retrospective cohort study. 2019 , 32, 933-948	4
1018	Cardiovascular inflammation: RNA takes the lead. 2019 , 129, 247-256	12
1017	Circulating Markers of Inflammation Persist in Children and Adults With Giant Aneurysms After Kawasaki Disease. 2019 , 12, e002433	11
1016	Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. 2019 , 14, e0214150	17
1015	Statins: Rationale, Mode of Action, and Side Effects. 2019 , 171-200	3
1014	Cardiovascular Risk: Assumptions, Limitations, and Research. 2019 , 201-266	
1013	Chronic Low-grade Inflammatory Phenotype (CLIP) and Senescent Immune Dysregulation. 2019 , 41, 400-409	38
1012	Colchicine for Stroke Prevention: A Systematic Review and Meta-analysis. 2019 , 41, 582-590.e3	23
1011	Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy?. 2019 , 125, 139-143	5
1010	Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing After Myocardial Infarction in Mice. 2019 , 124, 1323-1336	46
1009	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. 2019 , 4, 314-320	44
1008	Inflammation and Cardiovascular Diseases. 2019 , 53-117	0
1007	A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. 2019 , 25, 487-495	162

1006	Topical applications of an emollient reduce circulating pro-inflammatory cytokine levels in chronically aged humans: a pilot clinical study. 2019 , 33, 2197-2201	24
1005	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. 2019 , 11,	7
1004	Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. 2019 , 14, 33-38	10
1003	Immunoprofiling comes of age. 2019 , 25, 362-364	2
1002	Crosstalk between macrophage and T cell in atherosclerosis: Potential therapeutic targets for cardiovascular diseases. 2019 , 202, 11-17	4
1001	[Microbiome, diabetes and heart: a novel link?]. 2019 , 44, 223-230	3
1000	Novel Antiatherosclerotic Therapies. 2019 , 39, 538-545	58
999	Human Papillomavirus Infection. 2019 , 124, 677-678	
998	Inflammation in coronary artery disease: Which biomarker and which treatment?. 2019 , 26, 869-871	8
997	Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach. 2019 , 14, e0213025	7
996	Green Coffee Extract Improves Cardiometabolic Parameters and Modulates Gut Microbiota in High-Fat-Diet-Fed ApoE Mice. 2019 , 11,	24
995	Cholesterol and Inflammation in Stroke Recurrence. 2019 , 26, 406-407	1
994	Targeting Mechanosensitive Transcription Factors in Atherosclerosis. 2019 , 40, 253-266	66
993	Atherogenic index of plasma is related to arterial stiffness but not to blood pressure in normotensive and never-treated hypertensive subjects. 2019 , 28, 157-167	19
992	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. 2019 , 73, 1016-1025	35
991	Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology. 2019 , 115, 824-829	49
990	Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype?. 2019 , 10, 205	8
989	Coronary Vessel Wall Imaging: State of the Art and Future Directions. 2019 , 12, 1	4

988	Genetics of Common, Complex Coronary Artery Disease. 2019 , 177, 132-145	84
987	Precarious Symbiosis Between Host and Microbiome in Cardiovascular Health. 2019 , 73, 926-935	8
986	Synthesis and Biological Evaluation of Fangchinoline Derivatives as Anti-Inflammatory Agents through Inactivation of Inflammasome. 2019 , 24,	7
985	Inflammation during acute coronary syndromes - Risk of cardiovascular events and bleeding. 2019 , 287, 13-18	12
984	The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: immune homeostatic mechanisms in the artery wall. 2019 , 115, 1408-1415	13
983	[Immunity and inflammation in atherosclerosis]. 2019 , 44, 107-120	8
982	Bioactive Materials Facilitating Targeted Local Modulation of Inflammation. 2019 , 4, 56-71	20
981	Intercepting the Lipid-Induced Integrated Stress Response Reduces Atherosclerosis. 2019 , 73, 1149-1169	30
980	Integrated Stress Response Inhibition in Atherosclerosis: Preventing the Stressed-Out Plaque. 2019 , 73, 1170-1172	4
979	Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability: An In Vivo Optical Coherence Tomography Study. 2019 , 4, 321-329	55
978	Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. 2019 , 108, 1093-1101	25
977	Human Genetics and Drug Development. <i>New England Journal of Medicine</i> , 2019 , 380, 1076-1079	59.2 16
976	Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study. 2019 , 6, ofz112	20
975	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review. 2019 , 4, 380-387	24
974	Most Promising Therapies in Interventional Cardiology. 2019 , 21, 26	3
973	The Role of Platelets in Inflammation. 2019 , 505-522	4
972	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. 2019 , 212, 1-12	21
971	Short term Pm2.5 exposure caused a robust lung inflammation, vascular remodeling, and exacerbated transition from left ventricular failure to right ventricular hypertrophy. 2019 , 22, 101161	66

970	Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. 2019 , 16, 389-406	379
969	Metabolically Healthy Obesity Is Characterized by a Proinflammatory Phenotype of Circulating Monocyte Subsets. 2019 , 17, 259-265	13
968	Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. 2019 , 79, 531-541	24
967	Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. 2019 , 21, 1642-1651	20
966	Update on heart failure management and future directions. 2019 , 34, 11-43	48
965	Bicuspid aortic valve, atherosclerosis and changes of lipid metabolism: Are there pathological molecular links?. 2019 , 129, 231-235	8
964	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. 2019 , 6, 16	60
963	The Role of Platelets in Atherothrombosis. 2019 , 459-467	4
962	[Atherosclerosis as an Inflammatory Disease - Pathophysiology, Clinical Relevance and Therapeutic Implications]. 2019 , 144, 315-321	7
961	Three in a Box: Understanding Cardiomyocyte, Fibroblast, and Innate Immune Cell Interactions to Orchestrate Cardiac Repair Processes. 2019 , 6, 32	19
960	Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study. 2019 , 284, 202-208	6
959	Modulating Adaptive Immunity in Vascular Disease: CD4 to the Fore. 2019 , 73, 1824-1826	1
958	Inflammation Is Strongly Associated With Cardiorespiratory Fitness, Sex, BMI, and the Metabolic Syndrome in a Self-reported Healthy Population: HUNT3 Fitness Study. 2019 , 94, 803-810	13
957	Interaction between inflammation, mineral metabolism and the renin-angiotensin system: implications for cardiorenal outcomes in chronic kidney disease. 2019 , 34, 547-551	2
956	Managing Clonal Hematopoiesis in Patients With Solid Tumors. 2019 , 37, 7-11	33
955	Therapeutic targeting of trained immunity. 2019 , 18, 553-566	169
954	The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. 2019 , 2019, 7434376	45
953	Extent of Ischemic Brain Injury After Thrombotic Stroke Is Independent of the NLRP3 (NACHT, LRR and PYD Domains-Containing Protein 3) Inflammasome. 2019 , 50, 1232-1239	27

952	Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia. 2019 , 56, 899-906	7
951	Direct CD137 costimulation of CD8 T cells promotes retention and innate-like function within nascent atherogenic foci. 2019 , 316, H1480-H1494	6
950	TAM receptors in cardiovascular disease. 2019 , 115, 1286-1295	21
949	Choline Uptake and Metabolism Modulate Macrophage IL-1 β and IL-18 Production. 2019 , 29, 1350-1362.e7	74
948	Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art. 2019 , 24, 1116-1131	11
947	Novel findings in neutrophil biology and their impact on cardiovascular disease. 2019 , 115, 1266-1285	67
946	Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients. 2019 , 115, 1886-1906	51
945	'Precision medicine' and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory). 2019 , 21, B73-B75	0
944	Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation. 2019 , 316, H1354-H1365	4
943	Vaccination against atherosclerosis. 2019 , 59, 15-24	21
942	Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. 2019 , 30, 286-298	25
941	When, where, and how to target vascular inflammation in the post-CANTOS era?. 2019 , 40, 2492-2494	9
940	Selective C-Reactive Protein-Apheresis in Patients. 2019 , 23, 570-574	19
939	Role of NLRP3 Inflammasome in Cardiac Inflammation and Remodeling after Myocardial Infarction. 2019 , 42, 518-523	35
938	Mouse Models for Atherosclerosis Research-Which Is My Line?. 2019 , 6, 46	58
937	Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications. 2019 , 58, 828-838	11
936	[Immunization as Treatment for arteriosclerosis-a realistic vision?]. 2019 , 44, 93-95	
935	State-of-the-art review article. Atherosclerosis affecting fat: What can we learn by imaging perivascular adipose tissue?. 2019 , 13, 288-296	33

934	Editorial commentary: Arson in the artery: Who set the atheroma aflame?. 2019 , 29, 473-475	1
933	Impaired Retinal Vessel Dilation Predicts Mortality in End-Stage Renal Disease. 2019 ,	23
932	Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories. 2019 , 14, e0214784	1
931	NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. 2019 , 20,	71
930	Sulindac-derived retinoid X receptor- β modulator attenuates atherosclerotic plaque progression and destabilization in ApoE mice. 2019 , 176, 2559-2572	12
929	Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. 2019 , 18, 559-572	129
928	Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFer-RITU2: study protocol. 2019 , 9, e022826	8
927	Inflammatory biomarkers and subclinical carotid atherosclerosis in HIV-infected and HIV-uninfected men in the Multicenter AIDS Cohort Study. 2019 , 14, e0214735	26
926	Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review. 2019 , 73, 1691-1706	74
925	The complex interplay between fitness, genetics, lifestyle, and inflammation in the pathogenesis of coronary atherosclerosis: lessons from the Amazon rainforest. 2019 , 21, B76-B79	1
924	DNA Damage and Senescence-Associated Inflammation in Cardiovascular Disease. 2019 , 42, 531-537	12
923	A sequential interferon gamma directed chemotactic cellular immune response determines survival and cardiac function post-myocardial infarction. 2019 , 115, 1907-1917	9
922	The polarity protein Scrib limits atherosclerosis development in mice. 2019 , 115, 1963-1974	5
921	Cardiovascular Disease and Cancer: Is There Increasing Overlap?. 2019 , 21, 47	20
920	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. 2019 , 36, 493-510	6
919	Nanoparticle Therapy for Vascular Diseases. 2019 , 39, 635-646	55
918	Evidence-Based Cardiovascular Risk Management in Diabetes. 2019 , 19, 439-448	5
917	Noninvasive Precursors of Coronary Chronic Total Occlusions: Fantasy or Reality?. 2019 , 12, 2207-2209	2

916	Lipid core nanoparticles as vehicle for docetaxel reduces atherosclerotic lesion, inflammation, cell death and proliferation in an atherosclerosis rabbit model. 2019 , 115, 46-54	19
915	Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe: Results From the BiomarcARE Consortium. 2019 , 7, 204-213	30
914	Assessing inflammation and its role in comorbidities among persons living with HIV. 2019 , 32, 8-15	18
913	Full Issue PDF. 2019 , 4, I-CXLII	
912	Laboratory test based assessment of WHO alcohol risk drinking levels. 2019 , 79, 58-64	7
911	Current pharmacotherapies for atherosclerotic cardiovascular diseases. 2019 , 42, 206-223	6
910	Therapeutic Targeting of Neutrophil Extracellular Traps in Atherogenic Inflammation. 2019 , 119, 542-552	25
909	High-Risk Human Papillomavirus Infection and the Risk of Cardiovascular Disease in Korean Women. 2019 , 124, 747-756	11
908	Critical inflammatory mechanisms underlying arrhythmias. 2019 , 44, 121-129	12
907	La relación bidireccional entre el cñcer y la aterosclerosis. 2019 , 72, 487-494	8
906	Chemokines as Therapeutic Targets in Cardiovascular Disease. 2019 , 39, 583-592	44
905	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. 2019 , 39, 787-798	33
904	Leducq Transatlantic Network on Clonal Hematopoiesis and Atherosclerosis. 2019 , 124, 481-483	2
903	Shift Work Including Night Work and Long Working Hours in Industrial Plants Increases the Risk of Atherosclerosis. 2019 , 16,	19
902	A Control-Theoretic Model of Atherosclerosis. 2019 , 20,	7
901	Autoinflammation: Past, Present, and Future. 2019 , 3-15	1
900	Interleukin-1 Mediated Autoinflammation from Heart Disease to Cancer. 2019 , 711-725	1
899	Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases. 2019 , 751-774	

898	Stress-induced mast cell activation contributes to atherosclerotic plaque destabilization. 2019 , 9, 2134	11
897	Mechanisms of Trained Innate Immunity in oxLDL Primed Human Coronary Smooth Muscle Cells. 2019 , 10, 13	32
896	Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. 2019 , 10, 55	137
895	Cardiovascular prevention starts from your mouth. 2019 , 40, 1146-1148	3
894	Serum IL8 is not associated with cardiovascular events but with all-cause mortality. 2019 , 19, 34	9
893	Editorial commentary: The pleiotropic effect of statins on the atherosclerotic plaque and coronary heart disease. 2019 , 29, 456-457	4
892	Editorial: IL-1 Inhibition. 2019 , 10, 87	1
891	Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. 2019 , 139, e603-e634	108
890	ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. 2019 , 20, 791-803	27
889	Gout and cardiovascular disease: crystallized confusion. 2019 , 31, 118-124	20
888	Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. 2019 , 26, 820-823	3
887	Cardiac Complications in the Adult Bone Marrow Transplant Patient. 2019 , 21, 28	10
886	Relationship between changes in pericoronary adipose tissue attenuation and coronary plaque burden quantified from coronary computed tomography angiography. 2019 , 20, 636-643	57
885	The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation. 2019 , 18, e12913	41
884	Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. 2019 , 26, 872-882	13
883	The year in cardiology 2018: heart failure. 2019 , 40, 651-661	19
882	LongShengZhi Capsule Reduces Established Atherosclerotic Lesions in apoE-Deficient Mice by Ameliorating Hepatic Lipid Metabolism and Inhibiting Inflammation. 2019 , 73, 105-117	12
881	Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes. 2019 , 41, 477-489	15

880	Markers or Makers: Inflammatory Cytokines in Treatment-Resistant Hypertension. 2019 , 73, 767-769	9
879	Inflammasomes, neutrophil extracellular traps, and cholesterol. 2019 , 60, 721-727	43
878	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. 2019 , 139, e579-e602	86
877	Diabetes Mellitus and Cardiovascular Disease. 2019 , 39, 558-568	51
876	How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?. 2019 , 19, 107-111	10
875	Detecting Coronary Inflammation With Perivascular Fat Attenuation Imaging: Making Sense From Perivascular Attenuation Maps. 2019 , 12, 2011-2014	10
874	LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. 2019 , 10, 138	94
873	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. 2019 , 16, 325-343	39
872	Stable Ischemic Heart Disease. 2019 , 171, ITC17-ITC32	8
871	Relationship of Interleukin-1 β Blockade With Incident Gout and Serum Uric Acid Levels. 2019 , 170, 737-738	1
870	AB0131 THE CORRELATION OF EXPRESSION OF DIFFERENTIAL DRUG-RESISTANT PROTEINS AND INFLAMMATORY CYTOKINES IN COLLAGEN INDUCED ARTHRITIS MODEL. 2019 ,	
869	AB0132 A NOVEL TARGET FOR TREATMENT OF INFLAMMATORY JOINT DISEASES. 2019 ,	
868	Management of established coronary artery disease in aircrew without myocardial infarction or revascularisation. 2019 , 105, s25-s30	9
867	AB0130 THE EFFECTS OF METHOTREXATE ON THE VASCULAR ENDOTHELIUM. 2019 ,	
866	Valor terapùtico potencial de las estrategias dirigidas contra la interleucina 1 β en la enfermedad cardiovascular aterosclerùtica. 2019 , 72, 760-766	10
865	Convalescent troponin and cardiovascular death following acute coronary syndrome. 2019 , 105, 1717-1724	7
864	Revisiting the Hallmarks of Aging to Identify Markers of Biological Age. 2020 , 7, 56-64	30
863	Angeborene Immunität und Adipositas Die Rolle der Nod-like-Rezeptoren (NLR). 2019 , 44, 248-260	0

862	Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). 2019 , 6, e001108	28
861	Thromboinflammation and Vascular Dysfunction. 2019 , 39, 180-187	6
860	Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in Thrombotic Disease. 2019 , 39, 152-163	5
859	Medical therapeutics: mortality effects, uncertainty, and informed consent. 2019 , 4, e35	1
858	A Theranostic Cathepsin Activity-Based Probe for Noninvasive Intervention in Cardiovascular Diseases. 2019 , 9, 5731-5738	12
857	Optimal management of coronary artery disease in cancer patients. 2019 , 5, 221-233	5
856	Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future. 2019 , 132, 2972-2983	5
855	Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. 2019 , 134, 1859-1872	58
854	The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. 2019 , 3, 2949-2961	20
853	Interleukin-1 β deficiency reduces adiposity, glucose intolerance and hepatic de-novo lipogenesis in diet-induced obese mice. 2019 , 7, e000650	9
852	Correlation study of venous thromboembolism with SAA, IL-1, and TNF- α levels and gene polymorphisms in Chinese population. 2019 , 11, 5527-5534	5
851	sCD40L: An overestimated marker for cardiovascular risk prediction?. 2019 , 291, 122-123	
850	Cardiovascular disease in the QUEST-RA study, 10 years later. 2019 , 21, 242	2
849	Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor- α and Beyond. 2019 , 40, 721-739	22
848	References. 2019 , 415-510	
847	Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. 2019 , 56, 100980	51
846	IL1 inhibition in gout-where are we a decade on?. 2019 , 21, 233	4
845	Perivascular Adipose Tissue and Coronary Atherosclerosis: from Biology to Imaging Phenotyping. 2019 , 21, 47	27

844	Western Diet and the Immune System: An Inflammatory Connection. 2019 , 51, 794-811		163
843	Latent Inflammation and Defect in Adipocyte Renewal as a Mechanism of Obesity-Associated Insulin Resistance. 2019 , 84, 1329-1345		11
842	Hypertension and Its Impact on Stroke Recovery: From a Vascular to a Parenchymal Overview. 2019 , 2019, 6843895		15
841	Inflammation as a Treatment Target after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019 , 381, 2562-2563	59.2	26
840	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019 , 381, 2497-2505	59.2	861
839	Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. 2019 , 11, 1759720X19895492		17
838	Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome. 2019 , 14, e0227142		3
837	. 2019 ,		7
836	Redox Regulation of the Microcirculation. 2019 , 10, 229-259		2
835	Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'. 2019 , 6, 1140-1148		21
834	New evidence on the role of inflammation in CVD risk. 2019 , 34, 418-423		16
833	The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. 2019 , 13, 24-30		7
832	Targeting macrophage immunometabolism to prevent atherosclerosis. 2019 , 1, 1173-1174		1
831	Immune and Smooth Muscle Cells Interactions in Atherosclerosis: How to Target a Breaking Bad Dialogue?. 2019 , 10, 1276		13
830	Role of NLRP3 Inflammasome in Atherosclerosis and Aortic Aneurysm. 2019 , 59, 83-87		
829	Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles. 2019 , 8,		10
828	Interleukin-1 β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. 2019 , 8,		37
827	Full Issue PDF. 2019 , 12, I-CCXLIII		1

826	Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. 2019 , 2, e1916526	34
825	Does early diagnosis and treatment of myelodysplastic syndromes make a difference?. 2019 , 32, 101099	2
824	Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. 2019 , 8, e013716	19
823	Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis. 2019 , 10, 1242	8
822	Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation. 2019 , 11,	7
821	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 2019 , 11,	11
820	Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction. 2019 , 74, 188-193	23
819	Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes. 2019 , 74, 297-305	13
818	Association between new circulating proinflammatory and anti-inflammatory adipocytokines with coronary artery disease. 2019 , 30, 528-535	10
817	Trained immunity and atherosclerotic cardiovascular disease. 2019 , 30, 395-400	12
816	Oligonucleotide-based Preconditioning of DCD Cardiac Donors and Its Impact on Cardiac Viability. 2019 , 103, 2479-2485	5
815	Neopterin is Associated with Disease Severity and Outcome in Patients with Non-Ischaemic Heart Failure. 2019 , 8,	7
814	Hypertension in Relation to Dioxins and Polychlorinated Biphenyls from the Anniston Community Health Survey Follow-Up. 2019 , 127, 127007	9
813	Pivotal micro factors associated with endothelial cells. 2019 , 132, 1965-1973	1
812	Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation via ATP-Citrate Lyase. 2019 , 51, 997-1011.e7	104
811	Neutralization of IL-1 β ameliorates Crohn's disease-like ileitis by functional alterations of the gut microbiome. 2019 ,	24
810	Evaluating Longitudinal Associations Between Depressive Symptoms, Smoking, and Biomarkers of Cardiovascular Disease in the CARDIA Study. 2019 , 81, 372-379	3
809	Is hypertriglyceridemia atherogenic?. 2019 , 30, 291-299	6

808	GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. 2019 , 33, 547-557	21
807	RNA-sequencing reveals that STRN, ZNF484 and WNK1 add to the value of mitochondrial MT-COI and COX10 as markers of unstable coronary artery disease. 2019 , 14, e0225621	3
806	Management of Hyperlipidemia After Stroke. 2019 , 21, 93	5
805	Single-cell immune landscape of human atherosclerotic plaques. 2019 , 25, 1576-1588	247
804	NLRP3 Inflammasome in Acute Myocardial Infarction. 2019 , 74, 175-187	45
803	The NLRP3 Inflammasome as a Pharmacological Target. 2019 , 74, 285-296	13
802	Vascular Macrophages in Atherosclerosis. 2019 , 2019, 4354786	53
801	A review of canakinumab and its therapeutic potential for non-small cell lung cancer. 2019 , 30, 879-885	10
800	NLRP3 Inflammasome: A Novel Player in Metabolically Induced Inflammation-Potential Influence on the Myocardium. 2019 , 74, 276-284	12
799	Inflammatory Basis of Pulmonary Arterial Hypertension: Implications for Perioperative and Critical Care Medicine. 2019 , 131, 898-907	16
798	Associations Between Features of Nonstenosing Carotid Plaque on Computed Tomographic Angiography and Ischemic Stroke Subtypes. 2019 , 8, e014818	8
797	Role of serum amyloid A in atherosclerosis. 2019 , 30, 320-325	20
796	B Lymphocytes and Macrophages in the Perivascular Adipose Tissue Are Associated With Coronary Atherosclerosis: An Autopsy Study. 2019 , 8, e013793	18
795	Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages. 2019 , 10, 2712	5
794	Twenty Novel Disease Group-Specific and 12 New Shared Macrophage Pathways in Eight Groups of 34 Diseases Including 24 Inflammatory Organ Diseases and 10 Types of Tumors. 2019 , 10, 2612	17
793	Chronic inflammation in the etiology of disease across the life span. 2019 , 25, 1822-1832	830
792	Changes in C-reactive protein, neopterin and lactoferrin differ after conservative and surgical weight loss in individuals with morbid obesity. 2019 , 9, 17695	8
791	Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake. 2019 , 12, 2573-2574	6

790 . **2019**, 161, 16

789 Single-Cell RNA Sequencing of the Cardiovascular System: New Looks for Old Diseases. **2019**, 6, 173 23

788 Coagulation Signalling and Metabolic Disorders: Lessons Learned from Animal Models. **2019**, 39, 164-172 4

787 "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer. **2019**, 24, e960-e967 14

786 Rising Plasma Beta-Carotene Is Associated With Diminishing C-Reactive Protein in Patients Consuming a Dark Green Leafy Vegetable-Rich, Low Inflammatory Foods Everyday (LIFE) Diet.. **2021**, 15, 634-643 7

785 [Monoclonal antibodies in cardiovascular diseases and metabolic disorders today]. **2019**, 35, 1014-1016

784 Loss of sterol metabolic homeostasis triggers inflammasomes - how and why. **2019**, 56, 1-9 15

783 Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. **2019**, 14, 153-184 38

782 Tanshinonella Alleviates Inflammatory Response and Directs Macrophage Polarization in Lipopolysaccharide-Stimulated RAW264.7 Cells. **2019**, 42, 264-275 13

781 The Role of Colchicine in Acute Coronary Syndromes. **2019**, 41, 11-20 25

780 In a Nutshell: Findings from the Bruneck Study. **2019**, 65, 9-19 16

779 Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?. **2019**, 98, 101-109 5

778 Posttraumatic stress disorder is associated with enhanced interleukin-6 response to mental stress in subjects with a recent myocardial infarction. **2019**, 75, 26-33 31

777 Nanoimmunotherapy to treat ischaemic heart disease. **2019**, 16, 21-32 26

776 Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death. **2019**, 40, 372-382 17

775 Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. **2019**, 92, 61-70 74

774 Prevention is back in the spotlight - Highlights from American Heart Association Scientific Sessions 2018. **2019**, 26, 502-506

773 Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage. **2019**, 139, 1407-1421 204

772	Long-Term Predictive Value of High-Sensitivity C-Reactive Protein for Cancer Mortality in Patients Undergoing Percutaneous Coronary Intervention. 2019 , 83, 630-636	2
771	Innate immunity as a target for acute cardioprotection. 2019 , 115, 1131-1142	70
770	Circulating biomarkers to identify cardiometabolic complications in patients with Obstructive Sleep Apnea: A systematic review. 2019 , 44, 48-57	12
769	A novel nitroalkene-β-tocopherol analogue inhibits inflammation and ameliorates atherosclerosis in Apo E knockout mice. 2019 , 176, 757-772	6
768	Myeloid cells in cardiovascular organs. 2019 , 285, 491-502	9
767	Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. 2019 , 39, 109-117	29
766	Uremic Toxins Activate Macrophages. 2019 , 139, 97-100	3
765	Targeting inflammation in CVD: advances and challenges. 2019 , 16, 74-75	16
764	Improved oral hygiene care attenuates the cardiovascular risk of oral health disease: a population-based study from Korea. 2019 , 40, 1138-1145	62
763	CHIPping Away at the Pathogenesis of Heart Failure. 2019 , 4, 5-6	5
762	Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. 2019 , 38, 263-265	6
761	Hypertension: Key Biomarkers of Injury and Prognosis. 2019 , 21-40	
760	Diabetes: Key Markers of Injury and Prognosis. 2019 , 41-51	5
759	Blood Inflammatory Biomarkers of Cardiovascular Disease. 2019 , 71-79	2
758	Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease. 2019 , 171-177	
757	Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. 2019 , 26, 244-254.e4	16
756	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. 2019 , 115, 10-19	32
755	Inflammation in Chronic Kidney Disease. 2019 , 208-223.e9	

754	Colchicine in Cardiovascular Disease: Repurposing an Ancient Gout Drug. 2019 , 41, 8-10	12
753	Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. 2019 , 41, 41-48	47
752	Recent advances in therapeutic targeting of inflammation in atherosclerosis. 2019 , 69, 944-951	15
751	The year in cardiology 2018: acute coronary syndromes. 2019 , 40, 271-282	7
750	Niclosamide activates the NLRP3 inflammasome by intracellular acidification and mitochondrial inhibition. 2019 , 2, 2	16
749	Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. 2019 , 4, 25-33	159
748	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. 2019 , 19, 113-131	2
747	Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. 2019 , 11, 258-260	
746	Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. 2019 , 99, 893-948	39
745	Usefulness of a Coronary Artery Disease Predictive Algorithm to Predict Global Risk for Cardiovascular Disease and Acute Coronary Syndrome. 2019 , 123, 769-775	4
744	Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. 2019 , 139, 256-268	67
743	Colchicine in Stable Coronary Artery Disease. 2019 , 41, 30-40	20
742	The role of B cells in atherosclerosis. 2019 , 16, 180-196	96
741	Dietary metabolism, the gut microbiome, and heart failure. 2019 , 16, 137-154	209
740	Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. 2019 , 285, 503-509	23
739	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e1144-e1161	55
738	Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Findings from the Moli-sani Study. 2019 , 276, 248-254	9
737	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019 , 380, 752-762	59.2 538

736	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019 , 380, 11-22	59.2	1316
735	The "Fragility" of Mortality Benefit of Coronary Artery Bypass Graft Surgery in Diabetics. 2019 , 73, 639-642		0
734	Clonal hematopoiesis: Genes and underlying mechanisms in cardiovascular disease development. 2019 , 234, 8396-8401		4
733	Lipid Abnormalities in Persons Living With HIV Infection. 2019 , 35, 249-259		17
732	FISHing for the Miracle of Eicosapentaenoic Acid. <i>New England Journal of Medicine</i> , 2019 , 380, 89-90	59.2	46
731	Identification and regulation of the long non-coding RNA Heat2 in heart failure. 2019 , 126, 13-22		19
730	Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity. 2019 , 670, 116-139		17
729	The SCFFBXO3 ubiquitin E3 ligase regulates inflammation in atherosclerosis. 2019 , 126, 50-59		4
728	Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation. 2019 , 123, 396-401		14
727	Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. 2019 , 196, 15-43		66
726	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study. 2019 , 199, 381-384		51
725	Inflammation and pericarditis: Are neutrophils actors behind the scenes?. 2019 , 234, 5390-5398		16
724	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, 3210-3227		58
723	Homocysteine Modification in Protein Structure/Function and Human Disease. 2019 , 99, 555-604		82
722	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. 2019 , 139, 1289-1299		223
721	Cholesterol and inflammatory risk: Insights from secondary and primary prevention. 2019 , 280, 192-193		2
720	Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. 2019 , 195, 322-333		22
719	Psoriasis and cardiovascular disease: the elusive link. 2019 , 38, 33-54		13

718	Novel biomarkers of cardiovascular disease: Applications in clinical practice. 2019 , 56, 33-60	37
717	General health benefits from good oral health. 2019 , 64, 199-200	3
716	Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. 2019 , 4, 128-135	42
715	Amino Acids and Their Metabolism in Atherosclerosis. 2019 , 39, 319-330	27
714	Atherosclerosis: cell biology and lipoproteins. 2019 , 30, 50-52	1
713	What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. 2019 , 115, e26-e31	30
712	Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice. 2019 , 79, 43-61	24
711	TNF Receptor 1 Contributes to Activation-Induced Cell Death of Pathological CD4+ T Lymphocytes During Ischemic Heart Failure. 2022 ,	4
710	Smooth muscle cell specific NEMO deficiency inhibits atherosclerosis in ApoE ^{0/0} mice. 2022 , 12,	
709	Pleiotropic Benefits of Statins in Cardiovascular Diseases.	0
708	The Impact of Mental Stress on Cardiovascular Health Part II. 2022 , 11, 4405	1
707	Identification of hub biomarkers of myocardial infarction by single-cell sequencing, bioinformatics, and machine learning. 9,	0
706	Addressing gaps in cardiovascular care for people with HIV: bridging scientific evidence and practice. 2022 , 17, 279-285	
705	Translational Medicine – The Bridging Discipline. Role and Tools in the Drug Development Process. 2022 , 119-138	
704	Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers. 9,	1
703	Sustained Pro-Inflammatory Effects of Hypoglycemia in People with Type 2 Diabetes and in People Without Diabetes.	2
702	Mouse models of atherosclerosis in translational research. 2022 ,	1
701	Major cardiovascular events in patients with severe chronic obstructive pulmonary disease with and without asthma: a nationwide cohort study. 00200-2022	

700	Prognostic performance of multiple biomarkers in patients with acute coronary syndrome without standard cardiovascular risk factors. 9,	0
699	Colchicine as a Modulator of Platelet Function: A Systematic Review. 2022 , 48, 552-567	0
698	HIV and cardiovascular disease: the role of inflammation. 2022 , 17, 286-292	0
697	Bempedoic Acid: for Whom and When.	1
696	High Human T-Cell Leukemia Virus Type 1c Proviral Loads Are Associated With Diabetes and Chronic Kidney Disease: Results of a Cross-Sectional Community Survey in Central Australia.	0
695	Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.	0
694	The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. 13,	2
693	Increased serum IL-6 is predictive of long-term cardiovascular events in high-risk patients submitted to coronary angiography: an observational study. 2022 , 14,	1
692	YB1 dephosphorylation attenuates atherosclerosis by promoting CCL2 mRNA decay. 9,	0
691	Immunosuppressive drugs for non-transplant comorbidities are not associated with abdominal aortic aneurysm growth. 2022 ,	
690	Long non-coding RNAs in the pathogenesis of heart failure: A literature review. 9,	1
689	Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.	1
688	Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients. 9,	0
687	Treatment of Periodontitis and C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.	0
686	Gut immune cells: A novel therapeutical target for cardiovascular disease?. 9,	
685	CHIPing away the progression potential of CHIP: A new reality in the making. 2022 , 101001	0
684	Systemic inflammation after stroke: implications for post-stroke comorbidities.	0
683	Statin Prescription Patterns and Associations with Subclinical Inflammation. 2022 , 58, 1096	

682 Klonale Hämatoopoese Ursachen und klinische Implikationen.

681 Critical Functions of Histone Deacetylases (HDACs) in Modulating Inflammation Associated with Cardiovascular Diseases. **2022**, 29, 471-486 1

680 Potential of immune-related genes as promising biomarkers for premature coronary heart disease through high throughput sequencing and integrated bioinformatics analysis. 9, 1

679 Identification of potential biomarkers of inflammation-related genes for ischemic cardiomyopathy. 9,

678 Global research trends in atherosclerosis: A bibliometric and visualized study. 9, 0

677 Development and validation of a carotid atherosclerosis risk prediction model based on a Chinese population. 9, 0

676 Editorial: Targeting innate and adaptive immunity for improvement of cardiovascular disease. 13,

675 Miltefosine attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice.

674 Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. **2022**, 97, 1551-1571

673 New insights into macrophage subsets in atherosclerosis. **2022**, 100, 1239-1251 1

672 The association of serum immunoglobulins with risk of cardiovascular disease and mortality: the Rotterdam Study.

671 Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease. **2022**, 0

670 Molekulare Biomarker der Atherosklerose.

669 Neutrophils and Neutrophil Extracellular Traps in Cardiovascular Disease: An Overview and Potential Therapeutic Approaches. **2022**, 10, 1850 1

668 Cardiovascular Events and Gout Flares. **2022**, 328, 425 0

667 Targeting Epsins by nanotherapy regulates lipid metabolism and promotes ABCG1-mediated cholesterol efflux to fortify atheroma regression.

666 N-acetylcysteine attenuates atherosclerosis progression in aging LDL receptor deficient mice with preserved M2 macrophages and increased CD146. **2022**,

665 Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. **2022**, 328, 440 5

664 Causal discoveries for high dimensional mixed data.

663 Potential Markers of Coronary Artery Plaque and Future Events. **2022**, 15, 1439-1441

662 The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I. **2022**, 101689

661 Topography of immune cell infiltration in different stages of coronary atherosclerosis revealed by multiplex immunohistochemistry. **2022**, 101111

660 Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.

659 The relationship between platelet indices and residual syntax score in patients with ST-segment elevation myocardial infarction. 1-11

658 Inflammation and vascular diseases. **2022**, 68, 309-314

657 OxLDL induces IL-1 β release from human EC and VSMC via different caspase-1 dependent mechanisms. **2022**,

656 Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1 β , Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. **2022**, 146, 372-379

655 Systemic lupus erythematosus and cardiovascular disease.

654 Actions of Dendritic Cells in the Kidney during Hypertension. 1-15

653 Involvement of kallikrein-PAR2 -proinflammatory pathway in severe trastuzumab-induced cardiotoxicity.

652 Extracellular vesicles modulate inflammatory signaling in chronically ischemic myocardium of swine with metabolic syndrome. **2022**,

651 The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases.

650 Predictive Significance of High-Sensitivity C-Reactive Protein Combined with Homocysteine for Coronary Heart Disease in Patients with Anxiety Disorders. **2022**, 2022, 1-8

649 Systemic consequences of abnormal cholesterol handling: Interdependent pathways of inflammation and dyslipidemia. 13,

648 Colchicine and acute coronary syndromes: a new trick for an old drug?. **2022**, Publish Ahead of Print,

647 Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases. **2022**, 11, 2575

- 646 The comparison of cardiovascular disease risk prediction scores and evaluation of subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study.
- 645 Interleukin 1 receptor antagonist relation to cardiovascular disease risk in patients with rheumatoid arthritis. **2022**, 12, 0
- 644 Early atherogenesis: new insights from new approaches. Publish Ahead of Print, 0
- 643 Sex differences in natural history of cardiovascular magnetic resonance- and biopsy-proven lymphocytic myocarditis.
- 642 Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. 4
- 641 Investigation of the Associations of Novel Inflammatory Biomarkers Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI) With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence. **2022**, 23, 9553 3
- 640 Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. **2022**,
- 639 Inactivity and obesity: consequences for macrophage-mediated inflammation and the development of cardiometabolic disease. 1-18 0
- 638 High C-Reactive Protein/Low Serum Albumin: A Hidden Villain in Cardiovascular Disease. **2022**, 73, 797-799
- 637 Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review. 0
- 636 Mitochondrial calpain-1 activates NLRP3 inflammasome by cleaving ATP5A1 and inducing mitochondrial ROS in CVB3-induced myocarditis. **2022**, 117, 0
- 635 Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. **2022**, 109093 1
- 634 Biomarkers for Non-Invasive Stratification of Coronary Artery Disease and Prognostic Impact on Long-Term Survival in Patients with Stable Coronary Heart Disease. **2022**, 14, 3433 0
- 633 Risk of Cancer After Diagnosis of Cardiovascular Disease. 0
- 632 Novel Diagnostic Biomarkers Related to Oxidative Stress and Macrophage Ferroptosis in Atherosclerosis. **2022**, 2022, 1-18 1
- 631 New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. **2022**, 12, 1189 0
- 630 Biomarkers in Chronic Chagas Cardiomyopathy. **2022**, 10, 1602
- 629 The Hippo-YAP pathway in various cardiovascular diseases: Focusing on the inflammatory response. 13, 0

628 Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment.

627 Endoplasmic reticulum stress: A common pharmacologic target of cardioprotective drugs. **2022**, 931, 175221 0

626 Crocin mitigates atherosclerotic progression in LDLR knockout mice by hepatic oxidative stress and inflammatory reaction reduction, and intestinal barrier improvement and gut microbiota modulation. **2022**, 96, 105221 0

625 The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. **2022**, 111, 109080 1

624 Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis. **2022**, 21, 103160 0

623 How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?. **2022**, 365, 61-68

622 GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis. **2022**, 12, 100373 2

621 Targeted delivery of platelet membrane modified extracellular vesicles into atherosclerotic plaque to regress atherosclerosis. **2022**, 138992 1

620 Whole-Transcriptome Sequencing Analyses of Nuclear Antioxidant-1 in Endothelial Cells: Role in Inflammation and Atherosclerosis. **2022**, 11, 2919 0

619 Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. 11, 0

618 Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials. 9, 0

617 Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection Fraction. 2

616 PAPEL TERAPÉUTICO DE LA COLCHICINA EN LA REDUCCIÓN DEL RIESGO CARDIOVASCULAR ASOCIADO A LA INFLAMACIÓN. **2022**, 69, 551-553 0

615 Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study. **2022**, 21, 889-898 0

614 Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?. **2022**, 66, 102283 0

613 Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS). **2022**, 146, 107098 1

612 Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial. **2022**, 178, 106288 0

611 Evaluating the clinical utility of measuring levels of factor H and the related proteins. **2022**, 151, 166-182 0

610	Canakinumab in patients with COVID-19 and type 2 diabetes: A multicentre, randomised, double-blind, placebo-controlled trial. 2022 , 53, 101649	1
609	Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry. 2022 , 160, 156053	0
608	Trained innate immunity and diseases: Bane with the boon. 2022 , 2, 118-129	0
607	Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis. 2022 , 100, 110471	0
606	Interface inhibitory action on Interleukin-1β using selected anti-inflammatory compounds to mitigate the depression: A computational investigation. 2022 , 101, 107774	0
605	Machine learning in the context of better healthcare in aging. 2023 , 625-647	0
604	The aging cardiovascular system. 2023 , 109-119	0
603	Cardiac Inflammasome and Arrhythmia. 2022 , 259-285	0
602	?????????????????????????????. 2022 , 31, 11-16	0
601	Chlamydia pneumoniae is Prevalent in Symptomatic Coronary Atherosclerotic Plaque Samples Obtained From Directional Coronary Atherectomy, but its Quantity is Not Associated With Plaque Instability: An Immunohistochemical and Molecular Study. 2022 , 15, 2632010X2211251	1
600	Macroangiopathy In Diabetic Patients. Role Of The Nurse In The Prevention Of Cardiovascular Complications.	0
599	Expression profiles and functions of ferroptosis-related genes in intimal hyperplasia induced by carotid artery ligation in mice. 13,	0
598	Pathogenesis of Acute Coronary Syndromes. 2022 , 205-215	0
597	Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications. 13,	0
596	Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.	1
595	Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction. 2022 ,	2
594	Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population.	0
593	Endothelial Function Assessment by Flow-Mediated Dilation Method: A Valuable Tool in the Evaluation of the Cardiovascular System. 2022 , 19, 11242	3

592	Meningeal IL-17 producing T cells mediate cognitive impairment in salt-sensitive hypertension.	0
591	Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE ^{-/-} Mice Fed High-Fat Diet. Volume 16, 3145-3168	0
590	Regulated Necrosis in Atherosclerosis.	1
589	Immune Cell Activation in Obesity and Cardiovascular Disease.	0
588	Gut microbiota-derived metabolites in inflammatory diseases based on targeted metabolomics. 13,	1
587	Research advance and clinical implication of circZNF609 in human diseases. 2022, 36, 668-683	0
586	Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients with Three-Vessel Coronary Disease After Revascularization: Results from a Large Cohort of 3561 Patients. Volume 15, 5283-5292	0
585	Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial. 2022, 11,	2
584	Examining the Potential Direct Cardiovascular Benefit of Tumor-Necrosis Factor Inhibitor in Rheumatoid Arthritis: Natural and Controlled Direct Effect Analyses.	0
583	B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis. Volume 15, 5541-5555	0
582	Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research.	2
581	New play for an old actress: A Cinderella in cardiovascular disease. 2022,	0
580	Water-soluble tomato concentrate modulates shear-induced platelet aggregation and blood flow in vitro and in vivo. 9,	0
579	Neue Aspekte für kardiale Diagnostik und Therapie: Inflammation bei Herzinsuffizienz und Infarkt.	0
578	A Decade On: The Evolving Renaissance in Intracranial Atherosclerotic Disease.	0
577	Cathepsin S Levels and Survival Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 2022, 80, 998-1010	1
576	Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. 13,	0
575	Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells.	0

- 574 Involvement of Inflammation and Its Resolution in Disease and Therapeutics. **2022**, 23, 10719 ○
- 573 Additional prognostic value of stress cardiovascular magnetic resonance for cardiovascular risk stratification after a cryptogenic ischemic stroke. 9, ○
- 572 Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction. **2022**, 11, 5776 ○
- 571 Preoperative systemic inflammatory response index predicts long-term outcomes in type B aortic dissection after endovascular repair. 13, ○
- 570 Outcomes Following Acute Coronary Syndrome in Patients With and Without Rheumatic Immune-Mediated Inflammatory Diseases. **2022**, 11, ○
- 569 NLRP3 inflammasome: The rising star in cardiovascular diseases. 9, ○
- 568 Bedeutung der klonalen Hämatopoese für hämatologische Neoplasien. ○
- 567 Traditional and Non-traditional Cardiovascular Risk Factors and Cardiovascular Disease in Women with Psoriasis. ○
- 566 lncRNA260 siRNA Accelerates M2 Macrophage Polarization and Alleviates Oxidative Stress via Inhibiting IL28RA Gene Alternative Splicing. **2022**, 2022, 1-9 1
- 565 Low-density lipoprotein cholesterol in oldest old with acute myocardial infarction: Is lower the better?. **2022**, 51, ○
- 564 Combined protein and transcript single-cell RNA sequencing in human peripheral blood mononuclear cells. **2022**, 20, ○
- 563 How dysregulation of the immune system promotes diabetes mellitus and cardiovascular risk complications. 9, ○
- 562 RNA modification by m6A methylation in cardiovascular diseases: Current trends and future directions. **2022**, 2, 158-177 ○
- 561 Measures of Endothelial Function in Type 2 Diabetes: A Focus on Circulatory Biomarkers. **2023**, 867-888 ○
- 560 Advances in Glycolysis Metabolism of Atherosclerosis. ○
- 559 The role of T17 cells in cardiovascular disease. ○
- 558 Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLER trial. ○
- 557 New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. 9, ○

556	Clonal hematopoiesis of indeterminate potential and cardiovascular disease. 2022 ,	0
555	The effects of RNA methylation on immune cells development and function. 2022 , 36,	0
554	Distinct role of mitochondrial function and protein kinase C in intimal and medial calcification in vitro. 9,	0
553	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. 9,	0
552	Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis.	0
551	Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity. 2022 , 65, 11985-12001	0
550	Pathophysiology and genetics of salt-sensitive hypertension. 13,	0
549	Comparison of High-Sensitivity C-Reactive Protein vs C-reactive Protein for Cardiovascular Risk Prediction in Chronic Cardiac Disease.	0
548	Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. 2022 , 400, 733-743	3
547	Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.	2
546	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.	2
545	Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. 2200302	0
544	Novel Biomarkers for Risk Stratification in NSTEMI-ACS. 2022 , 80, 1011-1013	0
543	Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. 2022 , 13,	1
542	Inflammasome signaling in colorectal cancer. 2022 ,	0
541	Decoding the Link Between Inflammation and Pulmonary Arterial Hypertension. 2022 , 146, 1023-1025	0
540	Clonal Hematopoiesis, Somatic Mosaicism, and Age-Associated Disease.	1
539	Incident gout and risk of first-time acute coronary syndrome: a prospective, population-based, cohort study in Sweden.	0

- 538 Enhanced platelet NLRP3 inflammasome expression in patients with acute coronary syndrome and stable coronary artery disease: A prospective observational study. Publish Ahead of Print, ○
- 537 Demographic, behavioral, dietary, and clinical predictors of high-sensitivity C-reactive protein: The National Health and Nutrition Examination Surveys (NHANES). **2022**, 21, 100196 ○
- 536 Amygdalin attenuates PM2.5-induced human umbilical vein endothelial cell injury via the TLR4/NF- κ B and Bcl-2/Bax signaling pathways. **2022**, ○
- 535 Digital positron emission tomography \square Making cardiac risk stratification fit for the future. **2022**, ○
- 534 Management of Idiopathic Viral Pericarditis in the Pediatric Population. **2022**, 27, 595-608 ○
- 533 Determining distinct roles of IL-1 β through generation of an IL-1 β knockout mouse with no defect in IL-1 β expression. ○
- 532 Myeloid But Not Endothelial Expression of the CB2 Receptor Promotes Atherogenesis in the Context of Elevated Levels of the Endocannabinoid 2-Arachidonoylglycerol. ○
- 531 Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Are Associated with Recurrent Ischemic Stroke in Patients with Embolic Stroke of Undetermined Source. **2022**, 24, 421-424 ○
- 530 Fenótipo Inflamatório por Imagem de OCT Coronária: Características Específicas Entre Lesões De Novo , Hiperplasia Intimal e Neoaterosclerose Intra-Stent. **2022**, ○
- 529 Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations. **2022**, 30, 3106-3117 ○
- 528 Building a better NET : Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders. **2022**, 6, 1
- 527 Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. **2022**, 18, 597-607 ○
- 526 Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. **2022**, 97, 1808-1823 ○
- 525 LncRNA KCNQ1OT1 predicts further cerebral events in patients with transient ischemic attack. 13, ○
- 524 Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. **2022**, 12, e062602 ○
- 523 Therapie der Aortenklappenstenose jenseits des Klappenersatzes \square Was bringt die Zukunft?. **2022**, 11, 434-443 ○
- 522 Clinical, genetic, and experimental increase in soluble urokinase plasminogen activator receptor levels promotes atherosclerosis. ○
- 521 Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases. 9, ○

- 520 Repurposing nitazoxanide as a novel anti-atherosclerotic drug based on mitochondrial uncoupling mechanisms. ○
- 519 Role of CD40(L)-TRAF signaling in inflammation and resolution— double-edged sword. 13, ○
- 518 Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis. ○
- 517 Impact of psychological status on cardiovascular diseases: Is it time for upgrading risk score charts?. **2022**, 359, 42-43 ○
- 516 Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial. **2022**, 18, e647-e655 ○
- 515 Elevated Serum Ninjurin-1 Is Associated with a High Risk of Large Artery Atherosclerotic Acute Ischemic Stroke. ○
- 514 Biomarkers associated with coronary high-risk plaques. ○
- 513 Emerging injectable therapies for osteoarthritis. 1-10 ○
- 512 Pristane attenuates atherosclerosis in Apoe mice via IL-4-secreting regulatory plasma cell-mediated M2 macrophage polarization. **2022**, 155, 113750 ○
- 511 Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction. **2022**, 47, 101398 ○
- 510 TACE/ADAM17 substrates associate with ACS (Ep-CAM, HB-EGF) and follow-up MACE (TNFR1 and TNFR2). **2022**, 50, 40-49 ○
- 509 Sustained release of drug-loaded nanoparticles from injectable hydrogels enables long-term control of macrophage phenotype. ○
- 508 Infections in primary immunodeficiency. **2022**, 747-790 ○
- 507 Peripheral Arterial Atherogenesis. **2022**, 1-48 ○
- 506 Atherosclerosis Imaging. **2022**, 241-254 ○
- 505 Management of autoinflammatory syndromes and periodic fevers. **2022**, 1399-1429 ○
- 504 Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases. **2022**, 17, ○
- 503 Macroangiopathy In Diabetic Patients. Role Of The Nurse In The Prevention Of Cardiovascular Complications. 5-20 ○

502	Nelumbo nucifera Gaertn. leaves: network pharmacology and molecular docking analysis of active ingredients and their mechanisms of action in treating atherosclerosis. 2022 , 36, 802-817	0
501	Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention. 2022 , 11, 40-50	0
500	Mechanism of NLRP3/IL-1/ NF- κ B signaling pathway and macrophage polarization in VTE. 2022 ,	0
499	Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction.	0
498	Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis. 2022 , 11, 3198	1
497	LXR agonist inhibits inflammation through regulating MyD88 mRNA alternative splicing. 13,	0
496	Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis. 9,	0
495	Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. 2022 ,	1
494	Prior Cancer Is Associated with Lower Atherosclerotic Cardiovascular Disease Risk at First Acute Myocardial Infarction. 2022 , 10, 2681	0
493	Genetic Variants of the TERT Gene and Telomere Length in Obstructive Sleep Apnea. 2022 , 10, 2755	1
492	Editorial: Advances on targeted nanomedicines for atherosclerosis. 13,	0
491	Trained immunity [Basic concepts and contributions to immunopathology.	1
490	NLRP1 in Cutaneous SCCs: An Example of the Complex Roles of Inflammasomes in Cancer Development. 2022 , 23, 12308	0
489	Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. 13,	2
488	Clinical Impact of Influenza Vaccination after ST- and Non-ST-segment elevation Myocardial Infarction Insights from the IAMI trial. 2022 ,	0
487	A bibliometric analysis of T cell and atherosclerosis. 13,	0
486	Interleukin-1 in Coronary Artery Disease. 2022 , 23,	4
485	Vascular inflammation and cardiovascular disease: review about the role of PET imaging	0

484	Construction of an immune-related signature for predicting the ischemic events in patients undergoing carotid endarterectomy. 13,	0
483	Magnitude of low-density lipoprotein reduction and impact on major cardiovascular outcomes. Publish Ahead of Print,	0
482	Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation. 2022 , 23, 12433	0
481	Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Publish Ahead of Print,	1
480	Immune checkpoint inhibitors and the cardiovascular system: Reflecting on the past and looking towards the future. 2022 ,	0
479	The cardiac wound healing response to myocardial infarction.	0
478	Clonal Hematopoiesis in Cancer. 1-9	0
477	Accelerated Atherosclerosis in SLE: Mechanisms, Consequences, and Future Directions.	0
476	Clustering of patients with inconclusive non-invasive stress testing referred for vasodilator stress cardiovascular magnetic resonance. 2022 ,	0
475	Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers.	2
474	The role of the gut microbiota in health and cardiovascular diseases. 2022 , 3,	3
473	The Association between Serum Vitamin D Concentration and New Inflammatory Biomarkers Systemic Inflammatory Index (SII) and Systemic Inflammatory Response (SIRI) in Patients with Ischemic Heart Disease. 2022 , 14, 4212	0
472	Role of interleukin-1 in human diseases: pharmacotherapy prospects: A review. 2022 , 94, 999-1005	0
471	Clonal Hematopoiesis in Cardiogenic Shock. 2022 , 80, 1557-1559	0
470	Platelet-Neutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches. 2022 , 11,	0
469	A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis.	0
468	Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. 9,	1
467	Oats Lower Age-Related Systemic Chronic Inflammation (iAge) in Adults at Risk for Cardiovascular Disease. 2022 , 14, 4471	0

466	Olfactory receptors in macrophages and inflammation. 13,	1
465	Blockade of Wnt Secretion Attenuates Myocardial Ischemia/Reperfusion Injury by Modulating the Inflammatory Response. 2022 , 23, 12252	1
464	Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. 2022 , 23, 12054	1
463	Clonal hematopoiesis transcending species barriers. 2022 , 140, 1748-1750	0
462	Body mass index and outcomes of patients with cardiogenic shock: A systematic review and meta-analysis. 10, 10956-10966	0
461	Mortality Analysis of Endovascular Aneurysm Sealing versus Endovascular Aneurysm Repair. 2022 ,	0
460	Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure.	0
459	Atherosclerotic Cardiovascular Risk as an Emerging Priority in Pediatrics. 2022 , 150,	0
458	D-dopachrome tautomerase in cardiovascular and inflammatory diseases: A new kid on the block or just another MIF ?. 2022 , 36,	0
457	Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population. 2022 , 21,	0
456	The relationships between cholesterol crystals, NLRP3 inflammasome, and coronary atherosclerotic plaque vulnerability in acute coronary syndrome: An optical coherence tomography study. 9,	0
455	Exploiting the potential of lung stem cells to develop pro-regenerative therapies. 2022 , 11,	0
454	Neutrophils in aging and aging-related pathologies.	0
453	Cohort profile: the Food Chain Plus (FoCus) cohort. 2022 , 37, 1087-1105	0
452	IKK β binds NLRP3 providing a shortcut to inflammasome activation for rapid immune responses. 2022 , 7,	0
451	Radiomics features of pericoronary adipose tissue improve CT-FFR performance in predicting hemodynamically significant coronary artery stenosis.	0
450	The Role of Inflammation in Cardiovascular Disease. 2022 , 23, 12906	2
449	Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association.	0

- 448 Non-fasting changes of Hs-CRP level in Chinese patients with coronary heart disease after a daily meal. **2022**, 12, ○
- 447 Inflammation in heart failure: causal determinant or bystander?. **2022**, 23, 736-737 ○
- 446 Long-term Management of Patients with Myocardial Infarction: An Updated Review. Publish Ahead of Print, ○
- 445 Level of Vascular Inflammation Is Higher in Acute Coronary Syndromes Compared with Chronic Coronary Disease. ○
- 444 Clinical utility of coronary artery computed tomography angiography- What we know and What's new?. **2022**, ○
- 443 The AIM2 Inflammasome: A Novel Biomarker and Target in Cardiovascular Disease. **2022**, 106533 ○
- 442 Vulnerable Plaque Imaging. **2022**, ○
- 441 Pinocembrin alleviates the susceptibility to atrial fibrillation in isoproterenol-induced rats. **2022**, 636, 33-40 ○
- 440 PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis. **2022**, 113, 109318 ○
- 439 Toll-like receptor 7 regulates cardiovascular diseases. **2022**, 113, 109390 1
- 438 Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations. 71-78 4
- 437 Efeitos Anti-inflamatórios e Cardioprotetores do HDL-C: Associação com Autoanticorpos contra LDL Oxidada?. **2022**, 119, 722-723 ○
- 436 Autoinflammatory Diseases: Consequences of Uncontrolled Inflammasome Activation. 106-113 ○
- 435 Chemokines: A Potential Therapeutic Target for the Stabilisation of Vulnerable Plaque. 128-138 ○
- 434 Glucagon-Like Peptide-1 Receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction. **2022**, 101641 ○
- 433 Association between high-sensitivity C-reactive protein and bleeding in non-ST-segment elevation acute coronary syndrome: A multicentre cohort of Chinese population. ○
- 432 Endothelial cell dysfunction: Implications for the pathogenesis of peripheral artery disease. 9, 1
- 431 Immuno-cardio-oncology: Killing two birds with one stone?. 13, ○

430	2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities. 2022,	0
429	Longitudinal evolution of 68 Ga-Pentixafor uptake in the remote myocardium early after acute myocardial infarction and its association with left ventricular remodelling.	0
428	Involvement of Atopic Dermatitis in the Development of Systemic Inflammatory Diseases. 2022, 23, 13445	1
427	A broader perspective on autoimmune diseases and cardiovascular risk.	0
426	A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults. 2022, 23, 13540	1
425	Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. 2022, 101509	1
424	Gout. 2022, 387, 1877-1887	0
423	Transcriptome profiling of abdominal aortic tissues reveals alterations in mRNAs of Takayasu arteritis. 13,	1
422	Clonal hematopoiesis and cardiovascular disease: deciphering interconnections. 2022, 117,	2
421	Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults. 2022, 2,	0
420	Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions. 9,	0
419	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. 2022, 20,	0
418	Impact of Physical Activity on the Characteristics and Metabolic Consequences of Alcohol Consumption: A Cross-Sectional Population-Based Study. 2022, 19, 15048	1
417	Targeting Theranostics of Atherosclerosis by Dual-Responsive Nanoplatfrom via Photoacoustic Imaging and Three-In-One Integrated Lipid Management. 2206129	0
416	Neuregulin-1β Biomarkers of Inflammation and Myocardial Fibrosis in Heart Failure Patients. 2022, 18, 522-529	0
415	Rapid Drop in Coronary Heart Disease Mortality in Czech Male Population—What Was Actually behind It?. 2022, 10, 2871	0
414	Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis. 2022, 23, 13731	1
413	Therapeutic role of colchicine in reducing cardiovascular risk associated with inflammation. 2022,	0

- 412 Rolle der Metaflammation als systemische Manifestation bei Stoffwechselerkrankungen. ○
- 411 C-reactive protein and coronary atheroma regression following statin therapy: A meta-regression of randomized controlled trials. 9, ○
- 410 The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. 9, 2
- 409 Synergistic effect of lipoprotein (a) and C-reactive protein on prognosis of familial hypercholesterolemia. **2022**, 12, 100428 ○
- 408 Therapeutic inhibition of MPO stabilizes pre-existing high risk atherosclerotic plaque. **2022**, 58, 102532 ○
- 407 Tuberculosis. **2022**, 351-368 ○
- 406 Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. **2022**, ○
- 405 Galectin-9: A novel promoter of atherosclerosis progression. **2022**, ○
- 404 Public Health Need, Molecular Targets, and Opportunities for the Accelerated Development of Function-Promoting Therapies: Proceedings of a National Institute on Aging Workshop. ○
- 403 Gut microbiota: a new risk factor for atherosclerosis?. **2022**, 25, 92 ○
- 402 Macrófagos e Neovasculariza na Neoaterosclerose Intra-Stent: um Fentipo Inflamatrio Acelerado por OCT com Implicaes Teraputicas. **2022**, 119, 938-939 ○
- 401 Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention. **2023**, 187, 106596 ○
- 400 Therapeutic targeting of inflammasome signaling by blocking interleukin-1. **2023**, 583-603 ○
- 399 Inflammasome implications in metabolic disorders. **2023**, 263-274 ○
- 398 The inflammasome in cardiovascular diseases. **2023**, 249-262 ○
- 397 Therapeutic opportunities targeting the NLRP3 inflammasome. **2023**, 555-563 ○
- 396 Are serum hsCRP and IL-6 prognostic markers in somatic symptom disorder and related disorders? An exploratory analysis in a prospective cohort study. **2023**, 157, 88-95 ○
- 395 Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. **2023**, 55, 101737 1

394	Prognostic impacts of Lipoxin A4 in patients with acute myocardial infarction: A prospective cohort study. 2023 , 187, 106618	0
393	Subthreshold splenic nerve stimulation prevents myocardial Ischemia-Reperfusion injury via neuroimmunomodulation of proinflammatory factor levels. 2023 , 114, 109522	0
392	Scavenging dicarbonyls with 5?-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance. 2023 , 67, 101651	1
391	Lessons from Cardiac and Vascular Biopsies from Patients with and without Inflammatory Rheumatic Diseases. 2023 , 49, 129-150	0
390	Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis. 2023 , 49, 165-178	0
389	Heart Failure in Rheumatic Disease. 2023 , 49, 67-79	0
388	A numerical approach to a 2D porous-medium mathematical model: Application to an atherosclerosis problem. 2023 , 441, 127675	0
387	Interleukin-1 Targeted Agents. 2022 , 173-185	0
386	Emerging drugs for the treatment of diabetic nephropathy. 2022 , 27, 417-430	0
385	Trem2 Promotes Foamy Macrophage Lipid Uptake and Survival in Atherosclerosis.	0
384	NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload.	0
383	Inflammatory Macrophage Interleukin-1 Mediates High-Fat Diet-Induced Heart Failure With Preserved Ejection Fraction. 2022 ,	1
382	The Role of Oxidative Stress in Atherosclerosis. 2022 , 11, 3843	2
381	The Role of Hydrogen Sulfide in Plaque Stability. 2022 , 11, 2356	1
380	The intracellular signaling pathways governing macrophage activation and function in human atherosclerosis. 2022 , 50, 1673-1682	0
379	Revisiting secondary prevention in coronary heart disease. 2022 , 74, 431-440	0
378	Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio.	0
377	Clonal Hematopoiesis and Its Impact on Human Health. 2023 , 74,	0

- 376 Angina in 2022: Current Perspectives. **2022**, 11, 6891 ○
- 375 Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis. 9, ○
- 374 NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. **2022**, 10, 3056 ○
- 373 Polycationic PAMAM ameliorates obesity-associated chronic inflammation and focal adiposity. **2022**, 121850 ○
- 372 Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR) recommendations for cardiovascular risk management?. *ard-2022-223315* ○
- 371 Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. *ard-2022-223302* ○
- 370 Inhibition of MLKL impairs abdominal aortic aneurysm development by attenuating smooth muscle cell necroptosis. ○
- 369 The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. **2022**, 23, 14914 1
- 368 PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials. **2022**, 12, e062046 1
- 367 A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis. **2022**, 11, 7068 ○
- 366 The Innate Immune System in Cardiovascular Diseases and Its Role in Doxorubicin-Induced Cardiotoxicity. **2022**, 23, 14649 ○
- 365 Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice. ○
- 364 Epsin Nanotherapy Regulates Cholesterol Transport to Fortify Atheroma Regression. 1
- 363 Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction. 13, ○
- 362 Shared decision-making in the realm of uncertainty: The example of coronary artery disease through an EBM and complexity science lens. ○
- 361 Targeting the reduction of inflammatory risk associated with cardiovascular disease by treating periodontitis either alone or in combination with a systemic anti-inflammatory agent: protocol for a pilot, parallel group, randomised controlled trial. **2022**, 12, e063148 1
- 360 Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial. ○
- 359 Determining distinct roles of IL-1 through generation of an IL-1 knockout mouse with no defect in IL-1 expression. 13, ○

- 358 Multiple Immunotherapy Related Cardiovascular Sequelae. **2022**, 0
- 357 Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases. **2022**, 101699 0
- 356 Sex-specific features of optical coherence tomography detected plaque vulnerability related to clinical outcomes: insights from the CLIMA study. 0
- 355 The Synthetic Flavonoid Hidrosmin Improves Endothelial Dysfunction and Atherosclerotic Lesions in Diabetic Mice. **2022**, 11, 2499 0
- 354 Natural products against inflammation and atherosclerosis: Targeting on gut microbiota. 13, 1
- 353 PET/MR imaging of inflammation in atherosclerosis. 0
- 352 Network pharmacological analysis of Xuefu Zhuyu decoction in the treatment of atherosclerosis. 13, 0
- 351 Translational opportunities of single-cell biology in atherosclerosis. 0
- 350 A Potential New Link Between Inflammation and Vascular Calcification. 0
- 349 C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. 9, 0
- 348 Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia. 1
- 347 The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. **2022**, 23, 15937 0
- 346 Ulcerative colitis increases risk of hypertension in a UK biobank cohort study. 1
- 345 Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review. **2022**, 21, 1
- 344 Towards universal comparability of pericoronary adipose tissue attenuation: a coronary computed tomography angiography phantom study. 0
- 343 Cardiovascular Disease and Thrombosis in HIV Infection. 0
- 342 Phenotyping for percutaneous coronary intervention and long-term recurrent weighted outcomes. **2022**, 0
- 341 Acute Coronary Syndrome: Unravelling the Biology to Identify New Therapies. **2022**, 11, 4136 0

- 340 Association of leukocyte mitochondrial DNA copy number with longitudinal C-reactive protein levels and survival in older adults: a cohort study. **2022**, 19, 0
- 339 The NLRP3 Genetic Variant (rs10754555) Reduces the Risk of Adverse Outcome in Middle-Aged Patients with Chronic Coronary Syndrome. **2022**, 2022, 1-9 0
- 338 Persistent Asthma Is Associated With Carotid Plaque in MESA. **2022**, 11, 1
- 337 The IL-1 Family and Its Role in Atherosclerosis. **2023**, 24, 17 1
- 336 Inflammation and oxidative stress in salt sensitive hypertension; The role of the NLRP3 inflammasome. 13, 1
- 335 Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction. **2022**, 13, 0
- 334 Uric Acid and Chronic Kidney Disease: Still More to Do. **2022**, 0
- 333 Quo Vadis? Immunodynamics of Myeloid Cells after Myocardial Infarction. **2022**, 23, 15814 1
- 332 Drug repurposing for cardiovascular diseases: New targets and indications for probenecid. 0
- 331 Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy. **2022**, 1
- 330 Colchicine in stroke prevention. Is it time to change our clinical practice?. **2022**, 0
- 329 Plant-Based Diets and Lipid, Lipoprotein, and Inflammatory Biomarkers of Cardiovascular Disease: A Review of Observational and Interventional Studies. **2022**, 14, 5371 0
- 328 The emerging role of pyroptosis-related inflammasome pathway in atherosclerosis. **2022**, 28, 0
- 327 Coronary Flow Reserve, Inflammation, and Myocardial Strain. **2022**, 0
- 326 Vascular smooth muscle cells in low SYNTAX scores coronary artery disease exhibit proinflammatory transcripts and proteins correlated with IL1B activation. **2022**, 0
- 325 LDL delivery of microbial small RNAs drives atherosclerosis through macrophage TLR8. **2022**, 24, 1701-1713 0
- 324 Pleiotropic effects of anti-thrombotic therapies: have direct oral anticoagulants any anti-inflammatory effect?. **2022**, 1, 0
- 323 Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. **2022**, 0

- 322 Deleting interleukin-10 from myeloid cells exacerbates atherosclerosis in ApoE^{-/-} mice. **2023**, 80, 0
- 321 The Potential of Nanoliposome-Encapsulated PCSK9 Vaccine for Active Immunization Against Atherosclerosis: A Review. **2023**, 293-300 0
- 320 Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle?. Publish Ahead of Print, 0
- 319 Translating atherosclerosis research from bench to bedside: navigating the barriers for effective preclinical drug discovery. **2022**, 136, 1731-1758 0
- 318 Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1 β secretion. 0
- 317 The prospect of tumor microenvironment-modulating therapeutical strategies. 12, 1
- 316 Oxidative Stress-Mediated Programmed Cell Death: a Potential Therapy Target for Atherosclerosis. 0
- 315 Targeting inflammation in hypertension. Publish Ahead of Print, 0
- 314 Fish intake and risk of cardiovascular events: an analysis of the VITAL cohort. 0
- 313 Endothelial Dysfunction and Chronic Inflammation: The Cornerstones of Vascular Alterations in Age-Related Diseases. **2022**, 23, 15722 1
- 312 The Presence of Residual Vascular and Adipose Tissue Inflammation on 18F-FDG PET in Patients with Chronic Coronary Artery Disease. 0
- 311 Human Macrophage Long Intergenic Noncoding RNA, SIMALR , Suppresses Inflammatory Macrophage Apoptosis via NTN1 (Netrin-1). 0
- 310 Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease. **2022**, 132, 1
- 309 Modifying Effect of the Interleukin-18 Level on the Association between BDNF Methylation and Long-Term Cardiovascular Outcomes in Patients with Acute Coronary Syndrome. **2022**, 23, 15270 0
- 308 Factors Associated with RANTES, EMMPIRIN, MMP2 and MMP9, and the Association of These Biomarkers with Cardiovascular Disease in a Multi-Ethnic Population. **2022**, 11, 7281 0
- 307 Macrophages regulate vascular smooth muscle cell function during atherosclerosis progression through IL-1 β /STAT3 signaling. **2022**, 5, 0
- 306 The predictive value of four serum biomarkers for major adverse events in patients with small abdominal aortic aneurysm. **2022**, 0
- 305 Serum from Stroke Patients with High-Grade Carotid Stenosis Promotes Cyclooxygenase-Dependent Endothelial Dysfunction in Non-ischemic Mice Carotid Arteries. 1

- 304 Monocyte to high-density lipoprotein ratio presents a linear association with atherosclerosis and nonlinear association with arteriosclerosis in elderly Chinese population: The Northern Shanghai Study. **2022**, 0
- 303 Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management The Plaque Hypothesis. 2
- 302 Leukocyte Count Predicts Carotid Artery Stenosis in Men with Ischemic Stroke: Sub Study of the Preventive Antibiotics in Stroke Study (PASS). **2022**, 11, 7286 0
- 301 Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial. 9, 0
- 300 Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF- β driven fibrotic remodeling in ischemic heart failure. 0
- 299 Inflammation and Heart Failure: Searching for the Enemy Reaching the Entelechy. **2023**, 10, 19 0
- 298 Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases. **2023**, 16, 78 0
- 297 A Ying-Yang Perspective on the Renin Angiotensin System in Cardiovascular Disease. **2023**, 159-172 0
- 296 Follicle-Stimulating Hormone Provokes Macrophages to Secrete IL-1 β Contributing to Atherosclerosis Progression. **2023**, 210, 25-32 0
- 295 Advances in immunotherapy modalities for atherosclerosis. 13, 1
- 294 Macrophages in cardiac remodelling after myocardial infarction. 0
- 293 Akutes Koronarsyndrom. **2022**, 1-53 0
- 292 Clonal hematopoiesis and associated cardiovascular diseases. 0
- 291 Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context. **2023**, 147, 83-100 0
- 290 Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure. 0
- 289 The oral microbiome in the pathophysiology of cardiovascular disease. 0
- 288 RNA-binding proteins in vascular inflammation and atherosclerosis. **2023**, 0
- 287 Immune Profiling Reveals Decreases in Circulating Regulatory and Exhausted T'Cells in Human Hypertension. **2023**, 0

286	Chromatin Remodeling Drives Immune-Fibroblast Crosstalk in Heart Failure Pathogenesis.	0
285	Association between dietary inflammatory index and atherosclerosis cardiovascular disease in U.S. adults. 9,	0
284	Mitochondria-derived damage associated molecular patterns and inflammation in the ischemic-reperfused heart.	0
283	Evaluation of the Association Between Circulating IL-1 β and Other Inflammatory Cytokines and Incident Atrial Fibrillation in a Cohort of Postmenopausal Women. 2023 ,	0
282	The Role of Neutrophils in Lower Limb Peripheral Artery Disease: State of the Art and Future Perspectives. 2023 , 24, 1169	1
281	A Transient Inflammatory Response Induced by Lipopolysaccharide Infusion Lowers Markers of Endogenous Cholesterol and Bile Acid Synthesis in Healthy Normocholesterolemic Young Men. 2023 , 11, 126	0
280	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. 2023 , 1-65	0
279	Natural Cell Patches: Melanin Nanoparticles for MR Imaging-Guided Antiatherosclerosis Therapy via Attenuating Macrophage Pyroptosis. 2212748	0
278	IL-1 β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH. 2023 , 13,	0
277	The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes.	0
276	HDL Functions Current Status and Future Perspectives. 2023 , 13, 105	1
275	Heart-Brain Team Approach of Acute Myocardial Infarction Complicating Acute Stroke: Characteristics of Guideline-Recommended Coronary Revascularization and Antithrombotic Therapy and Cardiovascular and Bleeding Outcomes. 2023 , 12,	0
274	SATB2 , coordinated with CUX1 , regulates IL -1 β induced senescence-like phenotype in endothelial cells by fine-tuning the atherosclerosis-associated p16 INK4a expression.	0
273	Impact of Metabolic Activity of Vertebra and Amygdala on Stroke Recurrence: A Prospective Cohort Study. 2023 , 16,	0
272	The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients. 2023 , 2023, 1-9	0
271	RA-associated atherosclerosis: mechanisms of development and therapeutic perspectives. 2023 , 11, 105-117	0
270	IgG N-Glycosylation Cardiovascular Age Tracks Cardiovascular Risk Beyond Calendar Age. 2023 ,	1
269	Single-cell atlas reveals different immune environments between stable and vulnerable atherosclerotic plaques. 13,	0

- 268 Circular RNAs at the intersection of cancer and heart disease: potential therapeutic targets in cardio-oncology. ○
- 267 AMPK integrates metabolite and kinase-based immunometabolic control in macrophages. **2023**, 68, 101661 ○
- 266 IRGM/Irgm1 deficiency inhibits neutrophil-platelet interactions and thrombosis in experimental atherosclerosis and arterial injury. **2023**, 158, 114152 1
- 265 Optimizing antihypertensive therapy in patients with diabetes mellitus. ○
- 264 Kounis syndrome risk factors, pathophysiology, and management. **2022**, 12, 188-192 ○
- 263 Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. 9, ○
- 262 Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study. ○
- 261 A textile-reinforced composite vascular graft that modulates macrophage polarization and enhances endothelial cell migration, adhesion and proliferation in vitro. ○
- 260 One-year nutrition counselling in the context of a Mediterranean diet reduced the dietary inflammatory index in women with breast cancer: a role for the dietary glycemic index. **2023**, 14, 1560-1572 ○
- 259 Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence. **2023**, 24, 2483 ○
- 258 Macrophage-Specific NLRC5 Protects From Cardiac Remodeling Through Interaction With HSPA8. **2023**, ○
- 257 A Non-Linear Role of Hyperlipidemia on Progression of Intracranial Atherosclerotic Plaques and Acute Downstream Ischemic Events. **2023**, ○
- 256 Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. ○
- 255 Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms. **2023**, 15, 729 ○
- 254 Immune cells drive new immunomodulatory therapies for myocardial infarction: From basic to clinical translation. 14, ○
- 253 Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy. **2023**, 13, 319 1
- 252 Co-supplementation of Vitamin K2 and Selenium Synergistically Improves Metabolic Status and Reduces Cardiovascular Risk Markers in Dyslipidemic Rabbits. ○
- 251 Sex-specific impact of body weight on atherosclerotic cardiovascular disease incidence in individuals with and without ideal cardiovascular health. ○

250	Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction. PHARMREV-AR-2022-000629	0
249	Associations among cardiorespiratory fitness, C-reactive protein, and all-cause mortality in men and women. 108155892211491	0
248	Is hypertension an extra-intestinal manifestation of inflammatory bowel disease?. 2023 , 11, 7-8	0
247	Proteomic profiling identifies novel independent relationships between inflammatory proteins and myocardial infarction.	0
246	Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. 2023 , 24, 2079	0
245	Nonalcoholic fatty liver disease and cardiovascular disease. 2023 , 11-16	0
244	Metformin Directly Binds to MMP-9 to Improve Plaque Stability. 2023 , 10, 54	0
243	Introduction to polymeric nanomaterials. 2023 , 3-25	0
242	Inflammatory Response: A Crucial Way for Gut Microbes to Regulate Cardiovascular Diseases. 2023 , 15, 607	2
241	Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease. 2023 ,	0
240	Validation and clinical impact of novel pericoronary adipose tissue measurement on ECG-gated non-contrast chest CT. 2023 ,	1
239	Improving Cardiovascular Risk Assessment to Optimize Therapy. 2023 , 13, 7-20	0
238	Natural Monoterpenes as Potential Therapeutic Agents against Atherosclerosis. 2023 , 24, 2429	0
237	The Development of Systemic Inflammatory Diseases in Hidradenitis Suppurativa. 2023 , 13, 502	0
236	Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases. 2023 , 15, 591	0
235	Klonale Hämatoese Ursachen und klinische Implikationen. 2023 , 56, 65-72	0
234	Cardiovascular Disease Causes Proinflammatory Microvascular Changes in the Human Right Atrium.	0
233	PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. 2023 , 24, 2319	0

- 232 Current Applications and New Perspectives in Optical Coherence Tomography (OCT) Coronary Atherosclerotic Plaque Assessment: From PCI Optimization to Pharmacological Treatment Guidance. **2023**, 10, 158 ○
- 231 Detecting the Vulnerable Patient: Toward Preventive Imaging by Coronary Computed Tomography Angiography. ○
- 230 Cx43 acts as a mitochondrial calcium regulator that promotes obesity by inducing the polarization of macrophages in adipose tissue. **2023**, 105, 110606 ○
- 229 Advanced therapeutics for targeting atherosclerosis. **2023**, 93-105 ○
- 228 Cytokines and Cytokine Receptors. **2023**, 186-214 ○
- 227 Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. **2023**, 12, ○
- 226 Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. **2023**, ○
- 225 Systemic inflammation indicators and risk of incident arrhythmias in 478,524 individuals: evidence from the UK Biobank cohort. **2023**, 21, ○
- 224 White blood cells and coronary heart disease: A mendelian randomization study. 14, ○
- 223 Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. **2023**, 11, 662 ○
- 222 Additive prognostic value of longitudinal myocardial deformation to SCORE2 in psoriasis. **2023**, 3, ○
- 221 Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. **2023**, 17, 297-302 ○
- 220 Integrated whole-genome gene expression analysis reveals an atlas of dynamic immune landscapes after myocardial infarction. 10, ○
- 219 Residual risks and evolving atherosclerotic plaques. ○
- 218 Redefying the therapeutic strategies against cardiorenal morbidity and mortality: Patient phenotypes. 15, 76-83 ○
- 217 Prognostic role of CRP -independent inflammatory patterns in patients undergoing primary percutaneous interventions.. ○
- 216 Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality. **2023**, 98, 549-558 ○
- 215 Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fed ApoE^{-/-}knockout mice. 11, ○

- 214 Macrophage function in adipose tissue homeostasis and metabolic inflammation. ○
- 213 Accelerated Vascular Aging in Chronic Kidney Disease: The Potential for Novel Therapies. **2023**, 132, 950-969 ○
- 212 Advances in nanomaterial-based targeted drug delivery systems. 11, ○
- 211 Immunotherapy-based combinations in metastatic NSCLC. **2023**, 116, 102545 ○
- 210 Non-invasive coronary imaging in elderly population. **2023**, 162, 110794 ○
- 209 Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis. **2023**, 378, 96-104 ○
- 208 Supporting evidence for lipoprotein(a) measurements in clinical practice. **2023**, 37, 101746 ○
- 207 The heterogeneous cellular landscape of atherosclerosis: Implications for future research and therapies. A collaborative review from the EAS young fellows. **2023**, 372, 48-56 ○
- 206 Inflammasomes as potential mediators of adverse cardiovascular events in diabetes and lupus: more questions than answers. **2023**, 24, 279-282 ○
- 205 Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment. **2023**, 161, 114545 2
- 204 Cigarette tar mediates macrophage ferroptosis in atherosclerosis through the hepcidin/FPN/SLC7A11 signaling pathway. **2023**, 201, 76-88 ○
- 203 *Buchholzia coriacea* seed induce antifertility by interfering with steroidogenic enzymes and inflammatory cytokines in rat testis. **2023**, 157, 103923 ○
- 202 Two decades of vaccine development against atherosclerosis. **2023**, 50, 101822 ○
- 201 A double-edged sword of platelet-derived extracellular vesicles in tissues, injury or repair: The current research overview. **2023**, 82, 102066 ○
- 200 Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions. ○
- 199 Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. ○
- 198 An update on the role of TRIM/NLRP3 signaling pathway in atherosclerosis. **2023**, 160, 114321 ○
- 197 Sex-specific differences in cytokine signaling pathways in circulating monocytes of cardiovascular disease patients. **2023**, ○

196	Impact of venous thromboembolism on incidence of arterial thromboembolism - An analysis of German outpatient claims data. 2023 , 226, 9-17	0
195	Mitochondrial OGG1 expression reduces age-associated neuroinflammation by regulating cytosolic mitochondrial DNA. 2023 , 203, 34-44	0
194	Diagnosis and management of cardiovascular risk in rheumatoid arthritis: main challenges and research agenda. 2023 , 19, 279-292	1
193	Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment. 2023 , 194, 114709	1
192	The role of NLRP3 inflammasome in sepsis: A potential therapeutic target. 2023 , 115, 109697	0
191	Small vessel disease: Connections between the kidney and the heart. 2023 , 26, 100257	0
190	A metal-organic framework-based immunomodulatory nanoplatfom for anti-atherosclerosis treatment. 2023 , 354, 615-625	3
189	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2023 , 24, 453-471	0
188	Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children. 2023 , 151, 607-618	0
187	Harnessing prostaglandin E2 signaling to ameliorate autoimmunity. 2023 , 44, 162-171	0
186	Could colchicine reduce cardiovascular events in coronary artery disease without increasing all-cause mortality: Avoid optical illusions!. 2023 , 376, 125-126	0
185	Personalised Approach to Atherosclerotic Cardiovascular Disease: The Future is Here. 2-10	0
184	The Association of Serum Immunoglobulins with Risk of Cardiovascular Disease and Mortality: the Rotterdam Study. 2023 , 43, 769-779	0
183	Associations of childhood adiposity with adult intima-media thickness and inflammation: a 20-year longitudinal population-based cohort. 2023 , 41, 402-410	0
182	Advances in the Assessment of Coronary Artery Disease Activity with PET/CT and CTA. 2023 , 9, 328-341	0
181	Herz-Kreislauf-Risiko bei rheumatoider Arthritis: Medikamente reduzieren Entzündungen in Arterien.	0
180	Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. 2023 , 12, 1162	0
179	NDRG1: A New Regulator of Vascular Inflammation and Atherothrombosis. 2023 , 132, 320-322	0

- 178 Characterization of the effect of the GLUT-1 inhibitor BAY-876 on T cells and macrophages. **2023**, 945, 175552 ○
- 177 Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ○
- 176 Inflammation, dysregulated iron metabolism, and cardiovascular disease. 4, ○
- 175 Effectiveness of targeting the NLRP3 inflammasome by using natural polyphenols: A systematic review of implications on health effects. **2023**, 165, 112567 ○
- 174 The antiatherosclerotic action of 1G244 [An inhibitor of dipeptidyl peptidases 8/9]s mediated by the induction of macrophage death. **2023**, 944, 175566 ○
- 173 Stroke induces early recurrent vascular events by inflammasome-dependent atherosclerotic plaque rupture. ○
- 172 Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheroma. **2023**, 18, e1099-e1107 ○
- 171 A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention. **2023**, 15, ○
- 170 Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. **2023**, 12, 1302 ○
- 169 The CRB and inflammatory parameters in myocardial infarction (STEMI-NSTEMI) and relationship with infarct site, significance and complication. ○
- 168 Walnut inclusion in a palm oil-based atherogenic diet promotes traits predicting stable atheroma plaque in Apoe-deficient mice. 10, ○
- 167 Unraveling the mechanistic link between atherosclerosis and inflammatory bowel disease. Can we find a target?. **2023**, ○
- 166 Cardiovascular Disease as a Consequence or a Cause of Cancer: Potential Role of Extracellular Vesicles. **2023**, 13, 321 ○
- 165 Actualité cardiologiques de la colchicine. **2022**, 191-197 ○
- 164 Chronic rheumatologic disorders and cardiovascular disease risk in women. **2023**, 27, 100267 ○
- 163 Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. ○
- 162 Higher Leukocyte Count Is Associated with Lower Presence of Carotid Lipid-Rich Necrotic Core: A Sub-Study in the Plaque at RISK (PARISK) Study. **2023**, 12, 1370 ○
- 161 Cholesteryl hemiazelate Identified in Cardiovascular Disease Patients Causes *in vitro* and *in vivo* Inflammation. ○

- 160 Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches. ○
- 159 Systemic proinflammatory/ profibrotic response in aortic stenosis patients with diabetes and its relationship with myocardial remodeling and clinical outcome. **2023**, 22, ○
- 158 Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. **2023**, 34, 210-215 ○
- 157 Apolipoprotein C3 induces inflammasome activation only in its delipidated form. **2023**, 24, 408-411 ○
- 156 A machine-learning algorithm integrating baseline serum proteomic signatures predicts exercise responsiveness in overweight males with prediabetes. **2023**, 4, 100944 ○
- 155 Konjac glucomannan defends against high-fat diet-induced atherosclerosis in rabbits by promoting the PI3K/Akt pathway. **2023**, 9, e13682 ○
- 154 Impact of COVID-19 on Cardiovascular Disease. **2023**, 15, 508 ○
- 153 ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation. **2023**, 55, 426-442 ○
- 152 Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation. Volume 17, 459-476 ○
- 151 The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. **2023**, 2, e000157 ○
- 150 Fir(e)ing the Rhythm. **2023**, ○
- 149 High triglyceride/ glucose index is associated with poor cardiovascular outcomes in Chinese acute coronary syndrome patients without diabetes mellitus who underwent emergency percutaneous coronary intervention with drug-eluting stents. 14, ○
- 148 IL-1 β knockdown inhibits cigarette smoke extract-induced inflammation and apoptosis in vascular smooth muscle cells. **2023**, 18, e0277719 ○
- 147 Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990-2022. 10, ○
- 146 Pathways linking aging and atheroprotection in Mif⁻deficient atherosclerotic mice. **2023**, 37, ○
- 145 Innate immune memory in cardiometabolic disease. ○
- 144 Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease. **2023**, 24, 3962 ○
- 143 Sex/gender-related differences in inflammaging. **2023**, 211, 111792 ○

- 142 From MIA to FIFA : The vicious matrix of frailty, inflammation, fluid overload and atherosclerosis in peritoneal dialysis. **2023**, 28, 215-226
- 141 Mechanism of oxidized phospholipid-related inflammatory response in vascular ageing. **2023**, 86, 101888
- 140 Role of the extracellular matrix in cell-cell communication: a new therapeutic target?.
- 139 Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's disease.
- 138 Clonal Hematopoiesis: Connecting Aging and Inflammation in Atherosclerosis. **2023**, 25, 105-111
- 137 Cholesterol efflux capacity is associated with lipoprotein size and vascular health in mild to moderate psoriasis. 10,
- 136 Multiancestry Genome-Wide Association Study of Aortic Stenosis Identifies Multiple Novel Loci in the Million Veteran Program. **2023**, 147, 942-955
- 135 Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. **2023**, 44, 1449-1460
- 134 Impact of Reperfusion on Temporal Immune Cell Dynamics After Myocardial Infarction. **2023**, 12,
- 133 microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation. 10,
- 132 Trained immunity in monocyte/macrophage: Novel mechanism of phytochemicals in the treatment of atherosclerotic cardiovascular disease. 14,
- 131 Obesity Paradox: Fact or Fiction?.
- 130 Cost-effectiveness of colchicine for recurrent cardiovascular events. **2023**,
- 129 Secondary calciprotein particle size is associated with patient mortality in peripheral artery disease. **2023**, 370, 12-17
- 128 Understanding autoimmunity in atherosclerosis paves the way for novel therapies. **2023**, 2, 227-229
- 127 The effect of Tabata-style functional high-intensity interval training on cardiometabolic health and physical activity in female university students. 14,
- 126 Revisiting IL-1
- 125 Mechanisms of antiinflammatory effects of naturally derived secondary metabolites. **2023**, 233-244

- 124 Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk. **2023**, 81, 913-923 ○
- 123 Targeting ADAMTS-7: A Vaccination Against Atherosclerosis and Its Complications?. **2023**, 147, 743-745 ○
- 122 Bulk and single-cell characterisation of the immune heterogeneity of atherosclerosis identifies novel targets for immunotherapy. **2023**, 21, ○
- 121 Remnant cholesterol is a risk factor for metabolic syndrome and cardiovascular disease: a cross-sectional study. ○
- 120 Peri-coronary adipose tissue is a predictor of stent failure in patients undergoing percutaneous coronary intervention. **2023**, ○
- 119 The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases. **2023**, 12, 598 ○
- 118 Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk. ○
- 117 Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. **2023**, 37, ○
- 116 Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study. **2023**, 90, 104503 ○
- 115 Emerging role of exosomes in vascular diseases. 10, ○
- 114 The role of pyroptosis in hepatocellular carcinoma. ○
- 113 Hyperlipidaemia elicits an atypical, T helper 1-like CD4+ T-cell response: a key role for very low-density lipoprotein. **2023**, 3, ○
- 112 The Role of Lp(a) in Atherosclerosis: An Overview. **2023**, 159-171 ○
- 111 Risk of coronary artery disease in patients with gout on treatment with Colchicine: A systematic review and meta-analysis. **2023**, 45, 101191 ○
- 110 Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. **2023**, 401, 1293-1301 1
- 109 Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond. **2023**, 16, 8-16 ○
- 108 Metabolic profiling of MRI -measured liver fat in the UK Biobank. **2023**, 31, 1121-1132 1
- 107 Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). **2023**, ○

- 106 Intracoronary Imaging of Coronary Atherosclerotic Plaque: From Assessment of Pathophysiological Mechanisms to Therapeutic Implication. **2023**, 24, 5155 ○
- 105 Mulberry extract upregulates cholesterol efflux and inhibits p38 MAPK-NLRP3 -mediated inflammation in foam cells. ○
- 104 Validation and Comparison of the Prognosis Predicting Ability of Inflammation-Based Scores Following Endovascular Treatment for Peripheral Artery Disease. 000331972311613 ○
- 103 NLRP3 Inflammasome Activation in Peripheral Arterial Disease. ○
- 102 Coronary artery disease-associated immune gene RBP1 and its pan-cancer analysis. 10, ○
- 101 Inflammatory Activity in Patients with Obstructive and Non-obstructive Coronary Artery Disease. **2023**, 19, 26-33 ○
- 100 Identification of immune-related genes in diagnosing atherosclerosis with rheumatoid arthritis through bioinformatics analysis and machine learning. 14, ○
- 99 The systemic deletion of interleukin-1 β reduces myocardial inflammation and attenuates ventricular remodeling in murine myocardial infarction. **2023**, 13, ○
- 98 Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. **2023**, 12, 2161 ○
- 97 Management of Dysregulated Immune Response in the Critically Ill: Heart and Circulation. **2023**, 171-188 ○
- 96 OCT Emerging Technologies: Coronary Micro-optical Coherence Tomography. **2023**, 12, 237-244 ○
- 95 Atherosclerotic Cardiovascular Disease in Inflammatory Bowel Disease: The Role of Chronic Inflammation and Platelet Aggregation. **2023**, 59, 554 ○
- 94 Intravascular Ultrasound and Optical Coherent Tomography Combined Catheter. **2023**, 12, 187-201 ○
- 93 The angiotensin receptor Tie2 is atheroprotective in arterial endothelium. **2023**, 2, 307-321 1
- 92 The diverse roles of macrophages in metabolic inflammation and its resolution. 11, ○
- 91 The Protective Role of TREM2 in the Heterogenous Population of Macrophages during Post-Myocardial Infarction Inflammation. **2023**, 24, 5556 ○
- 90 Monocyte to high-density lipoprotein ratio predicts clinical outcomes after acute ischemic stroke or transient ischemic attack. ○
- 89 A comparative gene expression matrix in Apoe-deficient mice identifies unique and atherosclerotic disease stage-specific gene regulation patterns in monocytes and macrophages. **2023**, 371, 1-13 ○

- 88 Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach. **2023**, 12, 2294 ○
- 87 Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study. **2023**, 1, 11-24 ○
- 86 Distinctive Signs of Disease as Deterrents for the Endothelial Function: A Systematic Review. **2023**, 13, 430 ○
- 85 Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases. 11, ○
- 84 Microglial IL-1RA ameliorates brain injury after ischemic stroke by inhibiting astrocytic CXCL1-mediated neutrophil recruitment and microvessel occlusion. ○
- 83 Role of plaque imaging for identification of vulnerable patients beyond the stage of myocardial ischemia. 10, ○
- 82 Cross-species single-cell comparison of systemic and cardiac inflammatory responses after cardiac injury. ○
- 81 DIAPH1 mediates progression of atherosclerosis and regulates hepatic lipid metabolism in mice. **2023**, 6, ○
- 80 Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation. 10, ○
- 79 Involvement of inflammasomes in tumor microenvironment and tumor therapies. **2023**, 16, ○
- 78 Proline/serine-rich coiled-coil protein 1 inhibits macrophage inflammation and delays atherosclerotic progression by binding to Annexin A2. **2023**, 13, ○
- 77 JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. ○
- 76 Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. ○
- 75 Internalization of Angiotensin-(1 α 2) in Adult Retinal Pigment Epithelial-19 Cells. ○
- 74 Emerging roles of interferon-stimulated gene-15 in age-related telomere attrition, the DNA damage response, and cardiovascular disease. 11, ○
- 73 Predictors of post-infarction left ventricular aneurysm. **2023**, 28, 5201 ○
- 72 Impavido attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice. **2023**, 26, 106453 ○
- 71 History of peripheral artery disease and cardiovascular risk of real-world patients with acute coronary syndrome: Role of inflammation and comorbidities. **2023**, ○

- 70 A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. **2023**, 24, 5983 ○
- 69 Improving diagnostic assessments in the ever-changing landscape of atherosclerosis. **2023**, 24, 221-229 ○
- 68 High-sensitivity C-reactive protein is a predictor of depression in patients with mild traumatic brain injury. **2023**, 9, e14783 ○
- 67 Oral health as a modifiable risk factor for cardiovascular diseases. **2023**, ○
- 66 Immunity and inflammation in cardiovascular disorders. **2023**, 23, ○
- 65 Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials. 1-9 ○
- 64 Diagnostic value of echocardiography combined with serum C-reactive protein level in chronic heart failure. **2023**, 18, ○
- 63 Potential traditional Chinese medicines with anti-inflammation in the prevention of heart failure following myocardial infarction. **2023**, 18, ○
- 62 Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease. **2023**, 32, 291-299 ○
- 61 Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease: A Translational Perspective. **2023**, 24, 6280 ○
- 60 Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω 3 and ω 6 PUFAs. **2023**, ○
- 59 Inflammation Beats Cholesterol: A Comment on the Unequivocal Driver of Cardiovascular Disease Risk. **2023**, 12, 2519 ○
- 58 Lipoprotein (a), Inflammation, and Atherosclerosis. **2023**, 12, 2529 ○
- 57 Neutrophils in Health and Disease: From Receptor Sensing to Inflammasome Activation. **2023**, 24, 6340 ○
- 56 Thymidine Phosphorylase Deficiency or Inhibition Preserves Cardiac Function in Mice With Acute Myocardial Infarction. **2023**, 12, ○
- 55 Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis. ○
- 54 Brazilin inhibits the inflammatory immune response induced by LPS in THP-1 cells. ○
- 53 Klonale Hämatopoese (CHIP) und klonale Zytopenie unbestimmter Signifikanz (CCUS). **2023**, 148, 441-450 ○

- 52 Crosstalk Between Cholesterol, ABC Transporters, and PIP2 in Inflammation and Atherosclerosis. **2023**, 353-377 ○
- 51 Aortic Inflammation. **2023**, 2, 100283 ○
- 50 Serum Amyloid A augments the atherogenic effects of Cholesteryl Ester Transfer Protein. **2023**, 100365 ○
- 49 No effect of omega-3 polyunsaturated fatty acid supplementation on inflammatory markers in familial hypercholesterolemia: a randomized crossover trial. 1-8 ○
- 48 Age-dependent loss of hepatic SIRT1 enhances NLRP3 inflammasome signaling and impairs capacity for liver fibrosis resolution. ○
- 47 A machine-learning based bio-psycho-social model for the prediction of non-obstructive and obstructive coronary artery disease. ○
- 46 Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials. **2023**, 373, 1-9 ○
- 45 Nanomedicines for cardiovascular disease. **2023**, 2, 351-367 ○
- 44 The role of frailty in advanced HF and cardiac transplantation. 10, ○
- 43 The regulation of self-tolerance and the role of inflammasome molecules. 14, ○
- 42 Colchicine may be considered for the secondary prevention of cardiovascular disease. ○
- 41 Chinese herbal prescription Qing-Xin-Jie-Yu granule combined with conventional treatment for intermediate coronary lesions: study protocol for a randomized, double-blinded, placebo-controlled trial. ○
- 40 Blocking Interleukin-1 β transiently limits left ventricular dilation and modulates cardiac lymphangiogenesis in a mouse pressure-overload model. ○
- 39 Immunologic Mechanisms of Atherosclerosis and Myocarditis. **2023**, 883-897 ○
- 38 Multiomics of human aortic endothelial cells reveals cell subtypes with heterogeneous responses to canonical endothelial-to-mesenchymal perturbations. ○
- 37 Anti-Inflammatory and Vasorelaxant Effects Induced by an Aqueous Aged Black Garlic Extract Supplemented with Vitamins D, C, and B12 on Cardiovascular System. **2023**, 12, 1558 ○
- 36 Chronic venous disease and cardiovascular disease. **2023**, 20, 17-24 ○
- 35 Risk of Cancer After Diagnosis of Cardiovascular Disease. **2023**, ○

- 34 High absolute neutrophil count with type 2 diabetes is associated with adverse outcome in patients with coronary artery disease: A large-scale cohort study. 14,
- 33 Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
- 32 Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases. **2023**, 15, 1850
- 31 Use of Computation Ecosystems to Analyze the Kidney-Heart Crosstalk. **2023**, 132, 1084-1100
- 30 Impact of risk factors on early cancer evolution. **2023**, 186, 1541-1563
- 29 Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review. **2023**, 12, 2833
- 28 Role of inflammation in the development of atrial fibrillation. **2023**, 25, 107-120
- 27 Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events.
- 26 Cardiac Metabolism in Heart Failure and Implications for Uremic Cardiomyopathy. **2023**, 132, 1034-1049
- 25 Cardiovascular Biomarkers in Acute Myocardial Infarction. **2023**, 139-169
- 24 Inflammaging: mechanisms and role in the cardiac and vasculature. **2023**,
- 23 A View on Drug Development for Cancer Prevention. OF1-OF26
- 22 Network analysis of the associations between personality traits, cognitive functioning, and inflammatory markers in elderly individuals without dementia. 15,
- 21 Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. **2023**, 21,
- 20 New Insights into Pathophysiology and New Risk Factors for ACS. **2023**, 12, 2883
- 19 The bidirectional association between atrial fibrillation and myocardial infarction.
- 18 Cholesterol Crystals as the Main Trigger of Interleukin-6 Production through Innate Inflammatory Response in Human Spontaneously Ruptured Aortic Plaques. **2023**,
- 17 Dihydrotestosterone, and Not Testosterone, Enhances the LPS-Induced Inflammatory Cytokine Gene Expression in Human Adipocytes. **2023**, 11, 1194

- 16 Presence of tophi and carotid plaque were risk factors of MACE in subclinical atherosclerosis patients with gout: a longitudinal cohort study. 14,
- 15 Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. **2023**, 8,
- 14 Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes. **2023**, 22,
- 13 The prognostic value of pre-operative systemic inflammation-based scoring in patients undergoing endovascular repair of AAA.. **2023**,
- 12 Not All Quiet on the Atherosclerosis Front. **2023**, 24, 7527
- 11 DNA methylation changes underlie the long-term association between periodontitis and atherosclerotic cardiovascular disease. 10,
- 10 Understanding the molecular mechanisms of statin pleiotropic effects.
- 9 Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction.
- 8 Premature Atherosclerosis: A review of current literature. **2023**, 100013
- 7 Can Myeloperoxidase Identify High-Risk Plaques and Subjects Harboring Them?. **2023**, 100313
- 6 Lipid metabolism. **2023**, 34, 93-95
- 5 Immunometabolism at the Heart of Cardiovascular Disease. **2023**,
- 4 Cardiac computed tomography: from anatomy to function. **2023**, 25, C49-C57
- 3 C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations. **2023**, 197, 13-23
- 2 Anti-inflammation Nanomedicine Shots through Atherosclerotic Plaques for Targeted Treatment and Precise Diagnosis. **2023**, 112005
- 1 Hallmarks of cardiovascular ageing.